



(51) International Patent Classification:

A61K 47/48 (2006.01) C07K 16/30 (2006.01)
C07K 16/28 (2006.01)

(21) International Application Number:

PCT/US2013/038742

(22) International Filing Date:

30 April 2013 (30.04.2013)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/641,074 1 May 2012 (01.05.2012) US
61/678,911 2 August 2012 (02.08.2012) US

(71) Applicant: **GENENTECH, INC.** [US/US]; 1 DNA Way,
South San Francisco, California 94080 (US).

(72) Inventors; and

(71) Applicants : **CHEN, Youjun** [US/US]; 1 DNA Way,
South San Francisco, California 94080 (US). **MALLET,**


William [US/US]; 1 DNA Way, South San Francisco,
California 94080 (US). **POLAKIS, Paul** [US/US]; 1 DNA
Way, South San Francisco, California 94080 (US). **TAN,**
Christine [US/US]; 1 DNA Way, South San Francisco,
California 94080 (US). **ASUNDI, Jyoti** [US/US]; 1 DNA
Way, South San Francisco, California 94080 (US).
CLARK, Suzanna [US/US]; 1 DNA Way, South San
Francisco, California 94080 (US).

(74) Agent: **SCARR, Rebecca B.**; 2275 Deming Way, Suite
310, Middleton, Wisconsin 53562 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP,
KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ,

[Continued on next page]

(54) Title: ANTI-PMEL17 ANTIBODIES AND IMMUNOCONJUGATES

**FIG. 5**

(57) Abstract: The invention provides anti-PMEL17 antibodies and immuno-conjugates and methods of using the same.



TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,

Published:

- with international search report (*Art. 21(3)*)
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (*Rule 48.2(h)*)
- with sequence listing part of description (*Rule 5.2(a)*)

ANTI-PMEL17 ANTIBODIES AND IMMUNOCONJUGATES

FIELD OF THE INVENTION

[001] The present invention relates to anti-PMEL17 antibodies and immunoconjugates and methods of using the same.

BACKGROUND

[002] Melanocyte protein PMEL17 is an integral membrane protein that undergoes export from the endoplasmic reticulum to the Golgi apparatus where it is glycosylated and ultimately trafficked to the melanosome. The specific route by which mature PMEL17 makes its way to the melanosome has been a subject of debate, however, it is apparent that some fraction of the protein is presented transiently at the cell surface prior to its entry into stage I melanosomes. Melanosomes are a specialized lysosome-related organelle that produce melanin pigments, which are deposited on fibrils composed of proteolytic fragments derived from the PMEL17 protein. The synthesis of melanin pigments is largely restricted to melanocytes and the post-mitotic pigment epithelium of the eye. Melanocytes uniquely express specialized genes required for pigment formation, some of which are maintained following their transformation to melanoma.

[003] Human PMEL17 is a 661 amino acid protein (including the amino-terminal signal sequence), with a transmembrane region located at amino acids 596 and 616. PMEL17 undergoes complex processing, but at least a portion of the protein's lifecycle is spent on the cell surface.

[004] There is a need in the art for agents that target PMEL17 for the diagnosis and treatment of PMEL17-associated conditions, such as cancer. The invention fulfills that need and provides other benefits.

SUMMARY

[005] The invention provides anti-PMEL17 antibodies and immunoconjugates and methods of using the same.

[006] In some embodiments, an isolated antibody that binds PMEL17 is provided. In some such embodiments, the antibody binds an epitope within amino acids 105 to 125 of SEQ ID NO: 26. In some such embodiments, the antibody binds to an epitope within amino acids 25 to 45 of SEQ ID NO: 26. In some embodiments, the antibody is a monoclonal antibody. In some embodiments, the antibody is a human, humanized, or chimeric antibody. In some embodiments, the antibody is an antibody fragment that binds PMEL17. In some

embodiments, PMEL17 is human PMEL17. In some embodiments, human PMEL17 has the sequence of SEQ ID NO: 26 or SEQ ID NO: 27. In some embodiments, the antibody is an IgG1, IgG2a or IgG2b antibody.

[007] In some embodiments, the antibody comprises: a) (i) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 5, (ii) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 8, and (iii) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 4; or b) (i) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 15, (ii) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 8, and (iii) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 14; or c) HVR-H3, HVR-L3, and HVR-H2 of the antibody produced by hybridoma 7509(31D1.6.7) having ATCC Accession No. PTA-12862.

[008] In some embodiments, the antibody comprises: a) (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 3, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 4, and (iii) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 5; or b) (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 13, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 14, and (iii) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 15; or c) HVR-H1, HVR-H2, and HVR-H3 of the antibody produced by hybridoma 7509(31D1.6.7) having ATCC Accession No. PTA-12862.

[009] In some embodiments, the antibody comprises: a) (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 3, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 4, (iii) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 5, (iv) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 6, (v) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 7, (vi) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 8; or b) (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 13, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 14, and (iii) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 15, (iv) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 16, (v) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 7, (vi) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 8; or c) HVR-H1, HVR-H2, HVR-H3, HVR-L1, HVR-L2, and HVR-L3 of the antibody produced by hybridoma 7509(31D1.6.7) having ATCC Accession No. PTA-12862.

[010] In some embodiments, the antibody comprises: a) (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 6, (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 7, (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 8; or b) (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 16, (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 7, (iii) HVR-L3 comprising the amino acid sequence of

SEQ ID NO: 8; or c) HVR-L1, HVR-L2, and HVR-L3 of the antibody produced by hybridoma 7509(31D1.6.7) having ATCC Accession No. PTA-12862.

[011] In some embodiments, the antibody comprises: a) a VH sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1 or 50; or b) a VL sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 2; or c) a VH sequence as in (a) and a VL sequence as in (b); or d) a VH sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 9 or 49; or e) a VL sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 10; or f) a VH sequence as in (d) and a VL sequence as in (e); or g) a VH sequence having at least 95% sequence identity to the VH sequence of the antibody produced by hybridoma 7509(31D1.6.7) having ATCC Accession No. PTA-12862; or h) a VL sequence having at least 95% sequence identity to the VL sequence of the antibody produced by hybridoma 7509(31D1.6.7) having ATCC Accession No. PTA-12862; or i) a VH sequence as in (g) and a VL sequence as in (h).

[012] In some embodiments, the antibody comprises a VH sequence having the amino acid sequence of SEQ ID NO: 1 or 50, a VH sequence having the amino acid sequence of SEQ ID NO: 9 or 49, or a VH sequence of the antibody produced by hybridoma 7509(31D1.6.7) having ATCC Accession No. PTA-12862. In some embodiments, the antibody comprises a VL sequence having the amino acid sequence of SEQ ID NO: 2, a VL sequence having the amino acid sequence of SEQ ID NO: 10, or a VL sequence of the antibody produced by hybridoma 7509(31D1.6.7) having ATCC Accession No. PTA-12862. In some embodiments, the antibody comprises (a) a VH sequence having the amino acid sequence of SEQ ID NO: 1 or 50 and a VL sequence having the amino acid sequence of SEQ ID NO: 2; or (b) a VH sequence having the amino acid sequence of SEQ ID NO: 9 or 49 and a VL sequence having the amino acid sequence of SEQ ID NO: 10; or (c) a VH sequence of the antibody produced by hybridoma 7509(31D1.6.7) having ATCC Accession No. PTA-12862 and a VL sequence of the antibody produced by hybridoma 7509(31D1.6.7) having ATCC Accession No. PTA-12862.


[013] In some embodiments, an isolated antibody that binds PMEL17 is provided, wherein the antibody comprises: a) (i) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 22, (ii) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 25, and (iii) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 21; or b) (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 20, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 21, and (iii) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 22; or c) (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 23, (ii)

HVR-L2 comprising the amino acid sequence of SEQ ID NO: 24, (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 25; or d) (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 20, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 21, and (iii) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 22, (iv) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 23, (v) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 24, (vi) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 25; or e) a VH sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 11 or 51; or f) a VL sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 12; or g) a VH sequence as in (e) and a VL sequence as in (f); or h) a VH sequence having the amino acid sequence of SEQ ID NO: 11 or 51; or i) a VL sequence having the amino acid sequence of SEQ ID NO: 12; or j) a VH sequence as in (h) and a VL sequence as in (i). In some embodiments, the antibody is an IgG1, IgG2a or IgG2b antibody.

[014] In some embodiments, an isolated nucleic acid encoding any of the foregoing antibodies is provided. In some embodiments, a host cell comprising the nucleic acid is provided. In some embodiments, a method of producing an antibody is provided, comprising culturing the host cell so that the antibody is produced.

[015] In some embodiments, an immunoconjugate is provided. In some such embodiments, the immunoconjugate comprises any of the foregoing antibodies and a cytotoxic agent. In some embodiments, the immunoconjugate has the formula Ab-(L-D)_p, wherein: (a) Ab is the antibody of any one of claim 1 to 16; (b) L is a linker; (c) D is a drug selected from a maytansinoid, an auristatin, a calicheamicin, a pyrrolobenzodiazepine, and a nemorubicin derivative; and (d) p ranges from 1-8.


[016] In some embodiments, D is an auristatin. In some such embodiments, D has formula D_E



and wherein R² and R⁶ are each methyl, R³ and R⁴ are each isopropyl, R⁵ is H, R⁷ is sec-butyl, each R⁸ is independently selected from CH₃, O-CH₃, OH, and H; R⁹ is H; and R¹⁸ is -C(R⁸)₂-C(R⁸)₂-aryl.

In some embodiments, the drug (D) is MMAE.

[017] In some embodiments, D is a pyrrolobenzodiazepine of Formula A:



wherein the dotted lines indicate the optional presence of a double bond between C1 and C2 or C2 and C3;

R² is independently selected from H, OH, =O, =CH₂, CN, R, OR, =CH-R^D, =C(R^D)₂, O-SO₂-R, CO₂R and COR, and optionally further selected from halo or dihalo, wherein R^D is independently selected from R, CO₂R, COR, CHO, CO₂H, and halo;

R⁶ and R⁹ are independently selected from H, R, OH, OR, SH, SR, NH₂, NHR, NRR', NO₂, Me₃Sn and halo;

R⁷ is independently selected from H, R, OH, OR, SH, SR, NH₂, NHR, NRR', NO₂, Me₃Sn and halo;

Q is independently selected from O, S and NH;

R¹¹ is either H, or R or, where Q is O, SO₃M, where M is a metal cation;


R and R' are each independently selected from optionally substituted C₁₋₈ alkyl, C₃₋₈ heterocyclyl and C₅₋₂₀ aryl groups, and optionally in relation to the group NRR', R and R' together with the nitrogen atom to which they are attached form an optionally substituted 4-, 5-, 6- or 7-membered heterocyclic ring;

R^{12}, R^{16}, R^{19} and R^{17} are as defined for R^2, R^6, R^9 and R^7 respectively;

R" is a C₃₋₁₂ alkylene group, which chain may be interrupted by one or more heteroatoms and/or aromatic rings that are optionally substituted; and





X and X' are independently selected from O, S and N(H).

In some such embodiments, D has the structure:




wherein n is 0 or 1.


[018] In some embodiments, D has a structure selected from:



wherein R^E and $R^{E''}$ are each independently selected from H or R^D , wherein R^D is independently selected from R, CO_2R , COR, CHO, CO_2H , and halo;
wherein Ar^1 and Ar^2 are each independently optionally substituted C_{5-20} aryl; and
wherein n is 0 or 1.


[019] In some embodiments, D is a nemorubicin derivative. In some such embodiments, D has a structure selected from:






[020] In some embodiments, the linker is cleavable by a protease. In some such embodiments, the linker comprises a val-cit dipeptide or a Phe-Lys dipeptide. In some embodiments, the linker is acid-labile. In some such embodiments, the linker comprises hydrazone.

[021] In some embodiments, an immunoconjugate has the formula:




wherein S is a sulfur atom.



[022] In some embodiments, an immunoconjugate has the formula:





[023] In some embodiments, an immunoconjugate has a formula selected from:



:



•
?



[024] In some embodiments of the foregoing immunoconjugates, p ranges from 2-5.

[025] In some embodiments, an immunoconjugate is provided, wherein the immunoconjugate comprises an antibody that comprises: a) (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 3, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 4, (iii) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 5, (iv) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 6, (v) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 7, (vi) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 8; or b) (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 13, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 14, and (iii) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 15, (iv) HVR-L1 comprising the amino acid sequence of

SEQ ID NO: 16, (v) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 7, (vi) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 8; or c) HVR-H1, HVR-H2, HVR-H3, HVR-L1, HVR-L2, and HVR-L3 of the antibody produced by hybridoma 7509(31D1.6.7) having ATCC Accession No. PTA-12862.

[026] In some embodiments, an immunoconjugate is provided, wherein the immunoconjugate comprises an antibody that comprises (a) a VH sequence having the amino acid sequence of SEQ ID NO: 1 or 50 and a VL sequence having the amino acid sequence of SEQ ID NO: 2; or (b) a VH sequence having the amino acid sequence of SEQ ID NO: 9 or 49 and a VL sequence having the amino acid sequence of SEQ ID NO: 10; or (c) a VH sequence of the antibody produced by hybridoma 7509(31D1.6.7) having ATCC Accession No. PTA-12862 and a VL sequence of the antibody produced by hybridoma 7509(31D1.6.7) having ATCC Accession No. PTA-12862.

[027] In some embodiments, pharmaceutical formulations are provided. In some such embodiments, the pharmaceutical formulation comprises an antibody described herein and a pharmaceutically acceptable carrier. In some embodiments, a pharmaceutical formulation further comprises an additional therapeutic agent.

[028] In some embodiments, methods of treating an individual having a PMEL17-positive cancer are provided. In some such embodiments, the method comprises administering to the individual an effective amount of an immunoconjugate comprising an antibody that binds to PMEL17. In some such embodiments, the method comprises administering to the individual an effective amount of an immunoconjugate comprising an antibody that binds to the extracellular domain of PMEL17. In some such embodiments, the method comprises administering to the individual an effective amount of an immunoconjugate comprising an antibody described herein. In some embodiments, the PMEL17-positive cancer is melanoma. In some embodiments, a method of treating an individual having a PMEL17-positive cancer further comprises administering an additional therapeutic agent to the individual.

[029] In some embodiments, methods of treating an individual having a PMEL17-positive cancer are provided, wherein the PMEL17-positive cancer is resistant to a first therapeutic. In some embodiments, the method comprises administering to the individual an effective amount of an immunoconjugate comprising an antibody that binds to PMEL17. In some embodiments, the PMEL17-positive cancer is melanoma. In some embodiments, the first therapeutic comprises a first antibody that binds an antigen other than PMEL17. In some embodiments, the first therapeutic is a first immunoconjugate comprising a first antibody that binds an antigen other than PMEL17 and a first cytotoxic agent. In some embodiments, the first antibody binds an antigen selected from endothelin B receptor (ETBR), tyrosinase-related

protein 1 (TYRP1), cytotoxic T lymphocyte antigen 4 (CTLA-4), and glycoprotein NMB (GPNMB). In some embodiments, the first antibody binds ETBR. In some embodiments, the first antibody is hu5E9.v1. In some embodiments, the first immunoconjugate is hu5E9.v1-MC-val-cit-PAB-MMAE. In some embodiments, the first cytotoxic agent and the cytotoxic agent of the immunoconjugate comprising an antibody that binds to PMEL17 are different. In some such embodiments, the first cytotoxic agent is MMAE and the cytotoxic agent of the immunoconjugate comprising an antibody that binds to PMEL17 is selected from a calicheamicin, a pyrrolobenzodiazepine, and a nemorubicin derivative. In some embodiments, the cytotoxic agent of the immunoconjugate comprising an antibody that binds to PMEL17 is selected from a pyrrolobenzodiazepine and a nemorubicin derivative.

[030] In some embodiments, a method of treating an individual with PMEL17-positive cancer is provided, wherein the method comprises administering to the individual an effective amount of a first immunoconjugate described herein in combination with a second immunoconjugate comprising an antibody that binds ETBR. In some embodiments, the antibody that binds ETBR comprises an HVR H1 comprising a sequence of SEQ ID NO: 33, an HVR H2 comprising a sequence of SEQ ID NO: 34, an HVR H3 comprising a sequence of SEQ ID NO: 35, an HVR L1 comprising a sequence of SEQ ID NO: 36, an HVR L2 comprising a sequence of SEQ ID NO: 37, and an HVR L3 comprising a sequence of SEQ ID NO: 38. In some embodiments, the antibody that binds ETBR comprises a heavy chain variable region comprising the sequence of SEQ ID NO: 40 and a light chain variable region comprising the sequence of SEQ ID NO: 39. In some embodiments, the first immunoconjugate comprises a cytotoxic agent selected from an auristatin, a pyrrolobenzodiazepine, and a nemorubicin derivative, and the second immunoconjugate comprises a cytotoxic agent selected from an auristatin, a pyrrolobenzodiazepine, and a nemorubicin derivative. In some embodiments, the first immunoconjugate comprises a cytotoxic agent selected from a pyrrolobenzodiazepine and a nemorubicin derivative, and the second immunoconjugate comprises an auristatin. In some embodiments, the second immunoconjugate comprises MMAE. In some such embodiments, the second immunoconjugate comprises a linker-drug portion comprising MC-val-cit-PAB-MMAE. In some embodiments, the second immunoconjugate is hu5E9.v1-MC-val-cit-PAB-MMAE. In any of the foregoing embodiments, the PMEL17-positive cancer may be melanoma. In some embodiments, the PMEL17-positive cancer is also ETBR-positive.

[031] In some embodiments, a method of inhibiting proliferation of PMEL17-positive cell is provided. In some such embodiments, the method comprises exposing the cell to an immunoconjugate described herein under conditions permissive for binding of the

immunoconjugate to PMEL17 on the surface of the cell, thereby inhibiting proliferation of the cell. In some embodiments, the cell is a melanoma cell.

[032] In some embodiments, an antibody that binds to PMEL17 conjugated to a label is provided. In some embodiments, the label is a positron emitter. In some such embodiments, the positron emitter is ^{89}Zr .

[033] In some embodiments, a method of detecting human PMEL17 in a biological sample is provided. In some embodiments, the method comprises contacting the biological sample with an anti-PMEL17 antibody described herein under conditions permissive for binding of the anti-PMEL17 antibody to a naturally occurring human PMEL17. In some embodiments, the method further comprises detecting whether a complex is formed between the anti-PMEL17 antibody and a naturally occurring human PMEL17 in the biological sample. In some embodiments, the anti-PMEL17 antibody is the antibody produced by hybridoma 7509(31D1.6.7) having ATCC Accession No. PTA-12862. In some embodiments, the antibody comprises a) (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 3, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 4, (iii) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 5, (iv) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 6, (v) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 7, (vi) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 8; or b) (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 13, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 14, and (iii) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 15, (iv) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 16, (v) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 7, (vi) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 8; or c) HVR-H1, HVR-H2, HVR-H3, HVR-L1, HVR-L2, and HVR-L3 of the antibody produced by hybridoma 7509(31D1.6.7) having ATCC Accession No. PTA-12862. In some embodiments, the biological sample is a melanoma sample.

[034] In some embodiments, a method for detecting a PMEL17-positive cancer is provided. In some such embodiments, the method comprises (i) administering a labeled anti-PMEL17 antibody to a subject having or suspected of having a PMEL17-positive cancer, wherein the labeled anti-PMEL17 antibody comprises an anti-PMEL17 antibody described herein, and (ii) detecting the labeled anti-PMEL17 antibody in the subject, wherein detection of the labeled anti-PMEL17 antibody indicates a PMEL17-positive cancer in the subject. In some such embodiments, the labeled anti-PMEL17 antibody comprises an anti-PMEL17 antibody conjugated to a positron emitter. In some embodiments, the positron emitter is ^{89}Zr .

BRIEF DESCRIPTION OF THE FIGURES

[035] **Figure 1** shows (A) a graphic representation of the levels of human PMEL17 gene expression in various tissues, and (B) a graphic representation of the levels of human PMEL17 in various human cell lines, as described in Example A.

[036] **Figures 2A and 2B** show alignments of the (A) light chain and (B) heavy chain variable regions sequences for antibodies 8G3, 17A9, and 15F2.

[037] **Figures 3A to 3D** shows epitope mapping of 77E6 (A and B), 17A9 (C and D), and 31D1 (D), as described in Example D.

[038] **Figure 4** shows internalization of 17A9 in melanoma cells, as described in Example G.

[039] **Figure 5** shows killing of various PMEL17+ melanoma cell lines by increasing concentrations of 17A9 ADC, as described in Example I.

[040] **Figure 6** shows (A) distribution of 31D1 staining in normal skin, (B) 17A9 staining of normal melanocytes and melanoma cell line SK-MEL-5 by FACS, and (C) the IC50 of 17A9 on normal melanocytes is nearly 100-fold higher than the IC50 of 17A9 on melanoma cell lines, as described in Example J.

[041] **Figure 7** shows (A) exemplary staining for each level of PMEL17 staining and (B) IHC scores for a panel of human melanoma samples, as described in Example K.

[042] **Figure 8** shows efficacy of 17A9 ADC in an SK-MEL-23 cell line xenograft, as described in Example L.

[043] **Figures 9A and 9B** show an alignment of human, mouse, rat, and cynomolgus monkey PMEL17, as described in Example F.

[044] **Figure 10** shows (A) tumor volume over time in mice inoculated with UACC-257X2.2 melanoma cells and administered varying doses of anti-ETBR-vc-MMAE ("5E9v1-vcE"), and (B) parental and resistant UACC-257X2.2 cells grown *in vitro* in the presence of increasing concentrations of anti-ETBR-vc-MMAE ADC, as described in Example M.

[045] **Figure 11** shows expression of ETBR (A and B; also referred to as "EDNRB") and PMEL17 (C and D) in parental and resistant UACC-257X2.2 cells derived *in vivo* (A and C) and *in vitro* (B and D), as described in Example M.

[046] **Figure 12** shows sensitivity of (A) parental UACC-257X2.2 cells, (B) *in vivo* derived resistant UACC-257X2.2 cells, and (C) *in vitro* derived resistant UACC-257X2.2 cells to increasing concentrations of anti-ETBR-vc-MMAE, anti-PMEL17-vc-MMAE, and anti-gD-vc-MMAE, as described in Example M.

[047] **Figure 13** shows sensitivity of (A) parental UACC-257X2.2 cells, (B) *in vivo* derived resistant UACC-257X2.2 cells, and (C) *in vitro* derived resistant UACC-257X2.2 cells to increasing concentrations of anti-ETBR-PNU, anti-PMEL17-PNU, and anti-gD-PNU, as described in Example M.

[048] **Figure 14** shows sensitivity of (A) parental UACC-257X2.2 cells, (B) *in vivo* derived resistant UACC-257X2.2 cells, and (C) *in vitro* derived resistant UACC-257X2.2 cells to increasing concentrations of anti-ETBR-vc-PNU, anti-PMEL17-vc-PNU, and anti-gD-vc-PNU, as described in Example M.

[049] **Figure 15** shows the structures of various antibody-drug conjugates, including (A) Ab-MC-val-cit-PAB-MMAE; (B) Ab-MC-acetal-PNU-159682; (C) Ab-MC-val-cit-PAB-PNU-159682; (D) Ab-MC-val-cit-PAB-PBD; and (E) Ab-PNU-159682.

DETAILED DESCRIPTION OF CERTAIN EMBODIMENTS OF THE INVENTION

I. DEFINITIONS

[050] An “acceptor human framework” for the purposes herein is a framework comprising the amino acid sequence of a light chain variable domain (VL) framework or a heavy chain variable domain (VH) framework derived from a human immunoglobulin framework or a human consensus framework, as defined below. An acceptor human framework “derived from” a human immunoglobulin framework or a human consensus framework may comprise the same amino acid sequence thereof, or it may contain amino acid sequence changes. In some embodiments, the number of amino acid changes are 10 or less, 9 or less, 8 or less, 7 or less, 6 or less, 5 or less, 4 or less, 3 or less, or 2 or less. In some embodiments, the VL acceptor human framework is identical in sequence to the VL human immunoglobulin framework sequence or human consensus framework sequence.

[051] “Affinity” refers to the strength of the sum total of noncovalent interactions between a single binding site of a molecule (e.g., an antibody) and its binding partner (e.g., an antigen). Unless indicated otherwise, as used herein, “binding affinity” refers to intrinsic binding affinity which reflects a 1:1 interaction between members of a binding pair (e.g., antibody and antigen). The affinity of a molecule X for its partner Y can generally be represented by the dissociation constant (K_d). Affinity can be measured by common methods known in the art, including those described herein. Specific illustrative and exemplary embodiments for measuring binding affinity are described in the following.

[052] An “affinity matured” antibody refers to an antibody with one or more alterations in one or more hypervariable regions (HVRs), compared to a parent antibody which

does not possess such alterations, such alterations resulting in an improvement in the affinity of the antibody for antigen.

[053] The terms “anti-PMEL17 antibody” and “an antibody that binds to PMEL17” refer to an antibody that is capable of binding PMEL17 with sufficient affinity such that the antibody is useful as a diagnostic and/or therapeutic agent in targeting PMEL17. In one embodiment, the extent of binding of an anti-PMEL17 antibody to an unrelated, non-PMEL17 protein is less than about 10% of the binding of the antibody to PMEL17 as measured, e.g., by a radioimmunoassay (RIA). In certain embodiments, an antibody that binds to PMEL17 has a dissociation constant (Kd) of $\leq 1 \mu\text{M}$, $\leq 100 \text{ nM}$, $\leq 10 \text{ nM}$, $\leq 5 \text{ nM}$, $\leq 4 \text{ nM}$, $\leq 3 \text{ nM}$, $\leq 2 \text{ nM}$, $\leq 1 \text{ nM}$, $\leq 0.1 \text{ nM}$, $\leq 0.01 \text{ nM}$, or $\leq 0.001 \text{ nM}$ (e.g., 10^{-8} M or less, e.g. from 10^{-8} M to 10^{-13} M , e.g., from 10^{-9} M to 10^{-13} M). In certain embodiments, an anti-PMEL17 antibody binds to an epitope of PMEL17 that is conserved among PMEL17 from different species.

[054] The term “antibody” is used herein in the broadest sense and encompasses various antibody structures, including but not limited to monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), and antibody fragments so long as they exhibit the desired antigen-binding activity.

[055] An “antibody fragment” refers to a molecule other than an intact antibody that comprises a portion of an intact antibody and that binds the antigen to which the intact antibody binds. Examples of antibody fragments include but are not limited to Fv, Fab, Fab', Fab'-SH, F(ab')₂; diabodies; linear antibodies; single-chain antibody molecules (e.g. scFv); and multispecific antibodies formed from antibody fragments.

[056] An “antibody that binds to the same epitope” as a reference antibody refers to an antibody that blocks binding of the reference antibody to its antigen in a competition assay by 50% or more, and conversely, the reference antibody blocks binding of the antibody to its antigen in a competition assay by 50% or more. An exemplary competition assay is provided herein.

[057] The terms “cancer” and “cancerous” refer to or describe the physiological condition in mammals that is typically characterized by unregulated cell growth/proliferation. Examples of cancer include, but are not limited to, melanoma, carcinoma, lymphoma (e.g., Hodgkin's and non-Hodgkin's lymphoma), blastoma, sarcoma, and leukemia. More particular examples of such cancers include squamous cell cancer, small-cell lung cancer, non-small cell lung cancer, adenocarcinoma of the lung, squamous carcinoma of the lung, cancer of the peritoneum, hepatocellular cancer, gastrointestinal cancer, pancreatic cancer, glioma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, hepatoma, breast cancer, colon cancer, colorectal cancer, endometrial or uterine carcinoma, salivary gland carcinoma, kidney cancer,

liver cancer, prostate cancer, vulval cancer, thyroid cancer, hepatic carcinoma, leukemia and other lymphoproliferative disorders, and various types of head and neck cancer.

[058] The term “chimeric” antibody refers to an antibody in which a portion of the heavy and/or light chain is derived from a particular source or species, while the remainder of the heavy and/or light chain is derived from a different source or species.

[059] The “class” of an antibody refers to the type of constant domain or constant region possessed by its heavy chain. There are five major classes of antibodies: IgA, IgD, IgE, IgG, and IgM, and several of these may be further divided into subclasses (isotypes), e.g., IgG₁, IgG₂, IgG₃, IgG₄, IgA₁, and IgA₂. The heavy chain constant domains that correspond to the different classes of immunoglobulins are called α , δ , ϵ , γ , and μ , respectively.

[060] The term “cytotoxic agent” as used herein refers to a substance that inhibits or prevents a cellular function and/or causes cell death or destruction. Cytotoxic agents include, but are not limited to, radioactive isotopes (e.g., At²¹¹, I¹³¹, I¹²⁵, Y⁹⁰, Re¹⁸⁶, Re¹⁸⁸, Sm¹⁵³, Bi²¹², P³², Pb²¹² and radioactive isotopes of Lu); chemotherapeutic agents or drugs (e.g., methotrexate, adriamycin, vinca alkaloids (vincristine, vinblastine, etoposide), doxorubicin, melphalan, mitomycin C, chlorambucil, daunorubicin or other intercalating agents); growth inhibitory agents; enzymes and fragments thereof such as nucleolytic enzymes; antibiotics; toxins such as small molecule toxins or enzymatically active toxins of bacterial, fungal, plant or animal origin, including fragments and/or variants thereof; and the various antitumor or anticancer agents disclosed below.

[061] A “chemotherapeutic agent” is a chemical compound useful in the treatment of cancer. Examples of chemotherapeutic agents include alkylating agents such as thiotepa and cyclophosphamide (CYTOXAN[®]); alkyl sulfonates such as busulfan, improsulfan and piposulfan; aziridines such as benzodopa, carboquone, meturedopa, and uredopa; ethylenimines and methylamelamines including altretamine, triethylenemelamine, triethylenephosphoramide, triethylenethiophosphoramide and trimethylolomelamine; acetogenins (especially bullatacin and bullatacinone); delta-9-tetrahydrocannabinol (dronabinol, MARINOL[®]); beta-lapachone; lapachol; colchicines; betulinic acid; a camptothecin (including the synthetic analogue topotecan (HYCAMTIN[®]), CPT-11 (irinotecan, CAMPTOSAR[®]), acetylcamptothecin, scopoletin, and 9-aminocamptothecin); bryostatin; callystatin; CC-1065 (including its adozelesin, carzelesin and bizelesin synthetic analogues); podophyllotoxin; podophyllinic acid; teniposide; cryptophycins (particularly cryptophycin 1 and cryptophycin 8); dolastatin; duocarmycin (including the synthetic analogues, KW-2189 and CB1-TM1); eleutherobin; pancratistatin; a sarcodictyin; spongistatin;

nitrogen mustards such as chlorambucil, chlornaphazine, cholophosphamide, estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride, melphalan, novembichin, phenesterine, prednimustine, trofosfamide, uracil mustard; nitrosoureas such as carmustine, chlorozotocin, fotemustine, lomustine, nimustine, and ranimustine; antibiotics such as the enediyne antibiotics (e. g., calicheamicin, especially calicheamicin gammaII and calicheamicin omegaII (see, e.g., Agnew, Chem Intl. Ed. Engl., 33: 183-186 (1994)); dynemicin, including dynemicin A; an esperamicin; as well as neocarzinostatin chromophore and related chromoprotein enediyne antiobiotic chromophores), aclacinomysins, actinomycin, authramycin, azaserine, bleomycins, cactinomycin, carabycin, carminomycin, carzinophilin, chromomycins, dactinomycin, daunorubicin, detorubicin, 6-diazo-5-oxo-L-norleucine, doxorubicin (including morpholino-doxorubicin, cyanomorpholino-doxorubicin, 2-pyrrolino-doxorubicin and deoxydoxorubicin), epirubicin, esorubicin, idarubicin, marcellomycin, mitomycins such as mitomycin C, mycophenolic acid, nogalamycin, olivomycins, peplomycin, porfiromycin, puromycin, quelamycin, rodorubicin, streptonigrin, streptozocin, tubercidin, ubenimex, zinostatin, zorubicin; anti-metabolites such as methotrexate and 5-fluorouracil (5-FU); folic acid analogues such as denopterin, methotrexate, pteropterin, trimetrexate; purine analogs such as fludarabine, 6-mercaptopurine, thiamiprine, thioguanine; pyrimidine analogs such as ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, floxuridine; androgens such as calusterone, dromostanolone propionate, epitiostanol, mepitiothane, testolactone; anti-adrenals such as aminoglutethimide, mitotane, trilostane; folic acid replenisher such as frolinic acid; aceglatone; aldophosphamide glycoside; aminolevulinic acid; eniluracil; amsacrine; bestrabucil; bisantrene; edatraxate; defofamine; demecolcine; diaziquone; elfornithine; elliptinium acetate; an epothilone; etoglucid; gallium nitrate; hydroxyurea; lentinan; lonidainine; maytansinoids such as maytansine and ansamitocins; mitoguazone; mitoxantrone; mopidanmol; nitraerine; pentostatin; phenamet; pirarubicin; losoxantrone; 2-ethylhydrazide; procarbazine; PSK® polysaccharide complex (JHS Natural Products, Eugene, OR); razoxane; rhizoxin; sizofiran; spirogermanium; tenuazonic acid; triaziquone; 2,2',2"-trichlorotriethylamine; trichothecenes (especially T-2 toxin, verracurin A, roridin A and anguidine); urethan; vindesine (ELDISINE®, FILDESIN®); dacarbazine; mannomustine; mitobronitol; mitolactol; pipobroman; gacytosine; arabinoside ("Ara-C"); thiotepa; taxoids, e.g., paclitaxel (TAXOL®; Bristol-Myers Squibb Oncology, Princeton, N.J.), ABRAXANE™ Cremophor-free, albumin-engineered nanoparticle formulation of paclitaxel (American Pharmaceutical Partners, Schaumburg, Illinois), and docetaxel (TAXOTERE®, Rhône-Poulenc Rorer, Antony, France); chlorambucil; gemcitabine (GEMZAR®); 6-thioguanine; mercaptopurine; methotrexate; platinum analogs such as

cisplatin and carboplatin; vinblastine (VELBAN®); platinum; etoposide (VP-16); ifosfamide; mitoxantrone; vincristine (ONCOVIN®); oxaliplatin; leucovorin; vinorelbine (NAVELBINE®); novantrone; edatrexate; daunomycin; aminopterin; ibandronate; topoisomerase inhibitor RFS 2000; difluoromethylornithine (DMFO); retinoids such as retinoic acid; capecitabine (XELODA®); pharmaceutically acceptable salts, acids or derivatives of any of the above; as well as combinations of two or more of the above such as CHOP, an abbreviation for a combined therapy of cyclophosphamide, doxorubicin, vincristine, and prednisolone; CVP, an abbreviation for a combined therapy of cyclophosphamide, vincristine, and prednisolone; and FOLFOX, an abbreviation for a treatment regimen with oxaliplatin (ELOXATIN™) combined with 5-FU and leucovorin.

[062] “Effector functions” refer to those biological activities attributable to the Fc region of an antibody, which vary with the antibody isotype. Examples of antibody effector functions include: C1q binding and complement dependent cytotoxicity (CDC); Fc receptor binding; antibody-dependent cell-mediated cytotoxicity (ADCC); phagocytosis; down regulation of cell surface receptors (e.g. B cell receptor); and B cell activation.

[063] An “effective amount” of an agent, e.g., a pharmaceutical formulation, refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic or prophylactic result.

[064] The term “epitope” refers to the particular site on an antigen molecule to which an antibody binds.

[065] The term “Fc region” herein is used to define a C-terminal region of an immunoglobulin heavy chain that contains at least a portion of the constant region. The term includes native sequence Fc regions and variant Fc regions. In one embodiment, a human IgG heavy chain Fc region extends from Cys226, or from Pro230, to the carboxyl-terminus of the heavy chain. However, the C-terminal lysine (Lys447) of the Fc region may or may not be present. Unless otherwise specified herein, numbering of amino acid residues in the Fc region or constant region is according to the EU numbering system, also called the EU index, as described in Kabat et al., *Sequences of Proteins of Immunological Interest*, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD, 1991.

[066] “Framework” or “FR” refers to variable domain residues other than hypervariable region (HVR) residues. The FR of a variable domain generally consists of four FR domains: FR1, FR2, FR3, and FR4. Accordingly, the HVR and FR sequences generally appear in the following sequence in VH (or VL): FR1-H1(L1)-FR2-H2(L2)-FR3-H3(L3)-FR4.

[067] The terms “full length antibody,” “intact antibody,” and “whole antibody” are used herein interchangeably to refer to an antibody having a structure substantially similar to a native antibody structure or having heavy chains that contain an Fc region as defined herein.

[068] The term “glycosylated forms of PMEL17” refers to naturally occurring forms of PMEL17 that are post-translationally modified by the addition of carbohydrate residues.

[069] The terms “host cell,” “host cell line,” and “host cell culture” are used interchangeably and refer to cells into which exogenous nucleic acid has been introduced, including the progeny of such cells. Host cells include “transformants” and “transformed cells,” which include the primary transformed cell and progeny derived therefrom without regard to the number of passages. Progeny may not be completely identical in nucleic acid content to a parent cell, but may contain mutations. Mutant progeny that have the same function or biological activity as screened or selected for in the originally transformed cell are included herein.

[070] A “human antibody” is one which possesses an amino acid sequence which corresponds to that of an antibody produced by a human or a human cell or derived from a non-human source that utilizes human antibody repertoires or other human antibody-encoding sequences. This definition of a human antibody specifically excludes a humanized antibody comprising non-human antigen-binding residues.

[071] A “human consensus framework” is a framework which represents the most commonly occurring amino acid residues in a selection of human immunoglobulin VL or VH framework sequences. Generally, the selection of human immunoglobulin VL or VH sequences is from a subgroup of variable domain sequences. Generally, the subgroup of sequences is a subgroup as in Kabat et al., *Sequences of Proteins of Immunological Interest*, Fifth Edition, NIH Publication 91-3242, Bethesda MD (1991), vols. 1-3. In one embodiment, for the VL, the subgroup is subgroup kappa I as in Kabat et al., *supra*. In one embodiment, for the VH, the subgroup is subgroup III as in Kabat et al., *supra*.

[072] A “humanized” antibody refers to a chimeric antibody comprising amino acid residues from non-human HVRs and amino acid residues from human FRs. In certain embodiments, a humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the HVRs (e.g., CDRs) correspond to those of a non-human antibody, and all or substantially all of the FRs correspond to those of a human antibody. A humanized antibody optionally may comprise at least a portion of an antibody constant region derived from a human antibody. A “humanized form” of an antibody, e.g., a non-human antibody, refers to an antibody that has undergone humanization.

[073] The term “hypervariable region” or “HVR,” as used herein, refers to each of the regions of an antibody variable domain which are hypervariable in sequence and/or form structurally defined loops (“hypervariable loops”). Generally, native four-chain antibodies comprise six HVRs; three in the VH (H1, H2, H3), and three in the VL (L1, L2, L3). HVRs generally comprise amino acid residues from the hypervariable loops and/or from the “complementarity determining regions” (CDRs), the latter being of highest sequence variability and/or involved in antigen recognition. Exemplary hypervariable loops occur at amino acid residues 26-32 (L1), 50-52 (L2), 91-96 (L3), 26-32 (H1), 53-55 (H2), and 96-101 (H3). (Chothia and Lesk, *J. Mol. Biol.* 196:901-917 (1987).) Exemplary CDRs (CDR-L1, CDR-L2, CDR-L3, CDR-H1, CDR-H2, and CDR-H3) occur at amino acid residues 24-34 of L1, 50-56 of L2, 89-97 of L3, 31-35B of H1, 50-65 of H2, and 95-102 of H3. (Kabat et al., *Sequences of Proteins of Immunological Interest*, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD (1991).) With the exception of CDR1 in VH, CDRs generally comprise the amino acid residues that form the hypervariable loops. CDRs also comprise “specificity determining residues,” or “SDRs,” which are residues that contact antigen. SDRs are contained within regions of the CDRs called abbreviated-CDRs, or a-CDRs. Exemplary a-CDRs (a-CDR-L1, a-CDR-L2, a-CDR-L3, a-CDR-H1, a-CDR-H2, and a-CDR-H3) occur at amino acid residues 31-34 of L1, 50-55 of L2, 89-96 of L3, 31-35B of H1, 50-58 of H2, and 95-102 of H3. (See Almagro and Fransson, *Front. Biosci.* 13:1619-1633 (2008).) Unless otherwise indicated, HVR residues and other residues in the variable domain (e.g., FR residues) are numbered herein according to Kabat et al., *supra*.

[074] An “immunoconjugate” is an antibody conjugated to one or more heterologous molecule(s), including but not limited to a cytotoxic agent.

[075] An “individual” or “subject” is a mammal. Mammals include, but are not limited to, domesticated animals (e.g., cows, sheep, cats, dogs, and horses), primates (e.g., humans and non-human primates such as monkeys), rabbits, and rodents (e.g., mice and rats). In certain embodiments, the individual or subject is a human.

[076] An “isolated antibody” is one which has been separated from a component of its natural environment. In some embodiments, an antibody is purified to greater than 95% or 99% purity as determined by, for example, electrophoretic (e.g., SDS-PAGE, isoelectric focusing (IEF), capillary electrophoresis) or chromatographic (e.g., ion exchange or reverse phase HPLC). For review of methods for assessment of antibody purity, see, e.g., Flatman et al., *J. Chromatogr. B* 848:79-87 (2007).

[077] An “isolated nucleic acid” refers to a nucleic acid molecule that has been separated from a component of its natural environment. An isolated nucleic acid includes a

nucleic acid molecule contained in cells that ordinarily contain the nucleic acid molecule, but the nucleic acid molecule is present extrachromosomally or at a chromosomal location that is different from its natural chromosomal location.

[078] “Isolated nucleic acid encoding an anti-PMEL17 antibody” refers to one or more nucleic acid molecules encoding antibody heavy and light chains (or fragments thereof), including such nucleic acid molecule(s) in a single vector or separate vectors, and such nucleic acid molecule(s) present at one or more locations in a host cell.

[079] The term “PMEL17,” as used herein, refers to any native PMEL17. The term includes PMEL17 from any vertebrate source, including mammals such as primates (e.g. humans and cynomolgus monkeys) and rodents (e.g., mice and rats), unless otherwise indicated. The term encompasses “full-length,” unprocessed PMEL17, as well as any form of PMEL17 that results from processing in the cell. The term also includes naturally occurring variants of PMEL17, e.g., splice variants or allelic variants. The amino acid sequence of an exemplary human PMEL17 preproprotein, with signal sequence (amino acids 1-24) is shown in SEQ ID NO: 26. The amino acid sequence of an exemplary human PMEL17 proprotein is shown in SEQ ID NO: 27. The predicted sequence of an exemplary cynomolgus monkey PMEL17 (without signal sequence) is shown in SEQ ID NO: 28. The amino acid sequences for exemplary rat PMEL17 with signal sequence (amino acids 1-25) and without signal sequence are shown in SEQ ID NOs: 29 and 30, respectively. The amino acid sequences for exemplary mouse PMEL17 with signal sequence (amino acids 1-25) and without signal sequence are shown in SEQ ID NOs: 31 and 32, respectively.

[080] The term “PMEL17-positive cancer” refers to a cancer comprising cells that express (including transiently express) PMEL17 on their surface.

[081] The term “PMEL17-positive cell” refers to a cell that expresses PMEL17 on its surface.

[082] The term “monoclonal antibody” as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical and/or bind the same epitope, except for possible variant antibodies, e.g., containing naturally occurring mutations or arising during production of a monoclonal antibody preparation, such variants generally being present in minor amounts. In contrast to polyclonal antibody preparations, which typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody of a monoclonal antibody preparation is directed against a single determinant on an antigen. Thus, the modifier “monoclonal” indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies, and is not to be construed as requiring production of

the antibody by any particular method. For example, the monoclonal antibodies to be used in accordance with the present invention may be made by a variety of techniques, including but not limited to the hybridoma method, recombinant DNA methods, phage-display methods, and methods utilizing transgenic animals containing all or part of the human immunoglobulin loci, such methods and other exemplary methods for making monoclonal antibodies being described herein.

[083] A “naked antibody” refers to an antibody that is not conjugated to a heterologous moiety (e.g., a cytotoxic moiety) or radiolabel. The naked antibody may be present in a pharmaceutical formulation.

[084] “Native antibodies” refer to naturally occurring immunoglobulin molecules with varying structures. For example, native IgG antibodies are heterotetrameric glycoproteins of about 150,000 daltons, composed of two identical light chains and two identical heavy chains that are disulfide-bonded. From N- to C-terminus, each heavy chain has a variable region (VH), also called a variable heavy domain or a heavy chain variable domain, followed by three constant domains (CH1, CH2, and CH3). Similarly, from N- to C-terminus, each light chain has a variable region (VL), also called a variable light domain or a light chain variable domain, followed by a constant light (CL) domain. The light chain of an antibody may be assigned to one of two types, called kappa (κ) and lambda (λ), based on the amino acid sequence of its constant domain.

[085] The term “package insert” is used to refer to instructions customarily included in commercial packages of therapeutic products, that contain information about the indications, usage, dosage, administration, combination therapy, contraindications and/or warnings concerning the use of such therapeutic products.

[086] “Percent (%) amino acid sequence identity” with respect to a reference polypeptide sequence is defined as the percentage of amino acid residues in a candidate sequence that are identical with the amino acid residues in the reference polypeptide sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. Alignment for purposes of determining percent amino acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN or Megalign (DNASTAR) software. Those skilled in the art can determine appropriate parameters for aligning sequences, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared. For purposes herein, however, % amino acid sequence identity values are generated using the sequence comparison computer program

ALIGN-2. The ALIGN-2 sequence comparison computer program was authored by Genentech, Inc., and the source code has been filed with user documentation in the U.S. Copyright Office, Washington D.C., 20559, where it is registered under U.S. Copyright Registration No. TXU510087. The ALIGN-2 program is publicly available from Genentech, Inc., South San Francisco, California, or may be compiled from the source code. The ALIGN-2 program should be compiled for use on a UNIX operating system, including digital UNIX V4.0D. All sequence comparison parameters are set by the ALIGN-2 program and do not vary.

[087] In situations where ALIGN-2 is employed for amino acid sequence comparisons, the % amino acid sequence identity of a given amino acid sequence A to, with, or against a given amino acid sequence B (which can alternatively be phrased as a given amino acid sequence A that has or comprises a certain % amino acid sequence identity to, with, or against a given amino acid sequence B) is calculated as follows:

$$100 \text{ times the fraction } X/Y$$

where X is the number of amino acid residues scored as identical matches by the sequence alignment program ALIGN-2 in that program's alignment of A and B, and where Y is the total number of amino acid residues in B. It will be appreciated that where the length of amino acid sequence A is not equal to the length of amino acid sequence B, the % amino acid sequence identity of A to B will not equal the % amino acid sequence identity of B to A. Unless specifically stated otherwise, all % amino acid sequence identity values used herein are obtained as described in the immediately preceding paragraph using the ALIGN-2 computer program.

[088] The term "pharmaceutical formulation" refers to a preparation which is in such form as to permit the biological activity of an active ingredient contained therein to be effective, and which contains no additional components which are unacceptably toxic to a subject to which the formulation would be administered.

[089] A "pharmaceutically acceptable carrier" refers to an ingredient in a pharmaceutical formulation, other than an active ingredient, which is nontoxic to a subject. A pharmaceutically acceptable carrier includes, but is not limited to, a buffer, excipient, stabilizer, or preservative.

[090] As used herein, "treatment" (and grammatical variations thereof such as "treat" or "treating") refers to clinical intervention in an attempt to alter the natural course of the individual being treated, and can be performed either for prophylaxis or during the course of clinical pathology. Desirable effects of treatment include, but are not limited to, preventing

occurrence or recurrence of disease, alleviation of symptoms, diminishment of any direct or indirect pathological consequences of the disease, preventing metastasis, decreasing the rate of disease progression, amelioration or palliation of the disease state, and remission or improved prognosis. In some embodiments, antibodies of the invention are used to delay development of a disease or to slow the progression of a disease.

[091] The term “variable region” or “variable domain” refers to the domain of an antibody heavy or light chain that is involved in binding the antibody to antigen. The variable domains of the heavy chain and light chain (VH and VL, respectively) of a native antibody generally have similar structures, with each domain comprising four conserved framework regions (FRs) and three hypervariable regions (HVRs). (See, e.g., Kindt et al. *Kuby Immunology*, 6th ed., W.H. Freeman and Co., page 91 (2007).) A single VH or VL domain may be sufficient to confer antigen-binding specificity. Furthermore, antibodies that bind a particular antigen may be isolated using a VH or VL domain from an antibody that binds the antigen to screen a library of complementary VL or VH domains, respectively. See, e.g., Portolano et al., *J. Immunol.* 150:880-887 (1993); Clarkson et al., *Nature* 352:624-628 (1991).

[092] The term “vector,” as used herein, refers to a nucleic acid molecule capable of propagating another nucleic acid to which it is linked. The term includes the vector as a self-replicating nucleic acid structure as well as the vector incorporated into the genome of a host cell into which it has been introduced. Certain vectors are capable of directing the expression of nucleic acids to which they are operatively linked. Such vectors are referred to herein as “expression vectors.”

[093] “Alkyl” is C₁-C₁₈ hydrocarbon containing normal, secondary, tertiary or cyclic carbon atoms. Examples are methyl (Me, -CH₃), ethyl (Et, -CH₂CH₃), 1-propyl (n-Pr, n-propyl, -CH₂CH₂CH₃), 2-propyl (i-Pr, i-propyl, -CH(CH₃)₂), 1-butyl (n-Bu, n-butyl, -CH₂CH₂CH₂CH₃), 2-methyl-1-propyl (i-Bu, i-butyl, -CH₂CH(CH₃)₂), 2-butyl (s-Bu, s-butyl, -CH(CH₃)CH₂CH₃), 2-methyl-2-propyl (t-Bu, t-butyl, -C(CH₃)₃), 1-pentyl (n-pentyl, -CH₂CH₂CH₂CH₂CH₃), 2-pentyl (-CH(CH₃)CH₂CH₂CH₃), 3-pentyl (-CH(CH₂CH₃)₂), 2-methyl-2-butyl (-C(CH₃)₂CH₂CH₃), 3-methyl-2-butyl (-CH(CH₃)CH(CH₃)₂), 3-methyl-1-butyl (-CH₂CH₂CH(CH₃)₂), 2-methyl-1-butyl (-CH₂CH(CH₃)CH₂CH₃), 1-hexyl (-CH₂CH₂CH₂CH₂CH₂CH₃), 2-hexyl (-CH(CH₃)CH₂CH₂CH₂CH₃), 3-hexyl (-CH(CH₂CH₃)(CH₂CH₂CH₃)), 2-methyl-2-pentyl (-C(CH₃)₂CH₂CH₂CH₃), 3-methyl-2-pentyl (-CH(CH₃)CH(CH₃)CH₂CH₃), 4-methyl-2-pentyl (-CH(CH₃)CH₂CH(CH₃)₂), 3-

methyl-3-pentyl (-C(CH₃)(CH₂CH₃)₂), 2-methyl-3-pentyl (-CH(CH₂CH₃)CH(CH₃)₂), 2,3-dimethyl-2-butyl (-C(CH₃)₂CH(CH₃)₂), 3,3-dimethyl-2-butyl (-CH(CH₃)C(CH₃)₃).

[094] The term “C₁-C₈ alkyl,” as used herein refers to a straight chain or branched, saturated or unsaturated hydrocarbon having from 1 to 8 carbon atoms. Representative “C₁-C₈ alkyl” groups include, but are not limited to, -methyl, -ethyl, -n-propyl, -n-butyl, -n-pentyl, -n-hexyl, -n-heptyl, -n-octyl, -n-nonyl and -n-decyl; while branched C₁-C₈ alkyls include, but are not limited to, -isopropyl, -*sec*-butyl, -isobutyl, -*tert*-butyl, -isopentyl, 2-methylbutyl, unsaturated C₁-C₈ alkyls include, but are not limited to, -vinyl, -allyl, -1-butenyl, -2-butenyl, -isobutylene, -1-pentenyl, -2-pentenyl, -3-methyl-1-butenyl, -2-methyl-2-butenyl, -2,3-dimethyl-2-butenyl, 1-hexyl, 2-hexyl, 3-hexyl, -acetylenyl, -propynyl, -1-butyne, -2-butyne, -1-pentyne, -2-pentyne, -3-methyl-1-butyne. A C₁-C₈ alkyl group can be unsubstituted or substituted with one or more groups including, but not limited to, -C₁-C₈ alkyl, -O-(C₁-C₈ alkyl), -aryl, -C(O)R', -OC(O)R', -C(O)OR', -C(O)NH₂, -C(O)NHR', -C(O)N(R')₂, -NHC(O)R', -SO₃R', -S(O)₂R', -S(O)R', -OH, -halogen, -N₃, -NH₂, -NH(R'), -N(R')₂ and -CN; where each R' is independently selected from H, -C₁-C₈ alkyl and aryl.

[095] The term “C₁-C₁₂ alkyl,” as used herein refers to a straight chain or branched, saturated or unsaturated hydrocarbon having from 1 to 12 carbon atoms. A C₁-C₁₂ alkyl group can be unsubstituted or substituted with one or more groups including, but not limited to, -C₁-C₈ alkyl, -O-(C₁-C₈ alkyl), -aryl, -C(O)R', -OC(O)R', -C(O)OR', -C(O)NH₂, -C(O)NHR', -C(O)N(R')₂, -NHC(O)R', -SO₃R', -S(O)₂R', -S(O)R', -OH, -halogen, -N₃, -NH₂, -NH(R'), -N(R')₂ and -CN; where each R' is independently selected from H, -C₁-C₈ alkyl and aryl.

[096] The term “C₁-C₆ alkyl,” as used herein refers to a straight chain or branched, saturated or unsaturated hydrocarbon having from 1 to 6 carbon atoms. Representative “C₁-C₆ alkyl” groups include, but are not limited to, -methyl, -ethyl, -n-propyl, -n-butyl, -n-pentyl, -n-hexyl; while branched C₁-C₆ alkyls include, but are not limited to, -isopropyl, -*sec*-butyl, -isobutyl, -*tert*-butyl, -isopentyl, and 2-methylbutyl; unsaturated C₁-C₆ alkyls include, but are not limited to, -vinyl, -allyl, -1-butenyl, -2-butenyl, and -isobutylene, -1-pentenyl, -2-pentenyl, -3-methyl-1-butenyl, -2-methyl-2-butenyl, -2,3-dimethyl-2-butenyl, 1-hexyl, 2-hexyl, and 3-hexyl. A C₁-C₆ alkyl group can be unsubstituted or substituted with one or more groups, as described above for C₁-C₈ alkyl group.

[097] The term “C₁-C₄ alkyl,” as used herein refers to a straight chain or branched, saturated or unsaturated hydrocarbon having from 1 to 4 carbon atoms. Representative “C₁-C₄ alkyl” groups include, but are not limited to, -methyl, -ethyl, -n-propyl, -n-butyl; while branched C₁-C₄ alkyls include, but are not limited to, -isopropyl, -*sec*-butyl, -isobutyl, -

tert-butyl; unsaturated C₁-C₄ alkyls include, but are not limited to, -vinyl, -allyl, -1-butenyl, -2-butenyl, and -isobutylene. A C₁-C₄ alkyl group can be unsubstituted or substituted with one or more groups, as described above for C₁-C₈ alkyl group.

[0098] “Alkoxy” is an alkyl group singly bonded to an oxygen. Exemplary alkoxy groups include, but are not limited to, methoxy (-OCH₃) and ethoxy (-OCH₂CH₃). A “C₁-C₅ alkoxy” is an alkoxy group with 1 to 5 carbon atoms. Alkoxy groups may be unsubstituted or substituted with one or more groups, as described above for alkyl groups.

[0099] “Alkenyl” is C₂-C₁₈ hydrocarbon containing normal, secondary, tertiary or cyclic carbon atoms with at least one site of unsaturation, i.e. a carbon-carbon, *sp*² double bond. Examples include, but are not limited to: ethylene or vinyl (-CH=CH₂), allyl (-CH₂CH=CH₂), cyclopentenyl (-C₅H₇), and 5-hexenyl (-CH₂CH₂CH₂CH₂CH=CH₂). A “C₂-C₈ alkenyl” is a hydrocarbon containing 2 to 8 normal, secondary, tertiary or cyclic carbon atoms with at least one site of unsaturation, i.e. a carbon-carbon, *sp*² double bond.

[0100] “Alkynyl” is C₂-C₁₈ hydrocarbon containing normal, secondary, tertiary or cyclic carbon atoms with at least one site of unsaturation, i.e. a carbon-carbon, *sp* triple bond. Examples include, but are not limited to: acetylenic (-C≡CH) and propargyl (-CH₂C≡CH). A “C₂-C₈ alkynyl” is a hydrocarbon containing 2 to 8 normal, secondary, tertiary or cyclic carbon atoms with at least one site of unsaturation, i.e. a carbon-carbon, *sp* triple bond.

[0101] “Alkylene” refers to a saturated, branched or straight chain or cyclic hydrocarbon radical of 1-18 carbon atoms, and having two monovalent radical centers derived by the removal of two hydrogen atoms from the same or two different carbon atoms of a parent alkane. Typical alkylene radicals include, but are not limited to: methylene (-CH₂-), 1,2-ethyl (-CH₂CH₂-), 1,3-propyl (-CH₂CH₂CH₂-), 1,4-butyl (-CH₂CH₂CH₂CH₂-), and the like.

[0102] A “C₁-C₁₀ alkylene” is a straight chain, saturated hydrocarbon group of the formula -(CH₂)₁₋₁₀-. Examples of a C₁-C₁₀ alkylene include methylene, ethylene, propylene, butylene, pentylene, hexylene, heptylene, octylene, nonylene and decalene.

[0103] “Alkenylene” refers to an unsaturated, branched or straight chain or cyclic hydrocarbon radical of 2-18 carbon atoms, and having two monovalent radical centers derived by the removal of two hydrogen atoms from the same or two different carbon atoms of a parent alkene. Typical alkenylene radicals include, but are not limited to: 1,2-ethylene (-CH=CH-).


[0104] “Alkynylene” refers to an unsaturated, branched or straight chain or cyclic hydrocarbon radical of 2-18 carbon atoms, and having two monovalent radical centers derived by the removal of two hydrogen atoms from the same or two different carbon atoms of a parent

alkyne. Typical alkynylene radicals include, but are not limited to: acetylene ($-\text{C}\equiv\text{C}-$), propargyl ($-\text{CH}_2\text{C}\equiv\text{C}-$), and 4-pentynyl ($-\text{CH}_2\text{CH}_2\text{CH}_2\text{C}\equiv\text{C}-$).

[0105] “Aryl” refers to a carbocyclic aromatic group. Examples of aryl groups include, but are not limited to, phenyl, naphthyl and anthracenyl. A carbocyclic aromatic group or a heterocyclic aromatic group can be unsubstituted or substituted with one or more groups including, but not limited to, $-\text{C}_1\text{-C}_8$ alkyl, $-\text{O}-(\text{C}_1\text{-C}_8 \text{ alkyl})$, $-\text{aryl}$, $-\text{C}(\text{O})\text{R}'$, $-\text{OC}(\text{O})\text{R}'$, $-\text{C}(\text{O})\text{OR}'$, $-\text{C}(\text{O})\text{NH}_2$, $-\text{C}(\text{O})\text{NHR}'$, $-\text{C}(\text{O})\text{N}(\text{R}')_2$, $-\text{NHC}(\text{O})\text{R}'$, $-\text{S}(\text{O})_2\text{R}'$, $-\text{S}(\text{O})\text{R}'$, $-\text{OH}$, $-\text{halogen}$, $-\text{N}_3$, $-\text{NH}_2$, $-\text{NH}(\text{R}')$, $-\text{N}(\text{R}')_2$ and $-\text{CN}$; wherein each R' is independently selected from H , $-\text{C}_1\text{-C}_8$ alkyl and aryl.

[0106] A “ $\text{C}_5\text{-C}_{20}$ aryl” is an aryl group with 5 to 20 carbon atoms in the carbocyclic aromatic rings. Examples of $\text{C}_5\text{-C}_{20}$ aryl groups include, but are not limited to, phenyl, naphthyl and anthracenyl. A $\text{C}_5\text{-C}_{20}$ aryl group can be substituted or unsubstituted as described above for aryl groups. A “ $\text{C}_5\text{-C}_{14}$ aryl” is an aryl group with 5 to 14 carbon atoms in the carbocyclic aromatic rings. Examples of $\text{C}_5\text{-C}_{14}$ aryl groups include, but are not limited to, phenyl, naphthyl and anthracenyl. A $\text{C}_5\text{-C}_{14}$ aryl group can be substituted or unsubstituted as described above for aryl groups.

[0107] An “arylene” is an aryl group which has two covalent bonds and can be in the ortho, meta, or para configurations as shown in the following structures:



in which the phenyl group can be unsubstituted or substituted with up to four groups including, but not limited to, $-\text{C}_1\text{-C}_8$ alkyl, $-\text{O}-(\text{C}_1\text{-C}_8 \text{ alkyl})$, $-\text{aryl}$, $-\text{C}(\text{O})\text{R}'$, $-\text{OC}(\text{O})\text{R}'$, $-\text{C}(\text{O})\text{OR}'$, $-\text{C}(\text{O})\text{NH}_2$, $-\text{C}(\text{O})\text{NHR}'$, $-\text{C}(\text{O})\text{N}(\text{R}')_2$, $-\text{NHC}(\text{O})\text{R}'$, $-\text{S}(\text{O})_2\text{R}'$, $-\text{S}(\text{O})\text{R}'$, $-\text{OH}$, $-\text{halogen}$, $-\text{N}_3$, $-\text{NH}_2$, $-\text{NH}(\text{R}')$, $-\text{N}(\text{R}')_2$ and $-\text{CN}$; wherein each R' is independently selected from H , $-\text{C}_1\text{-C}_8$ alkyl and aryl.

[0108] “Arylalkyl” refers to an acyclic alkyl radical in which one of the hydrogen atoms bonded to a carbon atom, typically a terminal or sp^3 carbon atom, is replaced with an aryl radical. Typical arylalkyl groups include, but are not limited to, benzyl, 2-phenylethan-1-yl, 2-phenylethen-1-yl, naphthylmethyl, 2-naphthylethan-1-yl, 2-naphthylethen-1-yl, naphthobenzyl, 2-naphthophenylethan-1-yl and the like. The arylalkyl group comprises 6 to 20 carbon atoms, e.g. the alkyl moiety, including alkanyl, alkenyl or alkynyl groups, of the arylalkyl group is 1 to 6 carbon atoms and the aryl moiety is 5 to 14 carbon atoms.

[0109] "Heteroarylalkyl" refers to an acyclic alkyl radical in which one of the hydrogen atoms bonded to a carbon atom, typically a terminal or sp^3 carbon atom, is replaced with a heteroaryl radical. Typical heteroarylalkyl groups include, but are not limited to, 2-benzimidazolylmethyl, 2-furylethyl, and the like. The heteroarylalkyl group comprises 6 to 20 carbon atoms, e.g. the alkyl moiety, including alkanyl, alkenyl or alkynyl groups, of the heteroarylalkyl group is 1 to 6 carbon atoms and the heteroaryl moiety is 5 to 14 carbon atoms and 1 to 3 heteroatoms selected from N, O, P, and S. The heteroaryl moiety of the heteroarylalkyl group may be a monocycle having 3 to 7 ring members (2 to 6 carbon atoms or a bicycle having 7 to 10 ring members (4 to 9 carbon atoms and 1 to 3 heteroatoms selected from N, O, P, and S), for example: a bicyclo [4,5], [5,5], [5,6], or [6,6] system.

[0110] "Substituted alkyl," "substituted aryl," and "substituted arylalkyl" mean alkyl, aryl, and arylalkyl respectively, in which one or more hydrogen atoms are each independently replaced with a substituent. Typical substituents include, but are not limited to, -X, -R, -O⁻, -OR, -SR, -S⁻, -NR₂, -NR₃, =NR, -CX₃, -CN, -OCN, -SCN, -N=C=O, -NCS, -NO, -NO₂, =N₂, -N₃, NC(=O)R, -C(=O)R, -C(=O)NR₂, -SO₃⁻, -SO₃H, -S(=O)₂R, -OS(=O)₂OR, -S(=O)₂NR, -S(=O)R, -OP(=O)(OR)₂, -P(=O)(OR)₂, -PO⁻₃, -PO₃H₂, -C(=O)R, -C(=O)X, -C(=S)R, -CO₂R, -CO₂⁻, -C(=S)OR, -C(=O)SR, -C(=S)SR, -C(=O)NR₂, -C(=S)NR₂, -C(=NR)NR₂, where each X is independently a halogen: F, Cl, Br, or I; and each R is independently -H, C₂-C₁₈ alkyl, C₆-C₂₀ aryl, C₃-C₁₄ heterocycle, protecting group or prodrug moiety. Alkylene, alkenylene, and alkynylene groups as described above may also be similarly substituted.

[0111] "Heteroaryl" and "heterocycle" refer to a ring system in which one or more ring atoms is a heteroatom, e.g. nitrogen, oxygen, and sulfur. The heterocycle radical comprises 3 to 20 carbon atoms and 1 to 3 heteroatoms selected from N, O, P, and S. A heterocycle may be a monocycle having 3 to 7 ring members (2 to 6 carbon atoms and 1 to 3 heteroatoms selected from N, O, P, and S) or a bicycle having 7 to 10 ring members (4 to 9 carbon atoms and 1 to 3 heteroatoms selected from N, O, P, and S), for example: a bicyclo [4,5], [5,5], [5,6], or [6,6] system.

[0112] Exemplary heterocycles are described, e.g., in Paquette, Leo A., "Principles of Modern Heterocyclic Chemistry" (W.A. Benjamin, New York, 1968), particularly Chapters 1, 3, 4, 6, 7, and 9; "The Chemistry of Heterocyclic Compounds, A series of Monographs" (John Wiley & Sons, New York, 1950 to present), in particular Volumes 13, 14, 16, 19, and 28; and *J. Am. Chem. Soc.* (1960) 82:5566.

[0113] Examples of heterocycles include by way of example and not limitation pyridyl, dihydropyridyl, tetrahydropyridyl (piperidyl), thiazolyl, tetrahydrothiophenyl, sulfur oxidized

tetrahydrothiophenyl, pyrimidinyl, furanyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, tetrazolyl, benzofuranyl, thianaphthalenyl, indolyl, indolenyl, quinolinyl, isoquinolinyl, benzimidazolyl, piperidinyl, 4-piperidonyl, pyrrolidinyl, 2-pyrrolidonyl, pyrrolinyl, tetrahydrofuranyl, bis-tetrahydrofuranyl, tetrahydropyranyl, bis-tetrahydropyranyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, decahydroquinolinyl, octahydroisoquinolinyl, azocinyl, triazinyl, 6H-1,2,5-thiadiazinyl, 2H,6H-1,5,2-dithiazinyl, thienyl, thianthrenyl, pyranlyl, isobenzofuranyl, chromenyl, xanthenyl, phenoxathinyl, 2H-pyrrolyl, isothiazolyl, isoxazolyl, pyrazinyl, pyridazinyl, indoliziny, isoindolyl, 3H-indolyl, 1H-indazolyl, purinyl, 4H-quinoliziny, phthalazinyl, naphthyridinyl, quinoxalinyl, quinazolinyl, cinnoliny, pteridinyl, 4aH-carbazolyl, carbazolyl, β -carbolinyl, phenanthridinyl, acridinyl, pyrimidinyl, phenanthrolinyl, phenazinyl, phenothiazinyl, furazanyl, phenoxazinyl, isochromanyl, chromanyl, imidazolidinyl, imidazoliny, pyrazolidinyl, pyrazoliny, piperazinyl, indoliny, isoindoliny, quinuclidinyl, morpholiny, oxazolidinyl, benzotriazolyl, benzisoxazolyl, oxindolyl, benzoxazoliny, and isatinoyl.

[0114] By way of example and not limitation, carbon bonded heterocycles are bonded at position 2, 3, 4, 5, or 6 of a pyridine, position 3, 4, 5, or 6 of a pyridazine, position 2, 4, 5, or 6 of a pyrimidine, position 2, 3, 5, or 6 of a pyrazine, position 2, 3, 4, or 5 of a furan, tetrahydrofuran, thiofuran, thiophene, pyrrole or tetrahydropyrrole, position 2, 4, or 5 of an oxazole, imidazole or thiazole, position 3, 4, or 5 of an isoxazole, pyrazole, or isothiazole, position 2 or 3 of an aziridine, position 2, 3, or 4 of an azetidine, position 2, 3, 4, 5, 6, 7, or 8 of a quinoline or position 1, 3, 4, 5, 6, 7, or 8 of an isoquinoline. Still more typically, carbon bonded heterocycles include 2-pyridyl, 3-pyridyl, 4-pyridyl, 5-pyridyl, 6-pyridyl, 3-pyridazinyl, 4-pyridazinyl, 5-pyridazinyl, 6-pyridazinyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, 6-pyrimidinyl, 2-pyrazinyl, 3-pyrazinyl, 5-pyrazinyl, 6-pyrazinyl, 2-thiazolyl, 4-thiazolyl, or 5-thiazolyl.

[0115] By way of example and not limitation, nitrogen bonded heterocycles are bonded at position 1 of an aziridine, azetidine, pyrrole, pyrrolidine, 2-pyrroline, 3-pyrroline, imidazole, imidazolidine, 2-imidazoline, 3-imidazoline, pyrazole, pyrazoline, 2-pyrazoline, 3-pyrazoline, piperidine, piperazine, indole, indoline, 1H-indazole, position 2 of a isoindole, or isoindoline, position 4 of a morpholine, and position 9 of a carbazole, or β -carboline. Still more typically, nitrogen bonded heterocycles include 1-aziridyl, 1-azetedy, 1-pyrrolyl, 1-imidazolyl, 1-pyrazolyl, and 1-piperidinyl.

[0116] A "C₃-C₈ heterocycle" refers to an aromatic or non-aromatic C₃-C₈ carbocycle in which one to four of the ring carbon atoms are independently replaced with a heteroatom from the group consisting of O, S and N. Representative examples of a C₃-C₈ heterocycle

include, but are not limited to, benzofuranyl, benzothiophene, indolyl, benzopyrazolyl, coumarinyl, isoquinolinyl, pyrrolyl, thiophenyl, furanyl, thiazolyl, imidazolyl, pyrazolyl, triazolyl, quinolinyl, pyrimidinyl, pyridinyl, pyridonyl, pyrazinyl, pyridazinyl, isothiazolyl, isoxazolyl and tetrazolyl. A C₃-C₈ heterocycle can be unsubstituted or substituted with up to seven groups including, but not limited to, -C₁-C₈ alkyl, -O-(C₁-C₈ alkyl), -aryl, -C(O)R', -OC(O)R', -C(O)OR', -C(O)NH₂, -C(O)NHR', -C(O)N(R')₂, -NHC(O)R', -S(O)₂R', -S(O)R', -OH, -halogen, -N₃, -NH₂, -NH(R'), -N(R')₂ and -CN; wherein each R' is independently selected from H, -C₁-C₈ alkyl and aryl.

[0117] "C₃-C₈ heterocyclo" refers to a C₃-C₈ heterocycle group defined above wherein one of the heterocycle group's hydrogen atoms is replaced with a bond. A C₃-C₈ heterocyclo can be unsubstituted or substituted with up to six groups including, but not limited to, -C₁-C₈ alkyl, -O-(C₁-C₈ alkyl), -aryl, -C(O)R', -OC(O)R', -C(O)OR', -C(O)NH₂, -C(O)NHR', -C(O)N(R')₂, -NHC(O)R', -S(O)₂R', -S(O)R', -OH, -halogen, -N₃, -NH₂, -NH(R'), -N(R')₂ and -CN; wherein each R' is independently selected from H, -C₁-C₈ alkyl and aryl.

[0118] A "C₃-C₂₀ heterocycle" refers to an aromatic or non-aromatic C₃-C₈ carbocycle in which one to four of the ring carbon atoms are independently replaced with a heteroatom from the group consisting of O, S and N. A C₃-C₂₀ heterocycle can be unsubstituted or substituted with up to seven groups including, but not limited to, -C₁-C₈ alkyl, -O-(C₁-C₈ alkyl), -aryl, -C(O)R', -OC(O)R', -C(O)OR', -C(O)NH₂, -C(O)NHR', -C(O)N(R')₂, -NHC(O)R', -S(O)₂R', -S(O)R', -OH, -halogen, -N₃, -NH₂, -NH(R'), -N(R')₂ and -CN; wherein each R' is independently selected from H, -C₁-C₈ alkyl and aryl.

[0119] "C₃-C₂₀ heterocyclo" refers to a C₃-C₂₀ heterocycle group defined above wherein one of the heterocycle group's hydrogen atoms is replaced with a bond.

[0120] "Carbocycle" means a saturated or unsaturated ring having 3 to 7 carbon atoms as a monocycle or 7 to 12 carbon atoms as a bicycle. Monocyclic carbocycles have 3 to 6 ring atoms, still more typically 5 or 6 ring atoms. Bicyclic carbocycles have 7 to 12 ring atoms, e.g. arranged as a bicyclo [4,5], [5,5], [5,6] or [6,6] system, or 9 or 10 ring atoms arranged as a bicyclo [5,6] or [6,6] system. Examples of monocyclic carbocycles include cyclopropyl, cyclobutyl, cyclopentyl, 1-cyclopent-1-enyl, 1-cyclopent-2-enyl, 1-cyclopent-3-enyl, cyclohexyl, 1-cyclohex-1-enyl, 1-cyclohex-2-enyl, 1-cyclohex-3-enyl, cycloheptyl, and cyclooctyl.

[0121] A "C₃-C₈ carbocycle" is a 3-, 4-, 5-, 6-, 7- or 8-membered saturated or unsaturated non-aromatic carbocyclic ring. Representative C₃-C₈ carbocycles include, but are not limited to, -cyclopropyl, -cyclobutyl, -cyclopentyl, -cyclopentadienyl, -cyclohexyl, -cyclohexenyl, -1,3-cyclohexadienyl, -1,4-cyclohexadienyl, -cycloheptyl, -1,3-

cycloheptadienyl, -1,3,5-cycloheptatrienyl, -cyclooctyl, and -cyclooctadienyl. A C₃-C₈ carbocycle group can be unsubstituted or substituted with one or more groups including, but not limited to, -C₁-C₈ alkyl, -O-(C₁-C₈ alkyl), -aryl, -C(O)R', -OC(O)R', -C(O)OR', -C(O)NH₂, -C(O)NHR', -C(O)N(R')₂, -NHC(O)R', -S(O)₂R', -S(O)R', -OH, -halogen, -N₃, -NH₂, -NH(R'), -N(R')₂ and -CN; where each R' is independently selected from H, -C₁-C₈ alkyl and aryl.

[0122] A "C₃-C₈ carbocyclo" refers to a C₃-C₈ carbocycle group defined above wherein one of the carbocycle groups' hydrogen atoms is replaced with a bond.

[0123] "Linker" refers to a chemical moiety comprising a covalent bond or a chain of atoms that covalently attaches an antibody to a drug moiety. In various embodiments, linkers include a divalent radical such as an alkylidyl, an arylidyl, a heteroarylidyl, moieties such as: -(CR₂)_nO(CR₂)_n-, repeating units of alkyloxy (e.g. polyethylenoxy, PEG, polymethyleneoxy) and alkylamino (e.g. polyethyleneamino, JeffamineTM); and diacid ester and amides including succinate, succinamide, diglycolate, malonate, and caproamide. In various embodiments, linkers can comprise one or more amino acid residues, such as valine, phenylalanine, lysine, and homolysine.

[0124] The term "chiral" refers to molecules which have the property of non-superimposability of the mirror image partner, while the term "achiral" refers to molecules which are superimposable on their mirror image partner.

[0125] The term "stereoisomers" refers to compounds which have identical chemical constitution, but differ with regard to the arrangement of the atoms or groups in space.

[0126] "Diastereomer" refers to a stereoisomer with two or more centers of chirality and whose molecules are not mirror images of one another. Diastereomers have different physical properties, e.g. melting points, boiling points, spectral properties, and reactivities. Mixtures of diastereomers may separate under high resolution analytical procedures such as electrophoresis and chromatography.

[0127] "Enantiomers" refer to two stereoisomers of a compound which are non-superimposable mirror images of one another.

[0128] Stereochemical definitions and conventions used herein generally follow S. P. Parker, Ed., *McGraw-Hill Dictionary of Chemical Terms* (1984) McGraw-Hill Book Company, New York; and Eliel, E. and Wilen, S., *Stereochemistry of Organic Compounds* (1994) John Wiley & Sons, Inc., New York. Many organic compounds exist in optically active forms, i.e., they have the ability to rotate the plane of plane-polarized light. In describing an optically active compound, the prefixes D and L, or R and S, are used to denote the absolute

configuration of the molecule about its chiral center(s). The prefixes d and l or (+) and (-) are employed to designate the sign of rotation of plane-polarized light by the compound, with (-) or l meaning that the compound is levorotatory. A compound prefixed with (+) or d is dextrorotatory. For a given chemical structure, these stereoisomers are identical except that they are mirror images of one another. A specific stereoisomer may also be referred to as an enantiomer, and a mixture of such isomers is often called an enantiomeric mixture. A 50:50 mixture of enantiomers is referred to as a racemic mixture or a racemate, which may occur where there has been no stereoselection or stereospecificity in a chemical reaction or process. The terms "racemic mixture" and "racemate" refer to an equimolar mixture of two enantiomeric species, devoid of optical activity.

[0129] "Leaving group" refers to a functional group that can be substituted by another functional group. Certain leaving groups are well known in the art, and examples include, but are not limited to, a halide (*e.g.*, chloride, bromide, iodide), methanesulfonyl (mesyl), p-toluenesulfonyl (tosyl), trifluoromethylsulfonyl (triflate), and trifluoromethylsulfonate.

[0130] The term "protecting group" refers to a substituent that is commonly employed to block or protect a particular functionality while reacting other functional groups on the compound. For example, an "amino-protecting group" is a substituent attached to an amino group that blocks or protects the amino functionality in the compound. Suitable amino-protecting groups include, but are not limited to, acetyl, trifluoroacetyl, t-butoxycarbonyl (BOC), benzyloxycarbonyl (CBZ) and 9-fluorenylmethylenoxycarbonyl (Fmoc). For a general description of protecting groups and their use, see T. W. Greene, *Protective Groups in Organic Synthesis*, John Wiley & Sons, New York, 1991, or a later edition.

II. COMPOSITIONS AND METHODS

[0131] In one aspect, the invention is based, in part, on antibodies that bind to PMEL17 and immunoconjugates comprising such antibodies. Antibodies and immunoconjugates of the invention are useful, *e.g.*, for the diagnosis or treatment of PMEL17-positive cancers.

A. Exemplary Anti-PMEL17 Antibodies

[0132] In some embodiments, the invention provides isolated antibodies that bind to PMEL17. PMEL17 is an integral membrane protein that is presented transiently at the cell surface of melanocytes. As demonstrated herein, PMEL17 is expressed in the majority of human melanoma specimens examined.

[0133] An exemplary naturally occurring human PMEL17 preproprotein sequence, with signal sequence (amino acids 1-24) is provided in SEQ ID NO: 26, and the corresponding

PMEL17 proprotein sequence is shown in SEQ ID NO: 27 (corresponding to amino acids 25-661 of SEQ ID NO: 26).

[0134] In certain embodiments, an anti-PMEL17 antibody binds an epitope within amino acids 105 to 125 of SEQ ID NO: 26, or binds to an epitope within amino acids 25 to 45 of SEQ ID NO: 26. Nonlimiting exemplary such antibodies include 17A9, 8G3, and 31D1. In some embodiments, an anti-PMEL17 antibody binds human PMEL17. In some embodiments, an anti-PMEL17 antibody binds PMEL selected from human, cynomolgus monkey, mouse, and rat PMEL17.

[0135] In some embodiments, an anti-PMEL17 antibody binds to an epitope within amino acids 105 to 125 of SEQ ID NO: 26. In some such embodiments, the anti-PMEL17 antibody binds PMEL17 with an affinity of ≤ 5 nM, or ≤ 4 nM, or ≤ 3 nM, or ≤ 2 nM, or ≤ 1 nM, and optionally ≥ 0.0001 nM, or ≥ 0.001 nM, or ≥ 0.01 nM. Nonlimiting exemplary such antibodies include 17A9 and 8G3, described herein. In some embodiments, an anti-PMEL17 antibody that binds to an epitope within amino acids 105 to 125 of SEQ ID NO: 26 binds to human PMEL17. In some embodiments, an anti-PMEL17 antibody that binds to an epitope within amino acids 105 to 125 of SEQ ID NO: 26 binds to human PMEL17 and/or cynomolgus monkey PMEL17.

[0136] In some embodiments, an anti-PMEL17 antibody binds to an epitope within amino acids 25 to 45 of SEQ ID NO: 26. In some such embodiments, the anti-PMEL17 antibody binds PMEL17 with an affinity of ≤ 5 nM, or ≤ 4 nM, or ≤ 3 nM, or ≤ 2 nM, or ≤ 1 nM, and optionally ≥ 0.0001 nM, or ≥ 0.001 nM, or ≥ 0.01 nM. A nonlimiting exemplary such antibody is 31D1, described herein. In some embodiments, an anti-PMEL17 antibody that binds to an epitope within amino acids 25 to 45 of SEQ ID NO: 26 binds to human PMEL17. In some embodiments, an anti-PMEL17 antibody that binds to an epitope within amino acids 105 to 125 of SEQ ID NO: 26 binds to human PMEL17 and/or cynomolgus monkey PMEL17.

[0137] Further antibodies that bind PMEL17 are provided. A nonlimiting exemplary anti-PMEL17 antibody is 15F2, described herein. In some embodiments, the anti-PMEL17 antibody binds PMEL17 with an affinity of ≤ 5 nM, or ≤ 4 nM, or ≤ 3 nM, or ≤ 2 nM, or ≤ 1 nM, and optionally ≥ 0.0001 nM, or ≥ 0.001 nM, or ≥ 0.01 nM. In some embodiments, an anti-PMEL17 antibody binds to human PMEL17. In some embodiments, an anti-PMEL17 antibody binds to human PMEL17 and/or cynomolgus monkey PMEL17.

Assays

[0138] To determine whether an anti-PMEL17 antibody “binds to an epitope within amino acids 105 to 125 of SEQ ID NO: 26” or “binds to an epitope within amino acids 25 to 45 of SEQ ID NO: 26,” PMEL17 polypeptides with N- and C-terminal deletions are expressed

in 293 cells and binding of the antibody to the truncated polypeptides is tested by FACS as described in Example D, wherein a substantial reduction ($\geq 70\%$ reduction) or elimination of binding of the antibody to a truncated polypeptide relative to binding to full-length PMEL17 expressed in 293 cells indicates that the antibody does not bind to that truncated polypeptide.

[0139] Whether an anti-PMEL17 antibody “binds with an affinity of ≤ 5 nM, or ≤ 4 nM, or ≤ 3 nM, or ≤ 2 nM, or ≤ 1 nM,” is determined according to a BIAcore[®] assay. For example, K_d is measured using surface plasmon resonance assays using a BIAcore[®]-3000 (BIAcore, Inc., Piscataway, NJ). BIAcore[™] research grade CM5 chips are activated with 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) and N-hydroxysuccinimide (NHS) reagents according to the supplier’s instructions. Goat anti-human Fc IgGs are coupled to the chips to achieve approximately 10,000 response units (RU) in each flow cell. Unreacted coupling groups are blocked with 1M ethanolamine. For kinetics measurements, anti-PMEL17 antibodies are captured to achieve approximately 300 RU. Two-fold serial dilutions of human PMEL17 ECD (for example, amino acids 25 to 291 fused to a C-terminal Fc expressed in a baculovirus system, or amino acids 22-558 fused to Fc; 125 nM to 0.49 nM) are injected in HBS-P buffer (0.01M HEPES pH7.4, 0.15M NaCl, 0.005% surfactant P20) at 25°C with a flow rate of 30 μ l/min. Association rates (k_{on}) and dissociation rates (k_{off}) are calculated using a 1:1 Langmuir binding model (BIAcore[™] Evaluation Software version 3.2). The equilibrium dissociation constant (K_d) is calculated as the ratio k_{off}/k_{on} . If the on-rate exceeds $10^6 \text{ M}^{-1} \text{ s}^{-1}$ by the surface plasmon resonance assay above, then the on-rate can be determined by using a fluorescent quenching technique that measures the increase or decrease in fluorescence emission intensity (excitation = 295 nm; emission = 340 nm, 16 nm band-pass) at 25°C of a 20 nM anti-antigen antibody (Fab form) in PBS, pH 7.2, in the presence of increasing concentrations of antigen as measured in a spectrometer, such as a stop-flow equipped spectrophotometer (Aviv Instruments) or a 8000-series SLM-Aminco[®] spectrophotometer (ThermoSpectronic) with a stirred cuvette.

Antibody 17A9 and other embodiments

[0140] In some embodiments, the invention provides an anti-PMEL17 antibody comprising at least one, two, three, four, five, or six HVRs selected from (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 3; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 4; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 5; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 6; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 7; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 8.

[0141] In one aspect, the invention provides an antibody comprising at least one, at least two, or all three VH HVR sequences selected from (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 3; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 4; and (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 5. In one embodiment, the antibody comprises HVR-H3 comprising the amino acid sequence of SEQ ID NO: 5. In another embodiment, the antibody comprises HVR-H3 comprising the amino acid sequence of SEQ ID NO: 5 and HVR-L3 comprising the amino acid sequence of SEQ ID NO: 8. In a further embodiment, the antibody comprises HVR-H3 comprising the amino acid sequence of SEQ ID NO: 5, HVR-L3 comprising the amino acid sequence of SEQ ID NO: 8, and HVR-H2 comprising the amino acid sequence of SEQ ID NO: 4. In a further embodiment, the antibody comprises (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 3; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 4; and (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 5.

[0142] In another aspect, the invention provides an antibody comprising at least one, at least two, or all three VL HVR sequences selected from (a) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 6; (b) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 7; and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 8. In one embodiment, the antibody comprises (a) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 6; (b) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 7; and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 8.

[0143] In another aspect, an antibody of the invention comprises (a) a VH domain comprising at least one, at least two, or all three VH HVR sequences selected from (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 3, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 4, and (iii) HVR-H3 comprising an amino acid sequence selected from SEQ ID NO: 5; and (b) a VL domain comprising at least one, at least two, or all three VL HVR sequences selected from (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 6, (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 7, and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 8.

[0144] In another aspect, the invention provides an antibody comprising (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 3; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 4; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 5; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 6; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 7; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 8.

[0145] In some embodiments, the invention provides an anti-PMEL17 antibody comprising at least one, two, three, four, five, or six HVRs selected from (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 17; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 18; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 5; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 19; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 7; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 8.

[0146] In one aspect, the invention provides an antibody comprising at least one, at least two, or all three VH HVR sequences selected from (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 17; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 18; and (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 5. In a further embodiment, the antibody comprises HVR-H3 comprising the amino acid sequence of SEQ ID NO: 5, HVR-L3 comprising the amino acid sequence of SEQ ID NO: 8, and HVR-H2 comprising the amino acid sequence of SEQ ID NO: 18. In a further embodiment, the antibody comprises (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 17; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 18; and (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 5.

[0147] In another aspect, the invention provides an antibody comprising at least one, at least two, or all three VL HVR sequences selected from (a) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 19; (b) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 7; and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 8. In one embodiment, the antibody comprises (a) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 19; (b) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 7; and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 8.

[0148] In another aspect, an antibody of the invention comprises (a) a VH domain comprising at least one, at least two, or all three VH HVR sequences selected from (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 17, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 18, and (iii) HVR-H3 comprising an amino acid sequence selected from SEQ ID NO: 5; and (b) a VL domain comprising at least one, at least two, or all three VL HVR sequences selected from (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 19, (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 7, and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 8.

[0149] In another aspect, the invention provides an antibody comprising (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 17; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 18; (c) HVR-H3 comprising the amino acid sequence of SEQ ID

NO: 5; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 19; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 7; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 8.

[0150] In some embodiments, X_1 in SEQ ID NO: 17 is selected from Arg, Lys, Gln, Asn, Gly, and Ala. In some embodiments, X_1 in SEQ ID NO: 17 is selected from Arg, Lys, Gly, and Ala. In some embodiments, X_1 in SEQ ID NO: 17 is selected from Arg and Gly. In some embodiments, X_2 in SEQ ID NO: 18 is selected from Tyr, Trp, Phe, Thr, Ser, Ile, Leu, Val, Met, Ala, and Norleucine. In some embodiments, X_2 in SEQ ID NO: 18 is selected from Tyr, Phe, Ile, Leu, and Val. In some embodiments, X_2 in SEQ ID NO: 18 is selected from Tyr and Ile. In some embodiments, X_3 in SEQ ID NO: 19 is selected from Ser, Thr, and Val. In some embodiments, X_3 in SEQ ID NO: 19 is selected from Ser and Thr. In some embodiments, X_4 in SEQ ID NO: 19 is selected from Ser, Thr, and Val. In some embodiments, X_4 in SEQ ID NO: 19 is selected from Ser and Thr.

[0151] In any of the above embodiments, an anti-PMEL17 antibody is humanized. In one embodiment, an anti-PMEL17 antibody comprises HVRs as in any of the above embodiments, and further comprises a human acceptor framework, e.g. a human immunoglobulin framework or a human consensus framework. In certain embodiments, the human acceptor framework is the human VL kappa 1 (VL_{K1}) framework and/or the VH framework VH₁. In some embodiments, a humanized anti-PMEL17 antibody comprises (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 3; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 4; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 5; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 6; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 7; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 8. In some embodiments, a humanized anti-PMEL17 antibody comprises (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 17; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 18; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 5; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 19; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 7; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 8.

[0152] In another aspect, an anti-PMEL17 antibody comprises a heavy chain variable domain (VH) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 1 or 50. In certain embodiments, a VH sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the amino acid sequence of SEQ ID NO: 1 or 50 contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but

an anti-PMEL17 antibody comprising that sequence retains the ability to bind to PMEL17. In certain embodiments, a total of 1 to 10 amino acids have been substituted, inserted and/or deleted in SEQ ID NO: 1 or 50. In certain embodiments, a total of 1 to 5 amino acids have been substituted, inserted and/or deleted in SEQ ID NO: 1 or 50. In certain embodiments, substitutions, insertions, or deletions occur in regions outside the HVRs (i.e., in the FRs). Optionally, the anti-PMEL17 antibody comprises the VH sequence of SEQ ID NO: 1 or 50, including post-translational modifications of that sequence. In a particular embodiment, the VH comprises one, two or three HVRs selected from: (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 3, (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 4, and (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 5. In some embodiments, the VH comprises one, two or three HVRs selected from: (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 17, (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 18, and (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 5.

[0153] In some embodiments, an anti-PMEL17 antibody is provided, wherein the antibody comprises a light chain variable domain (VL) having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 2. In certain embodiments, a VL sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the amino acid sequence of SEQ ID NO: 2 contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti-PMEL17 antibody comprising that sequence retains the ability to bind to PMEL17. In certain embodiments, a total of 1 to 10 amino acids have been substituted, inserted and/or deleted in SEQ ID NO: 2. In certain embodiments, a total of 1 to 5 amino acids have been substituted, inserted and/or deleted in SEQ ID NO: 2. In certain embodiments, the substitutions, insertions, or deletions occur in regions outside the HVRs (i.e., in the FRs). Optionally, the anti-PMEL17 antibody comprises the VL sequence of SEQ ID NO: 2, including post-translational modifications of that sequence. In a particular embodiment, the VL comprises one, two or three HVRs selected from (a) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 6; (b) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 7; and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 8. In some embodiments, the VL comprises one, two or three HVRs selected from (a) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 19; (b) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 7; and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 8.

[0154] In another aspect, an anti-PMEL17 antibody is provided, wherein the antibody comprises a VH as in any of the embodiments provided above, and a VL as in any of the embodiments provided above. In one embodiment, the antibody comprises the VH and VL sequences in SEQ ID NO: 1 and SEQ ID NO: 2, respectively, including post-translational modifications of those sequences. In some embodiments, the antibody comprises the VH and VL sequences in SEQ ID NO: 50 and SEQ ID NO: 2, respectively, including post-translational modifications of those sequences.

[0155] In a further aspect, the invention provides an antibody that binds to the same epitope as an anti-PMEL17 antibody provided herein. For example, in certain embodiments, an antibody is provided that binds to the same epitope as an anti-PMEL17 antibody comprising a VH sequence of SEQ ID NO: 1 or 50 and a VL sequence of SEQ ID NO: 2. In certain embodiments, an antibody is provided that binds to an epitope of SEQ ID NO: 26 from, within, or overlapping amino acids 105 to 125.

[0156] In a further aspect of the invention, an anti-PMEL17 antibody according to any of the above embodiments is a monoclonal antibody, including a chimeric, humanized or human antibody. In one embodiment, an anti-PMEL17 antibody is an antibody fragment, e.g., a Fv, Fab, Fab', scFv, diabody, or F(ab')₂ fragment. In another embodiment, the antibody is a substantially full length antibody, e.g., an IgG1 antibody or other antibody class or isotype as defined herein.

[0157] In a further aspect, an anti-PMEL17 antibody according to any of the above embodiments may incorporate any of the features, singly or in combination, as described in Sections 1-7 below.

Antibody 8G3 and other embodiments

[0158] In some embodiments, the invention provides an anti-PMEL17 antibody comprising at least one, two, three, four, five, or six HVRs selected from (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 13; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 14; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 15; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 16; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 7; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 8.

[0159] In one aspect, the invention provides an antibody comprising at least one, at least two, or all three VH HVR sequences selected from (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 13; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 14; and (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 15. In one embodiment, the antibody comprises HVR-H3 comprising the amino acid sequence of SEQ ID

NO: 15. In another embodiment, the antibody comprises HVR-H3 comprising the amino acid sequence of SEQ ID NO: 15 and HVR-L3 comprising the amino acid sequence of SEQ ID NO: 8. In a further embodiment, the antibody comprises HVR-H3 comprising the amino acid sequence of SEQ ID NO: 15, HVR-L3 comprising the amino acid sequence of SEQ ID NO: 8, and HVR-H2 comprising the amino acid sequence of SEQ ID NO: 14. In a further embodiment, the antibody comprises (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 13; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 14; and (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 15.

[0160] In another aspect, the invention provides an antibody comprising at least one, at least two, or all three VL HVR sequences selected from (a) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 16; (b) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 7; and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 8. In one embodiment, the antibody comprises (a) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 16; (b) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 7; and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 8.

[0161] In another aspect, an antibody of the invention comprises (a) a VH domain comprising at least one, at least two, or all three VH HVR sequences selected from (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 13, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 14, and (iii) HVR-H3 comprising an amino acid sequence selected from SEQ ID NO: 15; and (b) a VL domain comprising at least one, at least two, or all three VL HVR sequences selected from (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 16, (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 7, and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 8.

[0162] In another aspect, the invention provides an antibody comprising (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 13; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 14; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 15; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 16; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 7; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 8.

[0163] In some embodiments, the invention provides an anti-PMEL17 antibody comprising at least one, two, three, four, five, or six HVRs selected from (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 17; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 18; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 15; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 19; (e) HVR-L2

comprising the amino acid sequence of SEQ ID NO: 7; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 8.

[0164] In one aspect, the invention provides an antibody comprising at least one, at least two, or all three VH HVR sequences selected from (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 17; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 18; and (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 15. In a further embodiment, the antibody comprises HVR-H3 comprising the amino acid sequence of SEQ ID NO: 15, HVR-L3 comprising the amino acid sequence of SEQ ID NO: 8, and HVR-H2 comprising the amino acid sequence of SEQ ID NO: 18. In a further embodiment, the antibody comprises (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 17; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 18; and (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 15.

[0165] In another aspect, the invention provides an antibody comprising at least one, at least two, or all three VL HVR sequences selected from (a) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 19; (b) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 7; and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 8. In one embodiment, the antibody comprises (a) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 19; (b) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 7; and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 8.

[0166] In another aspect, an antibody of the invention comprises (a) a VH domain comprising at least one, at least two, or all three VH HVR sequences selected from (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 17, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 18, and (iii) HVR-H3 comprising an amino acid sequence selected from SEQ ID NO: 15; and (b) a VL domain comprising at least one, at least two, or all three VL HVR sequences selected from (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 19, (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 7, and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 8.

[0167] In another aspect, the invention provides an antibody comprising (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 17; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 18; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 15; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 19; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 7; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 8.

[0168] In some embodiments, X₁ in SEQ ID NO: 17 is selected from Arg, Lys, Gln, Asn, Gly, and Ala. In some embodiments, X₁ in SEQ ID NO: 17 is selected from Arg, Lys,

Gly, and Ala. In some embodiments, X_1 in SEQ ID NO: 17 is selected from Arg and Gly. In some embodiments, X_2 in SEQ ID NO: 18 is selected from Tyr, Trp, Phe, Thr, Ser, Ile, Leu, Val, Met, Ala, and Norleucine. In some embodiments, X_2 in SEQ ID NO: 18 is selected from Tyr, Phe, Ile, Leu, and Val. In some embodiments, X_2 in SEQ ID NO: 18 is selected from Tyr and Ile. In some embodiments, X_3 in SEQ ID NO: 19 is selected from Ser, Thr, and Val. In some embodiments, X_3 in SEQ ID NO: 19 is selected from Ser and Thr. In some embodiments, X_4 in SEQ ID NO: 19 is selected from Ser, Thr, and Val. In some embodiments, X_4 in SEQ ID NO: 19 is selected from Ser and Thr.

[0169] In any of the above embodiments, an anti-PMEL17 antibody is humanized. In one embodiment, an anti-PMEL17 antibody comprises HVRs as in any of the above embodiments, and further comprises a human acceptor framework, e.g. a human immunoglobulin framework or a human consensus framework. In some embodiments, a humanized anti-PMEL17 antibody comprises (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 13; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 14; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 15; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 16; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 7; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 8. In some embodiments, a humanized anti-PMEL17 antibody comprises (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 17; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 18; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 15; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 19; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 7; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 8.

[0170] In another aspect, an anti-PMEL17 antibody comprises a heavy chain variable domain (VH) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 9 or 49. In certain embodiments, a VH sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the amino acid sequence of SEQ ID NO: 9 or 49 contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti-PMEL17 antibody comprising that sequence retains the ability to bind to PMEL17. In certain embodiments, a total of 1 to 10 amino acids have been substituted, inserted and/or deleted in SEQ ID NO: 9 or 49. In certain embodiments, a total of 1 to 5 amino acids have been substituted, inserted and/or deleted in SEQ ID NO: 9 or 49. In certain embodiments, substitutions, insertions, or deletions occur in regions outside the HVRs (i.e., in the FRs). Optionally, the anti-PMEL17 antibody comprises the VH sequence of SEQ ID NO: 9 or 49,

including post-translational modifications of that sequence. In a particular embodiment, the VH comprises one, two or three HVRs selected from: (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 13, (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 14, and (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 15. In some embodiments, the VH comprises one, two or three HVRs selected from: (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 17, (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 18, and (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 15.

[0171] In some embodiments, an anti-PMEL17 antibody is provided, wherein the antibody comprises a light chain variable domain (VL) having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 10. In certain embodiments, a VL sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the amino acid sequence of SEQ ID NO: 10 contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti-PMEL17 antibody comprising that sequence retains the ability to bind to PMEL17. In certain embodiments, a total of 1 to 10 amino acids have been substituted, inserted and/or deleted in SEQ ID NO: 10. In certain embodiments, a total of 1 to 5 amino acids have been substituted, inserted and/or deleted in SEQ ID NO: 10. In certain embodiments, the substitutions, insertions, or deletions occur in regions outside the HVRs (i.e., in the FRs). Optionally, the anti-PMEL17 antibody comprises the VL sequence of SEQ ID NO: 10, including post-translational modifications of that sequence. In a particular embodiment, the VL comprises one, two or three HVRs selected from (a) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 16; (b) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 7; and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 8. In some embodiments, the VL comprises one, two or three HVRs selected from (a) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 19; (b) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 7; and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 8.

[0172] In another aspect, an anti-PMEL17 antibody is provided, wherein the antibody comprises a VH as in any of the embodiments provided above, and a VL as in any of the embodiments provided above. In one embodiment, the antibody comprises the VH and VL sequences in SEQ ID NO: 9 and SEQ ID NO: 10, respectively, including post-translational modifications of those sequences. In some embodiments, the antibody comprises the VH and VL sequences in SEQ ID NO: 49 and SEQ ID NO: 10, respectively, including post-translational modifications of those sequences.

[0173] In a further aspect, the invention provides an antibody that binds to the same epitope as an anti-PMEL17 antibody provided herein. For example, in certain embodiments, an antibody is provided that binds to the same epitope as an anti-PMEL17 antibody comprising a VH sequence of SEQ ID NO: 9 or 49 and a VL sequence of SEQ ID NO: 10. In certain embodiments, an antibody is provided that binds to an epitope of SEQ ID NO: 26 from, within, or overlapping amino acids 105 to 125.

[0174] In a further aspect of the invention, an anti-PMEL17 antibody according to any of the above embodiments is a monoclonal antibody, including a chimeric, humanized or human antibody. In one embodiment, an anti-PMEL17 antibody is an antibody fragment, e.g., a Fv, Fab, Fab', scFv, diabody, or F(ab')₂ fragment. In another embodiment, the antibody is a substantially full length antibody, e.g., an IgG1 antibody or other antibody class or isotype as defined herein.

[0175] In a further aspect, an anti-PMEL17 antibody according to any of the above embodiments may incorporate any of the features, singly or in combination, as described in Sections 1-7 below.

Antibody 15F2 and other embodiments

[0176] In some embodiments, the invention provides an anti-PMEL17 antibody comprising at least one, two, three, four, five, or six HVRs selected from (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 20; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 21; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 22; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 23; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 24; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 25.

[0177] In one aspect, the invention provides an antibody comprising at least one, at least two, or all three VH HVR sequences selected from (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 20; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 21; and (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 22. In one embodiment, the antibody comprises HVR-H3 comprising the amino acid sequence of SEQ ID NO: 22. In another embodiment, the antibody comprises HVR-H3 comprising the amino acid sequence of SEQ ID NO: 22 and HVR-L3 comprising the amino acid sequence of SEQ ID NO: 25. In a further embodiment, the antibody comprises HVR-H3 comprising the amino acid sequence of SEQ ID NO: 22, HVR-L3 comprising the amino acid sequence of SEQ ID NO: 25, and HVR-H2 comprising the amino acid sequence of SEQ ID NO: 21. In a further embodiment, the antibody comprises (a) HVR-H1 comprising the amino acid sequence of SEQ

ID NO: 20; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 21; and (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 22.

[0178] In another aspect, the invention provides an antibody comprising at least one, at least two, or all three VL HVR sequences selected from (a) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 23; (b) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 24; and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 25. In one embodiment, the antibody comprises (a) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 23; (b) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 24; and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 25.

[0179] In another aspect, an antibody of the invention comprises (a) a VH domain comprising at least one, at least two, or all three VH HVR sequences selected from (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 20, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 21, and (iii) HVR-H3 comprising an amino acid sequence selected from SEQ ID NO: 22; and (b) a VL domain comprising at least one, at least two, or all three VL HVR sequences selected from (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 23, (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 24, and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 25.

[0180] In another aspect, the invention provides an antibody comprising (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 20; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 21; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 22; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 23; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 24; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 25.

[0181] In any of the above embodiments, an anti-PMEL17 antibody is humanized. In one embodiment, an anti-PMEL17 antibody comprises HVRs as in any of the above embodiments, and further comprises a human acceptor framework, e.g. a human immunoglobulin framework or a human consensus framework. In some embodiments, a humanized anti-PMEL17 antibody comprises (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 20; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 21; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 22; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 23; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 24; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 25.

[0182] In another aspect, an anti-PMEL17 antibody comprises a heavy chain variable domain (VH) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%,

99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 11 or 51. In certain embodiments, a VH sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the amino acid sequence of SEQ ID NO: 11 or 51 contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti-PMEL17 antibody comprising that sequence retains the ability to bind to PMEL17. In certain embodiments, a total of 1 to 10 amino acids have been substituted, inserted and/or deleted in SEQ ID NO: 11 or 51. In certain embodiments, a total of 1 to 5 amino acids have been substituted, inserted and/or deleted in SEQ ID NO: 11 or 51. In certain embodiments, substitutions, insertions, or deletions occur in regions outside the HVRs (i.e., in the FRs). Optionally, the anti-PMEL17 antibody comprises the VH sequence of SEQ ID NO: 11 or 51, including post-translational modifications of that sequence. In a particular embodiment, the VH comprises one, two or three HVRs selected from: (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 20, (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 21, and (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 22.

[0183] In some embodiments, an anti-PMEL17 antibody is provided, wherein the antibody comprises a light chain variable domain (VL) having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 12. In certain embodiments, a VL sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the amino acid sequence of SEQ ID NO: 12 contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti-PMEL17 antibody comprising that sequence retains the ability to bind to PMEL17. In certain embodiments, a total of 1 to 10 amino acids have been substituted, inserted and/or deleted in SEQ ID NO: 12. In certain embodiments, a total of 1 to 5 amino acids have been substituted, inserted and/or deleted in SEQ ID NO: 12. In certain embodiments, the substitutions, insertions, or deletions occur in regions outside the HVRs (i.e., in the FRs). Optionally, the anti-PMEL17 antibody comprises the VL sequence of SEQ ID NO: 12, including post-translational modifications of that sequence. In a particular embodiment, the VL comprises one, two or three HVRs selected from (a) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 23; (b) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 24; and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 25.

[0184] In another aspect, an anti-PMEL17 antibody is provided, wherein the antibody comprises a VH as in any of the embodiments provided above, and a VL as in any of the embodiments provided above. In one embodiment, the antibody comprises the VH and VL sequences in SEQ ID NO: 11 and SEQ ID NO: 12, respectively, including post-translational

modifications of those sequences. In some embodiments, the antibody comprises the VH and VL sequences in SEQ ID NO: 51 and SEQ ID NO: 12, respectively, including post-translational modifications of those sequences.

[0185] In a further aspect, the invention provides an antibody that binds to the same epitope as an anti-PMEL17 antibody provided herein. For example, in certain embodiments, an antibody is provided that binds to the same epitope as an anti-PMEL17 antibody comprising a VH sequence of SEQ ID NO: 11 or 51 and a VL sequence of SEQ ID NO: 12.

[0186] In a further aspect of the invention, an anti-PMEL17 antibody according to any of the above embodiments is a monoclonal antibody, including a chimeric, humanized or human antibody. In one embodiment, an anti-PMEL17 antibody is an antibody fragment, e.g., a Fv, Fab, Fab', scFv, diabody, or F(ab')₂ fragment. In another embodiment, the antibody is a substantially full length antibody, e.g., an IgG1 antibody or other antibody class or isotype as defined herein.

[0187] In a further aspect, an anti-PMEL17 antibody according to any of the above embodiments may incorporate any of the features, singly or in combination, as described in Sections 1-7 below.

Antibody 31D1 and other embodiments

[0188] In one aspect, the invention provides an anti-PMEL17 antibody comprising at least one, two, three, four, five, or six HVRs of the antibody produced by the hybridoma designated "7509(31D1.6.7)" and deposited with the ATCC on April 24, 2012 and having ATCC Accession No. PTA-12862. For purposes of this section, HVRs are delineated by the amino acid ranges corresponding to CDRs, i.e., CDRs that occur at amino acid residues 24-34, 50-56, and 89-97 of the light chain variable region, and amino acid residues 31-35B, 50-65, and 95-102 of the heavy chain variable region (CDR-L1, CDR-L2, CDR-L3, CDR-H1, CDR-H2, and CDR-H3, respectively). See Kabat et al., *Sequences of Proteins of Immunological Interest*, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD (1991).

[0189] In one aspect, the invention provides an antibody comprising at least one, at least two, or all three VH HVR sequences of the antibody produced by hybridoma 7509(31D1.6.7) having ATCC Accession No. PTA-12862. In one embodiment, the antibody comprises HVR-H3 of the antibody produced by hybridoma 7509(31D1.6.7) having ATCC Accession No. PTA-12862. In another embodiment, the antibody comprises HVR-H3 and HVR-L3 of the antibody produced by hybridoma 7509(31D1.6.7) having ATCC Accession No. PTA-12862. In a further embodiment, the antibody comprises HVR-H3, HVR-L3, and HVR-H2 of the antibody produced by hybridoma 7509(31D1.6.7) having ATCC Accession No. PTA-12862. In a further embodiment, the antibody comprises HVR-H1, HVR-H2, and

HVR-H3 of the antibody produced by hybridoma 7509(31D1.6.7) having ATCC Accession No. PTA-12862.

[0190] In another aspect, the invention provides an antibody comprising at least one, at least two, or all three VL HVR sequences of the antibody produced by hybridoma 7509(31D1.6.7) having ATCC Accession No. PTA-12862. In one embodiment, the antibody comprises HVR-L1, HVR-L2, and HVR-L3 of the antibody produced by hybridoma 7509(31D1.6.7) having ATCC Accession No. PTA-12862.

[0191] In another aspect, an antibody of the invention comprises (a) a VH domain comprising at least one, at least two, or all three VH HVR sequences of the antibody produced by hybridoma 7509(31D1.6.7) having ATCC Accession No. PTA-12862; and (b) a VL domain comprising at least one, at least two, or all three VL HVR sequences of the antibody produced by hybridoma 7509(31D1.6.7) having ATCC Accession No. PTA-12862.

[0192] In another aspect, the invention provides an antibody comprising HVR-H1, HVR-H2, HVR-H3, HVR-L1, HVR-L2, and HVR-L3 of the antibody produced by hybridoma 7509(31D1.6.7) having ATCC Accession No. PTA-12862.

[0193] In any of the above embodiments, an anti-PMEL17 antibody is humanized. In one such embodiment, the antibody is a humanized form of the antibody produced by hybridoma 7509(31D1.6.7) having ATCC Accession No. PTA-12862. In a further embodiment, an anti-PMEL17 antibody comprises HVRs as in any of the above embodiments, and further comprises an acceptor human framework, e.g. a human immunoglobulin framework or a human consensus framework.

[0194] In another aspect, an anti-PMEL17 antibody comprises a heavy chain variable domain (VH) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the VH of the antibody produced by hybridoma 7509(31D1.6.7) having ATCC Accession No. PTA-12862. In certain embodiments, a VH sequence contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti-PMEL17 antibody comprising that sequence retains the ability to bind to PMEL17. In certain embodiments, a total of 1 to 10 amino acids have been substituted, inserted and/or deleted in the VH of the antibody produced by hybridoma 7509(31D1.6.7) having ATCC Accession No. PTA-12862. In certain embodiments, substitutions, insertions, or deletions occur in regions outside the HVRs (i.e., in the FRs). Optionally, the anti-PMEL17 antibody comprises the VH sequence of the antibody produced by hybridoma 7509(31D1.6.7) having ATCC Accession No. PTA-12862, including post-translational modifications of that sequence. In a particular embodiment, the VH

comprises one, two, or three HVRs selected from HVR-H1, HVR-H2, and HVR-H3 of the antibody produced by hybridoma 7509(31D1.6.7) having ATCC Accession No. PTA-12862.

[0195] In another aspect, an anti-PMEL17 antibody is provided, wherein the antibody comprises a light chain variable domain (VL) having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the VL of the antibody produced by hybridoma 7509(31D1.6.7) having ATCC Accession No. PTA-12862. In certain embodiments, a VL sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti-PMEL17 antibody comprising that sequence retains the ability to bind to PMEL17. In certain embodiments, a total of 1 to 10 amino acids have been substituted, inserted and/or deleted in the VL of the antibody produced by hybridoma 7509(31D1.6.7) having ATCC Accession No. PTA-12862. In certain embodiments, the substitutions, insertions, or deletions occur in regions outside the HVRs (i.e., in the FRs). Optionally, the anti-PMEL17 antibody comprises the VL sequence of the antibody produced by hybridoma 7509(31D1.6.7) having ATCC Accession No. PTA-12862, including post-translational modifications of that sequence. In a particular embodiment, the VL comprises one, two or three HVRs selected from HVR-L1, HVR-L2, and HVR-L3 of the antibody produced by hybridoma 7509(31D1.6.7) having ATCC Accession No. PTA-12862.

[0196] In another aspect, an anti-PMEL17 antibody is provided, wherein the antibody comprises a VH as in any of the embodiments provided above, and a VL as in any of the embodiments provided above. In one embodiment, the antibody comprises the VH and VL sequences of the antibody produced by hybridoma 7509(31D1.6.7) having ATCC Accession No. PTA-12862, respectively, including post-translational modifications of those sequences.

[0197] In a further aspect, the invention provides an antibody that binds to the same epitope as an anti-PMEL17 antibody provided herein. For example, in certain embodiments, an antibody is provided that binds to the same epitope as the antibody produced by hybridoma 7509(31D1.6.7) having ATCC Accession No. PTA-12862.

[0198] In a further aspect of the invention, an anti-PMEL17 antibody according to any of the above embodiments is a monoclonal antibody, including a chimeric, humanized or human antibody. In one embodiment, an anti-PMEL17 antibody is an antibody fragment, e.g., a Fv, Fab, Fab', scFv, diabody, or F(ab')₂ fragment. In another embodiment, the antibody is a substantially full length antibody, e.g., an IgG2b antibody or other antibody class or isotype as defined herein.

[0199] In a further aspect, an anti-PMEL17 antibody according to any of the above embodiments may incorporate any of the features, singly or in combination, as described in Sections 1-7 below.

1. Antibody Affinity

[0200] In certain embodiments, an antibody provided herein has a dissociation constant (K_d) of $\leq 1\mu\text{M}$, $\leq 100\text{ nM}$, $\leq 10\text{ nM}$, $\leq 1\text{ nM}$, $\leq 0.1\text{ nM}$, $\leq 0.01\text{ nM}$, or $\leq 0.001\text{ nM}$, and optionally is $\geq 10^{-13}\text{ M}$. (e.g. 10^{-8} M or less, e.g. from 10^{-8} M to 10^{-13} M , e.g., from 10^{-9} M to 10^{-13} M).

[0201] In one embodiment, K_d is measured by a radiolabeled antigen binding assay (RIA) performed with the Fab version of an antibody of interest and its antigen as described by the following assay. Solution binding affinity of Fabs for antigen is measured by equilibrating Fab with a minimal concentration of (¹²⁵I)-labeled antigen in the presence of a titration series of unlabeled antigen, then capturing bound antigen with an anti-Fab antibody-coated plate (see, e.g., Chen et al., *J. Mol. Biol.* 293:865-881(1999)). To establish conditions for the assay, MICROTITER[®] multi-well plates (Thermo Scientific) are coated overnight with 5 $\mu\text{g/ml}$ of a capturing anti-Fab antibody (Cappel Labs) in 50 mM sodium carbonate (pH 9.6), and subsequently blocked with 2% (w/v) bovine serum albumin in PBS for two to five hours at room temperature (approximately 23°C). In a non-adsorbent plate (Nunc #269620), 100 pM or 26 pM [¹²⁵I]-antigen are mixed with serial dilutions of a Fab of interest (e.g., consistent with assessment of the anti-VEGF antibody, Fab-12, in Presta et al., *Cancer Res.* 57:4593-4599 (1997)). The Fab of interest is then incubated overnight; however, the incubation may continue for a longer period (e.g., about 65 hours) to ensure that equilibrium is reached. Thereafter, the mixtures are transferred to the capture plate for incubation at room temperature (e.g., for one hour). The solution is then removed and the plate washed eight times with 0.1% polysorbate 20 (TWEEN-20[®]) in PBS. When the plates have dried, 150 $\mu\text{l/well}$ of scintillant (MICROSCINT-20[™]; Packard) is added, and the plates are counted on a TOPCOUNT[™] gamma counter (Packard) for ten minutes. Concentrations of each Fab that give less than or equal to 20% of maximal binding are chosen for use in competitive binding assays.

[0202] According to another embodiment, K_d is measured using surface plasmon resonance assays using a BIACORE[®]-2000 or a BIACORE[®]-3000 (BIAcore, Inc., Piscataway, NJ) at 25°C with immobilized antigen CM5 chips at ~10 response units (RU). Briefly, carboxymethylated dextran biosensor chips (CM5, BIACORE, Inc.) are activated with *N*-ethyl-*N'*-(3-dimethylaminopropyl)-carbodiimide hydrochloride (EDC) and *N*-hydroxysuccinimide (NHS) according to the supplier's instructions. Antigen is diluted with 10 mM sodium acetate,

pH 4.8, to 5 µg/ml (~0.2 µM) before injection at a flow rate of 5 µl/minute to achieve approximately 10 response units (RU) of coupled protein. Following the injection of antigen, 1 M ethanolamine is injected to block unreacted groups. For kinetics measurements, two-fold serial dilutions of Fab (0.78 nM to 500 nM) are injected in PBS with 0.05% polysorbate 20 (TWEEN-20TM) surfactant (PBST) at 25°C at a flow rate of approximately 25 µl/min. Association rates (k_{ON}) and dissociation rates (k_{OFF}) are calculated using a simple one-to-one Langmuir binding model (BIAcore[®] Evaluation Software version 3.2) by simultaneously fitting the association and dissociation sensorgrams. The equilibrium dissociation constant (Kd) is calculated as the ratio k_{OFF}/k_{ON} . See, e.g., Chen et al., *J. Mol. Biol.* 293:865-881 (1999). If the on-rate exceeds $10^6 \text{ M}^{-1} \text{ s}^{-1}$ by the surface plasmon resonance assay above, then the on-rate can be determined by using a fluorescent quenching technique that measures the increase or decrease in fluorescence emission intensity (excitation = 295 nm; emission = 340 nm, 16 nm band-pass) at 25°C of a 20 nM anti-antigen antibody (Fab form) in PBS, pH 7.2, in the presence of increasing concentrations of antigen as measured in a spectrometer, such as a stop-flow equipped spectrophotometer (Aviv Instruments) or a 8000-series SLM-AMINCOTM spectrophotometer (ThermoSpectronic) with a stirred cuvette.

2. Antibody Fragments

[0203] In certain embodiments, an antibody provided herein is an antibody fragment. Antibody fragments include, but are not limited to, Fab, Fab', Fab'-SH, F(ab')₂, Fv, and scFv fragments, and other fragments described below. For a review of certain antibody fragments, see Hudson et al. *Nat. Med.* 9:129-134 (2003). For a review of scFv fragments, see, e.g., Pluckthün, in *The Pharmacology of Monoclonal Antibodies*, vol. 113, Rosenberg and Moore eds., (Springer-Verlag, New York), pp. 269-315 (1994); see also WO 93/16185; and U.S. Patent Nos. 5,571,894 and 5,587,458. For discussion of Fab and F(ab')₂ fragments comprising salvage receptor binding epitope residues and having increased in vivo half-life, see U.S. Patent No. 5,869,046.

[0204] Diabodies are antibody fragments with two antigen-binding sites that may be bivalent or bispecific. See, for example, EP 404,097; WO 1993/01161; Hudson et al., *Nat. Med.* 9:129-134 (2003); and Hollinger et al., *Proc. Natl. Acad. Sci. USA* 90: 6444-6448 (1993). Triabodies and tetrabodies are also described in Hudson et al., *Nat. Med.* 9:129-134 (2003).

[0205] Single-domain antibodies are antibody fragments comprising all or a portion of the heavy chain variable domain or all or a portion of the light chain variable domain of an

antibody. In certain embodiments, a single-domain antibody is a human single-domain antibody (Domantis, Inc., Waltham, MA; *see, e.g.*, U.S. Patent No. 6,248,516 B1).

[0206] Antibody fragments can be made by various techniques, including but not limited to proteolytic digestion of an intact antibody as well as production by recombinant host cells (e.g. *E. coli* or phage), as described herein.

3. *Chimeric and Humanized Antibodies*

[0207] In certain embodiments, an antibody provided herein is a chimeric antibody. Certain chimeric antibodies are described, e.g., in U.S. Patent No. 4,816,567; and Morrison et al., *Proc. Natl. Acad. Sci. USA*, 81:6851-6855 (1984)). In one example, a chimeric antibody comprises a non-human variable region (e.g., a variable region derived from a mouse, rat, hamster, rabbit, or non-human primate, such as a monkey) and a human constant region. In a further example, a chimeric antibody is a “class switched” antibody in which the class or subclass has been changed from that of the parent antibody. Chimeric antibodies include antigen-binding fragments thereof.

[0208] In certain embodiments, a chimeric antibody is a humanized antibody. Typically, a non-human antibody is humanized to reduce immunogenicity to humans, while retaining the specificity and affinity of the parental non-human antibody. Generally, a humanized antibody comprises one or more variable domains in which HVRs, e.g., CDRs, (or portions thereof) are derived from a non-human antibody, and FRs (or portions thereof) are derived from human antibody sequences. A humanized antibody optionally will also comprise at least a portion of a human constant region. In some embodiments, some FR residues in a humanized antibody are substituted with corresponding residues from a non-human antibody (e.g., the antibody from which the HVR residues are derived), e.g., to restore or improve antibody specificity or affinity.

[0209] Humanized antibodies and methods of making them are reviewed, e.g., in Almagro and Fransson, *Front. Biosci.* 13:1619-1633 (2008), and are further described, e.g., in Riechmann et al., *Nature* 332:323-329 (1988); Queen et al., *Proc. Nat'l Acad. Sci. USA* 86:10029-10033 (1989); US Patent Nos. 5, 821,337, 7,527,791, 6,982,321, and 7,087,409; Kashmiri et al., *Methods* 36:25-34 (2005) (describing SDR (a-CDR) grafting); Padlan, *Mol. Immunol.* 28:489-498 (1991) (describing “resurfacing”); Dall’Acqua et al., *Methods* 36:43-60 (2005) (describing “FR shuffling”); and Osbourn et al., *Methods* 36:61-68 (2005) and Klimka et al., *Br. J. Cancer*, 83:252-260 (2000) (describing the “guided selection” approach to FR shuffling).

[0210] Human framework regions that may be used for humanization include but are not limited to: framework regions selected using the "best-fit" method (see, e.g., Sims et al. *J. Immunol.* 151:2296 (1993)); framework regions derived from the consensus sequence of human antibodies of a particular subgroup of light or heavy chain variable regions (see, e.g., Carter et al. *Proc. Natl. Acad. Sci. USA*, 89:4285 (1992); and Presta et al. *J. Immunol.*, 151:2623 (1993)); human mature (somatically mutated) framework regions or human germline framework regions (see, e.g., Almagro and Fransson, *Front. Biosci.* 13:1619-1633 (2008)); and framework regions derived from screening FR libraries (see, e.g., Baca et al., *J. Biol. Chem.* 272:10678-10684 (1997) and Rosok et al., *J. Biol. Chem.* 271:22611-22618 (1996)).

4. Human Antibodies

[0211] In certain embodiments, an antibody provided herein is a human antibody. Human antibodies can be produced using various techniques known in the art. Human antibodies are described generally in van Dijk and van de Winkel, *Curr. Opin. Pharmacol.* 5: 368-74 (2001) and Lonberg, *Curr. Opin. Immunol.* 20:450-459 (2008).

[0212] Human antibodies may be prepared by administering an immunogen to a transgenic animal that has been modified to produce intact human antibodies or intact antibodies with human variable regions in response to antigenic challenge. Such animals typically contain all or a portion of the human immunoglobulin loci, which replace the endogenous immunoglobulin loci, or which are present extrachromosomally or integrated randomly into the animal's chromosomes. In such transgenic mice, the endogenous immunoglobulin loci have generally been inactivated. For review of methods for obtaining human antibodies from transgenic animals, see Lonberg, *Nat. Biotech.* 23:1117-1125 (2005). See also, e.g., U.S. Patent Nos. 6,075,181 and 6,150,584 describing XENOMOUSETM technology; U.S. Patent No. 5,770,429 describing HUMAB® technology; U.S. Patent No. 7,041,870 describing K-M MOUSE® technology, and U.S. Patent Application Publication No. US 2007/0061900, describing VELOCIMOUSE® technology). Human variable regions from intact antibodies generated by such animals may be further modified, e.g., by combining with a different human constant region.

[0213] Human antibodies can also be made by hybridoma-based methods. Human myeloma and mouse-human heteromyeloma cell lines for the production of human monoclonal antibodies have been described. (See, e.g., Kozbor *J. Immunol.*, 133: 3001 (1984); Brodeur et al., *Monoclonal Antibody Production Techniques and Applications*, pp. 51-63 (Marcel Dekker, Inc., New York, 1987); and Boerner et al., *J. Immunol.*, 147: 86 (1991).) Human antibodies generated via human B-cell hybridoma technology are also described in Li et al., *Proc. Natl.*

Acad. Sci. USA, 103:3557-3562 (2006). Additional methods include those described, for example, in U.S. Patent No. 7,189,826 (describing production of monoclonal human IgM antibodies from hybridoma cell lines) and Ni, *Xiandai Mianyixue*, 26(4):265-268 (2006) (describing human-human hybridomas). Human hybridoma technology (Trioma technology) is also described in Vollmers and Brandlein, *Histology and Histopathology*, 20(3):927-937 (2005) and Vollmers and Brandlein, *Methods and Findings in Experimental and Clinical Pharmacology*, 27(3):185-91 (2005).

[0214] Human antibodies may also be generated by isolating Fv clone variable domain sequences selected from human-derived phage display libraries. Such variable domain sequences may then be combined with a desired human constant domain. Techniques for selecting human antibodies from antibody libraries are described below.

5. Library-Derived Antibodies

[0215] Antibodies of the invention may be isolated by screening combinatorial libraries for antibodies with the desired activity or activities. For example, a variety of methods are known in the art for generating phage display libraries and screening such libraries for antibodies possessing the desired binding characteristics. Such methods are reviewed, e.g., in Hoogenboom et al. in *Methods in Molecular Biology* 178:1-37 (O'Brien et al., ed., Human Press, Totowa, NJ, 2001) and further described, e.g., in the McCafferty et al., *Nature* 348:552-554; Clackson et al., *Nature* 352: 624-628 (1991); Marks et al., *J. Mol. Biol.* 222: 581-597 (1992); Marks and Bradbury, in *Methods in Molecular Biology* 248:161-175 (Lo, ed., Human Press, Totowa, NJ, 2003); Sidhu et al., *J. Mol. Biol.* 338(2): 299-310 (2004); Lee et al., *J. Mol. Biol.* 340(5): 1073-1093 (2004); Fellouse, *Proc. Natl. Acad. Sci. USA* 101(34): 12467-12472 (2004); and Lee et al., *J. Immunol. Methods* 284(1-2): 119-132(2004).

[0216] In certain phage display methods, repertoires of VH and VL genes are separately cloned by polymerase chain reaction (PCR) and recombined randomly in phage libraries, which can then be screened for antigen-binding phage as described in Winter et al., *Ann. Rev. Immunol.*, 12: 433-455 (1994). Phage typically display antibody fragments, either as single-chain Fv (scFv) fragments or as Fab fragments. Libraries from immunized sources provide high-affinity antibodies to the immunogen without the requirement of constructing hybridomas. Alternatively, the naive repertoire can be cloned (e.g., from human) to provide a single source of antibodies to a wide range of non-self and also self antigens without any immunization as described by Griffiths et al., *EMBO J*, 12: 725-734 (1993). Finally, naive libraries can also be made synthetically by cloning unrearranged V-gene segments from stem cells, and using PCR primers containing random sequence to encode the highly variable CDR3

regions and to accomplish rearrangement *in vitro*, as described by Hoogenboom and Winter, *J. Mol. Biol.*, 227: 381-388 (1992). Patent publications describing human antibody phage libraries include, for example: US Patent No. 5,750,373, and US Patent Publication Nos. 2005/0079574, 2005/0119455, 2005/0266000, 2007/0117126, 2007/0160598, 2007/0237764, 2007/0292936, and 2009/0002360.

[0217] Antibodies or antibody fragments isolated from human antibody libraries are considered human antibodies or human antibody fragments herein.

6. Multispecific Antibodies

[0218] In certain embodiments, an antibody provided herein is a multispecific antibody, e.g. a bispecific antibody. Multispecific antibodies are monoclonal antibodies that have binding specificities for at least two different sites. In certain embodiments, one of the binding specificities is for PMEL17 and the other is for any other antigen. In certain embodiments, one of the binding specificities is for PMEL17 and the other is for CD3. *See, e.g.*, U.S. Patent No. 5,821,337. In certain embodiments, bispecific antibodies may bind to two different epitopes of PMEL17. Bispecific antibodies may also be used to localize cytotoxic agents to cells which express PMEL17. Bispecific antibodies can be prepared as full length antibodies or antibody fragments.

[0219] Techniques for making multispecific antibodies include, but are not limited to, recombinant co-expression of two immunoglobulin heavy chain-light chain pairs having different specificities (see Milstein and Cuello, *Nature* 305: 537 (1983)), WO 93/08829, and Traunecker et al., *EMBO J.* 10: 3655 (1991)), and “knob-in-hole” engineering (see, e.g., U.S. Patent No. 5,731,168). Multi-specific antibodies may also be made by engineering electrostatic steering effects for making antibody Fc-heterodimeric molecules (WO 2009/089004A1); cross-linking two or more antibodies or fragments (see, e.g., US Patent No. 4,676,980, and Brennan et al., *Science*, 229: 81 (1985)); using leucine zippers to produce bi-specific antibodies (see, e.g., Kostelny et al., *J. Immunol.*, 148(5):1547-1553 (1992)); using “diabody” technology for making bispecific antibody fragments (see, e.g., Hollinger et al., *Proc. Natl. Acad. Sci. USA*, 90:6444-6448 (1993)); and using single-chain Fv (sFv) dimers (see, e.g. Gruber et al., *J. Immunol.*, 152:5368 (1994)); and preparing trispecific antibodies as described, e.g., in Tutt et al. *J. Immunol.* 147: 60 (1991).

[0220] Engineered antibodies with three or more functional antigen binding sites, including “Octopus antibodies,” are also included herein (see, e.g. US 2006/0025576A1).

[0221] The antibody or fragment herein also includes a “Dual Acting FAb” or “DAF” comprising an antigen binding site that binds to PMEL17 as well as another, different antigen (see, US 2008/0069820, for example).

7. *Antibody Variants*

[0222] In certain embodiments, amino acid sequence variants of the antibodies provided herein are contemplated. For example, it may be desirable to improve the binding affinity and/or other biological properties of the antibody. Amino acid sequence variants of an antibody may be prepared by introducing appropriate modifications into the nucleotide sequence encoding the antibody, or by peptide synthesis. Such modifications include, for example, deletions from, and/or insertions into and/or substitutions of residues within the amino acid sequences of the antibody. Any combination of deletion, insertion, and substitution can be made to arrive at the final construct, provided that the final construct possesses the desired characteristics, e.g., antigen-binding.

a) Substitution, Insertion, and Deletion Variants

[0223] In certain embodiments, antibody variants having one or more amino acid substitutions are provided. Sites of interest for substitutional mutagenesis include the HVRs and FRs. Conservative substitutions are shown in Table 1 under the heading of "preferred substitutions." More substantial changes are provided in Table 1 under the heading of "exemplary substitutions," and as further described below in reference to amino acid side chain classes. Amino acid substitutions may be introduced into an antibody of interest and the products screened for a desired activity, e.g., retained/improved antigen binding, decreased immunogenicity, or improved ADCC or CDC.

TABLE 1

Original Residue	Exemplary Substitutions	Preferred Substitutions
Ala (A)	Val; Leu; Ile	Val
Arg (R)	Lys; Gln; Asn	Lys
Asn (N)	Gln; His; Asp, Lys; Arg	Gln
Asp (D)	Glu; Asn	Glu
Cys (C)	Ser; Ala	Ser
Gln (Q)	Asn; Glu	Asn
Glu (E)	Asp; Gln	Asp
Gly (G)	Ala	Ala
His (H)	Asn; Gln; Lys; Arg	Arg

Original Residue	Exemplary Substitutions	Preferred Substitutions
Ile (I)	Leu; Val; Met; Ala; Phe; Norleucine	Leu
Leu (L)	Norleucine; Ile; Val; Met; Ala; Phe	Ile
Lys (K)	Arg; Gln; Asn	Arg
Met (M)	Leu; Phe; Ile	Leu
Phe (F)	Trp; Leu; Val; Ile; Ala; Tyr	Tyr
Pro (P)	Ala	Ala
Ser (S)	Thr	Thr
Thr (T)	Val; Ser	Ser
Trp (W)	Tyr; Phe	Tyr
Tyr (Y)	Trp; Phe; Thr; Ser	Phe
Val (V)	Ile; Leu; Met; Phe; Ala; Norleucine	Leu

Amino acids may be grouped according to common side-chain properties:

- (1) hydrophobic: Norleucine, Met, Ala, Val, Leu, Ile;
- (2) neutral hydrophilic: Cys, Ser, Thr, Asn, Gln;
- (3) acidic: Asp, Glu;
- (4) basic: His, Lys, Arg;
- (5) residues that influence chain orientation: Gly, Pro;
- (6) aromatic: Trp, Tyr, Phe.

[0224] Non-conservative substitutions will entail exchanging a member of one of these classes for another class.

[0225] One type of substitutional variant involves substituting one or more hypervariable region residues of a parent antibody (*e.g.* a humanized or human antibody). Generally, the resulting variant(s) selected for further study will have modifications (*e.g.*, improvements) in certain biological properties (*e.g.*, increased affinity, reduced immunogenicity) relative to the parent antibody and/or will have substantially retained certain biological properties of the parent antibody. An exemplary substitutional variant is an affinity matured antibody, which may be conveniently generated, *e.g.*, using phage display-based affinity maturation techniques such as those described herein. Briefly, one or more HVR residues are mutated and the variant antibodies displayed on phage and screened for a particular biological activity (*e.g.* binding affinity).

[0226] Alterations (*e.g.*, substitutions) may be made in HVRs, *e.g.*, to improve antibody affinity. Such alterations may be made in HVR “hotspots,” *i.e.*, residues encoded by

codons that undergo mutation at high frequency during the somatic maturation process (see, e.g., Chowdhury, *Methods Mol. Biol.* 207:179-196 (2008)), and/or SDRs (a-CDRs), with the resulting variant VH or VL being tested for binding affinity. Affinity maturation by constructing and reselecting from secondary libraries has been described, e.g., in Hoogenboom et al. in *Methods in Molecular Biology* 178:1-37 (O'Brien et al., ed., Human Press, Totowa, NJ, (2001).) In some embodiments of affinity maturation, diversity is introduced into the variable genes chosen for maturation by any of a variety of methods (e.g., error-prone PCR, chain shuffling, or oligonucleotide-directed mutagenesis). A secondary library is then created. The library is then screened to identify any antibody variants with the desired affinity. Another method to introduce diversity involves HVR-directed approaches, in which several HVR residues (e.g., 4-6 residues at a time) are randomized. HVR residues involved in antigen binding may be specifically identified, e.g., using alanine scanning mutagenesis or modeling. CDR-H3 and CDR-L3 in particular are often targeted.

[0227] In certain embodiments, substitutions, insertions, or deletions may occur within one or more HVRs so long as such alterations do not substantially reduce the ability of the antibody to bind antigen. For example, conservative alterations (e.g., conservative substitutions as provided herein) that do not substantially reduce binding affinity may be made in HVRs. Such alterations may be outside of HVR "hotspots" or SDRs. In certain embodiments of the variant VH and VL sequences provided above, each HVR either is unaltered, or contains no more than one, two or three amino acid substitutions.

[0228] A useful method for identification of residues or regions of an antibody that may be targeted for mutagenesis is called "alanine scanning mutagenesis" as described by Cunningham and Wells (1989) *Science*, 244:1081-1085. In this method, a residue or group of target residues (e.g., charged residues such as arg, asp, his, lys, and glu) are identified and replaced by a neutral or negatively charged amino acid (e.g., alanine or polyalanine) to determine whether the interaction of the antibody with antigen is affected. Further substitutions may be introduced at the amino acid locations demonstrating functional sensitivity to the initial substitutions. Alternatively, or additionally, a crystal structure of an antigen-antibody complex is used to identify contact points between the antibody and antigen. Such contact residues and neighboring residues may be targeted or eliminated as candidates for substitution. Variants may be screened to determine whether they contain the desired properties.

[0229] Amino acid sequence insertions include amino- and/or carboxyl-terminal fusions ranging in length from one residue to polypeptides containing a hundred or more residues, as well as intrasequence insertions of single or multiple amino acid residues.

Examples of terminal insertions include an antibody with an N-terminal methionyl residue. Other insertional variants of the antibody molecule include the fusion to the N- or C-terminus of the antibody to an enzyme (e.g. for ADEPT) or a polypeptide which increases the serum half-life of the antibody.

b) Glycosylation variants

[0230] In certain embodiments, an antibody provided herein is altered to increase or decrease the extent to which the antibody is glycosylated. Addition or deletion of glycosylation sites to an antibody may be conveniently accomplished by altering the amino acid sequence such that one or more glycosylation sites is created or removed.

[0231] Where the antibody comprises an Fc region, the carbohydrate attached thereto may be altered. Native antibodies produced by mammalian cells typically comprise a branched, biantennary oligosaccharide that is generally attached by an N-linkage to Asn297 of the CH2 domain of the Fc region. See, e.g., Wright et al. *TIBTECH* 15:26-32 (1997). The oligosaccharide may include various carbohydrates, e.g., mannose, N-acetyl glucosamine (GlcNAc), galactose, and sialic acid, as well as a fucose attached to a GlcNAc in the “stem” of the biantennary oligosaccharide structure. In some embodiments, modifications of the oligosaccharide in an antibody of the invention may be made in order to create antibody variants with certain improved properties.

[0232] In one embodiment, antibody variants are provided having a carbohydrate structure that lacks fucose attached (directly or indirectly) to an Fc region. For example, the amount of fucose in such antibody may be from 1% to 80%, from 1% to 65%, from 5% to 65% or from 20% to 40%. The amount of fucose is determined by calculating the average amount of fucose within the sugar chain at Asn297, relative to the sum of all glycostructures attached to Asn 297 (e. g. complex, hybrid and high mannose structures) as measured by MALDI-TOF mass spectrometry, as described in WO 2008/077546, for example. Asn297 refers to the asparagine residue located at about position 297 in the Fc region (Eu numbering of Fc region residues); however, Asn297 may also be located about ± 3 amino acids upstream or downstream of position 297, i.e., between positions 294 and 300, due to minor sequence variations in antibodies. Such fucosylation variants may have improved ADCC function. See, e.g., US Patent Publication Nos. US 2003/0157108 (Presta, L.); US 2004/0093621 (Kyowa Hakko Kogyo Co., Ltd). Examples of publications related to “defucosylated” or “fucose-deficient” antibody variants include: US 2003/0157108; WO 2000/61739; WO 2001/29246; US 2003/0115614; US 2002/0164328; US 2004/0093621; US 2004/0132140; US 2004/0110704; US 2004/0110282; US 2004/0109865; WO 2003/085119; WO 2003/084570;

WO 2005/035586; WO 2005/035778; WO2005/053742; WO2002/031140; Okazaki et al. *J. Mol. Biol.* 336:1239-1249 (2004); Yamane-Ohnuki et al. *Biotech. Bioeng.* 87: 614 (2004). Examples of cell lines capable of producing defucosylated antibodies include Lec13 CHO cells deficient in protein fucosylation (Ripka et al. *Arch. Biochem. Biophys.* 249:533-545 (1986); US Pat Appl No US 2003/0157108 A1, Presta, L; and WO 2004/056312 A1, Adams *et al.*, especially at Example 11), and knockout cell lines, such as alpha-1,6-fucosyltransferase gene, *FUT8*, knockout CHO cells (see, e.g., Yamane-Ohnuki et al. *Biotech. Bioeng.* 87: 614 (2004); Kanda, Y. et al., *Biotechnol. Bioeng.*, 94(4):680-688 (2006); and WO2003/085107).

[0233] Antibodies variants are further provided with bisected oligosaccharides, e.g., in which a biantennary oligosaccharide attached to the Fc region of the antibody is bisected by GlcNAc. Such antibody variants may have reduced fucosylation and/or improved ADCC function. Examples of such antibody variants are described, e.g., in WO 2003/011878 (Jean-Mairet et al.); US Patent No. 6,602,684 (Umana et al.); and US 2005/0123546 (Umana *et al.*). Antibody variants with at least one galactose residue in the oligosaccharide attached to the Fc region are also provided. Such antibody variants may have improved CDC function. Such antibody variants are described, e.g., in WO 1997/30087 (Patel et al.); WO 1998/58964 (Raju, S.); and WO 1999/22764 (Raju, S.).

c) Fc region variants

[0234] In certain embodiments, one or more amino acid modifications may be introduced into the Fc region of an antibody provided herein, thereby generating an Fc region variant. The Fc region variant may comprise a human Fc region sequence (*e.g.*, a human IgG1, IgG2, IgG3 or IgG4 Fc region) comprising an amino acid modification (*e.g.* a substitution) at one or more amino acid positions.

[0235] In certain embodiments, the invention contemplates an antibody variant that possesses some but not all effector functions, which make it a desirable candidate for applications in which the half life of the antibody *in vivo* is important yet certain effector functions (such as complement and ADCC) are unnecessary or deleterious. *In vitro* and/or *in vivo* cytotoxicity assays can be conducted to confirm the reduction/depletion of CDC and/or ADCC activities. For example, Fc receptor (FcR) binding assays can be conducted to ensure that the antibody lacks FcγR binding (hence likely lacking ADCC activity), but retains FcRn binding ability. The primary cells for mediating ADCC, NK cells, express Fc(RIII only, whereas monocytes express Fc(RI, Fc(RII and Fc(RIII. FcR expression on hematopoietic cells is summarized in Table 3 on page 464 of Ravetch and Kinet, *Annu. Rev. Immunol.* 9:457-492 (1991). Non-limiting examples of *in vitro* assays to assess ADCC activity of a molecule of

interest is described in U.S. Patent No. 5,500,362 (see, e.g. Hellstrom, I. et al. *Proc. Nat'l Acad. Sci. USA* 83:7059-7063 (1986)) and Hellstrom, I et al., *Proc. Nat'l Acad. Sci. USA* 82:1499-1502 (1985); 5,821,337 (see Bruggemann, M. et al., *J. Exp. Med.* 166:1351-1361 (1987)). Alternatively, non-radioactive assays methods may be employed (see, for example, ACTITM non-radioactive cytotoxicity assay for flow cytometry (CellTechnology, Inc. Mountain View, CA; and CytoTox 96® non-radioactive cytotoxicity assay (Promega, Madison, WI). Useful effector cells for such assays include peripheral blood mononuclear cells (PBMC) and Natural Killer (NK) cells. Alternatively, or additionally, ADCC activity of the molecule of interest may be assessed *in vivo*, e.g., in a animal model such as that disclosed in Clynes et al. *Proc. Nat'l Acad. Sci. USA* 95:652-656 (1998). C1q binding assays may also be carried out to confirm that the antibody is unable to bind C1q and hence lacks CDC activity. See, e.g., C1q and C3c binding ELISA in WO 2006/029879 and WO 2005/100402. To assess complement activation, a CDC assay may be performed (see, for example, Gazzano-Santoro *et al.*, *J. Immunol. Methods* 202:163 (1996); Cragg, M.S. et al., *Blood* 101:1045-1052 (2003); and Cragg, M.S. and M.J. Glennie, *Blood* 103:2738-2743 (2004)). FcRn binding and *in vivo* clearance/half life determinations can also be performed using methods known in the art (see, e.g., Petkova, S.B. et al., *Int'l. Immunol.* 18(12):1759-1769 (2006)).

[0236] Antibodies with reduced effector function include those with substitution of one or more of Fc region residues 238, 265, 269, 270, 297, 327 and 329 (U.S. Patent No. 6,737,056). Such Fc mutants include Fc mutants with substitutions at two or more of amino acid positions 265, 269, 270, 297 and 327, including the so-called "DANA" Fc mutant with substitution of residues 265 and 297 to alanine (US Patent No. 7,332,581).

[0237] Certain antibody variants with improved or diminished binding to FcRs are described. (See, e.g., U.S. Patent No. 6,737,056; WO 2004/056312, and Shields et al., *J. Biol. Chem.* 9(2): 6591-6604 (2001).)

[0238] In certain embodiments, an antibody variant comprises an Fc region with one or more amino acid substitutions which improve ADCC, e.g., substitutions at positions 298, 333, and/or 334 of the Fc region (EU numbering of residues).

[0239] In some embodiments, alterations are made in the Fc region that result in altered (*i.e.*, either improved or diminished) C1q binding and/or Complement Dependent Cytotoxicity (CDC), e.g., as described in US Patent No. 6,194,551, WO 99/51642, and Idusogie et al. *J. Immunol.* 164: 4178-4184 (2000).

[0240] Antibodies with increased half lives and improved binding to the neonatal Fc receptor (FcRn), which is responsible for the transfer of maternal IgGs to the fetus (Guyer et al., *J. Immunol.* 117:587 (1976) and Kim et al., *J. Immunol.* 24:249 (1994)), are described in

US2005/0014934A1 (Hinton et al.). Those antibodies comprise an Fc region with one or more substitutions therein which improve binding of the Fc region to FcRn. Such Fc variants include those with substitutions at one or more of Fc region residues: 238, 256, 265, 272, 286, 303, 305, 307, 311, 312, 317, 340, 356, 360, 362, 376, 378, 380, 382, 413, 424 or 434, e.g., substitution of Fc region residue 434 (US Patent No. 7,371,826).

[0241] See also Duncan & Winter, *Nature* 322:738-40 (1988); U.S. Patent No. 5,648,260; U.S. Patent No. 5,624,821; and WO 94/29351 concerning other examples of Fc region variants.

d) Cysteine engineered antibody variants

[0242] In certain embodiments, it may be desirable to create cysteine engineered antibodies, e.g., “thioMAbs,” in which one or more residues of an antibody are substituted with cysteine residues. In particular embodiments, the substituted residues occur at accessible sites of the antibody. By substituting those residues with cysteine, reactive thiol groups are thereby positioned at accessible sites of the antibody and may be used to conjugate the antibody to other moieties, such as drug moieties or linker-drug moieties, to create an immunoconjugate, as described further herein. In certain embodiments, any one or more of the following residues may be substituted with cysteine: V205 (Kabat numbering) of the light chain; A118 (EU numbering) of the heavy chain; and S400 (EU numbering) of the heavy chain Fc region. Cysteine engineered antibodies may be generated as described, e.g., in U.S. Patent No. 7,521,541.

e) Antibody Derivatives

[0243] In certain embodiments, an antibody provided herein may be further modified to contain additional nonproteinaceous moieties that are known in the art and readily available. The moieties suitable for derivatization of the antibody include but are not limited to water soluble polymers. Non-limiting examples of water soluble polymers include, but are not limited to, polyethylene glycol (PEG), copolymers of ethylene glycol/propylene glycol, carboxymethylcellulose, dextran, polyvinyl alcohol, polyvinyl pyrrolidone, poly-1, 3-dioxolane, poly-1,3,6-trioxane, ethylene/maleic anhydride copolymer, polyaminoacids (either homopolymers or random copolymers), and dextran or poly(n-vinyl pyrrolidone)polyethylene glycol, propylene glycol homopolymers, polypropylene oxide/ethylene oxide co-polymers, polyoxyethylated polyols (e.g., glycerol), polyvinyl alcohol, and mixtures thereof. Polyethylene glycol propionaldehyde may have advantages in manufacturing due to its stability in water. The polymer may be of any molecular weight, and may be branched or unbranched. The number of polymers attached to the antibody may vary, and if more than one

polymer are attached, they can be the same or different molecules. In general, the number and/or type of polymers used for derivatization can be determined based on considerations including, but not limited to, the particular properties or functions of the antibody to be improved, whether the antibody derivative will be used in a therapy under defined conditions, etc.

[0244] In another embodiment, conjugates of an antibody and nonproteinaceous moiety that may be selectively heated by exposure to radiation are provided. In one embodiment, the nonproteinaceous moiety is a carbon nanotube (Kam et al., *Proc. Natl. Acad. Sci. USA* 102: 11600-11605 (2005)). The radiation may be of any wavelength, and includes, but is not limited to, wavelengths that do not harm ordinary cells, but which heat the nonproteinaceous moiety to a temperature at which cells proximal to the antibody-nonproteinaceous moiety are killed.

B. Recombinant Methods and Compositions

[0245] Antibodies may be produced using recombinant methods and compositions, e.g., as described in U.S. Patent No. 4,816,567. In one embodiment, isolated nucleic acid encoding an anti-PMEL17 antibody described herein is provided. Such nucleic acid may encode an amino acid sequence comprising the VL and/or an amino acid sequence comprising the VH of the antibody (e.g., the light and/or heavy chains of the antibody). In a further embodiment, one or more vectors (e.g., expression vectors) comprising such nucleic acid are provided. In a further embodiment, a host cell comprising such nucleic acid is provided. In one such embodiment, a host cell comprises (e.g., has been transformed with): (1) a vector comprising a nucleic acid that encodes an amino acid sequence comprising the VL of the antibody and an amino acid sequence comprising the VH of the antibody, or (2) a first vector comprising a nucleic acid that encodes an amino acid sequence comprising the VL of the antibody and a second vector comprising a nucleic acid that encodes an amino acid sequence comprising the VH of the antibody. In one embodiment, the host cell is eukaryotic, e.g. a Chinese Hamster Ovary (CHO) cell or lymphoid cell (e.g., Y0, NS0, Sp20 cell). In one embodiment, a method of making an anti-PMEL17 antibody is provided, wherein the method comprises culturing a host cell comprising a nucleic acid encoding the antibody, as provided above, under conditions suitable for expression of the antibody, and optionally recovering the antibody from the host cell (or host cell culture medium).

[0246] For recombinant production of an anti- PMEL17 antibody, nucleic acid encoding an antibody, e.g., as described above, is isolated and inserted into one or more vectors for further cloning and/or expression in a host cell. Such nucleic acid may be readily

isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of the antibody).

[0247] Suitable host cells for cloning or expression of antibody-encoding vectors include prokaryotic or eukaryotic cells described herein. For example, antibodies may be produced in bacteria, in particular when glycosylation and Fc effector function are not needed. For expression of antibody fragments and polypeptides in bacteria, see, e.g., U.S. Patent Nos. 5,648,237, 5,789,199, and 5,840,523. (See also Charlton, *Methods in Molecular Biology*, Vol. 248 (B.K.C. Lo, ed., Humana Press, Totowa, NJ, 2003), pp. 245-254, describing expression of antibody fragments in *E. coli*.) After expression, the antibody may be isolated from the bacterial cell paste in a soluble fraction and can be further purified.

[0248] In addition to prokaryotes, eukaryotic microbes such as filamentous fungi or yeast are suitable cloning or expression hosts for antibody-encoding vectors, including fungi and yeast strains whose glycosylation pathways have been "humanized," resulting in the production of an antibody with a partially or fully human glycosylation pattern. See Gerngross, *Nat. Biotech.* 22:1409-1414 (2004), and Li et al., *Nat. Biotech.* 24:210-215 (2006).

[0249] Suitable host cells for the expression of glycosylated antibody are also derived from multicellular organisms (invertebrates and vertebrates). Examples of invertebrate cells include plant and insect cells. Numerous baculoviral strains have been identified which may be used in conjunction with insect cells, particularly for transfection of *Spodoptera frugiperda* cells.

[0250] Plant cell cultures can also be utilized as hosts. See, e.g., US Patent Nos. 5,959,177, 6,040,498, 6,420,548, 7,125,978, and 6,417,429 (describing PLANTIBODIESTM technology for producing antibodies in transgenic plants).

[0251] Vertebrate cells may also be used as hosts. For example, mammalian cell lines that are adapted to grow in suspension may be useful. Other examples of useful mammalian host cell lines are monkey kidney CV1 line transformed by SV40 (COS-7); human embryonic kidney line (293 or 293 cells as described, e.g., in Graham et al., *J. Gen Virol.* 36:59 (1977)); baby hamster kidney cells (BHK); mouse sertoli cells (TM4 cells as described, e.g., in Mather, *Biol. Reprod.* 23:243-251 (1980)); monkey kidney cells (CV1); African green monkey kidney cells (VERO-76); human cervical carcinoma cells (HELA); canine kidney cells (MDCK; buffalo rat liver cells (BRL 3A); human lung cells (W138); human liver cells (Hep G2); mouse mammary tumor (MMT 060562); TRI cells, as described, e.g., in Mather et al., *Annals N.Y. Acad. Sci.* 383:44-68 (1982); MRC 5 cells; and FS4 cells. Other useful mammalian host cell lines include Chinese hamster ovary (CHO) cells, including DHFR⁻ CHO cells (Urlaub et al.,

Proc. Natl. Acad. Sci. USA 77:4216 (1980)); and myeloma cell lines such as Y0, NS0 and Sp2/0. For a review of certain mammalian host cell lines suitable for antibody production, see, e.g., Yazaki and Wu, *Methods in Molecular Biology*, Vol. 248 (B.K.C. Lo, ed., Humana Press, Totowa, NJ), pp. 255-268 (2003).

C. Assays

[0252] Anti- PMEL17 antibodies provided herein may be identified, screened for, or characterized for their physical/chemical properties and/or biological activities by various assays known in the art.

[0253] In one aspect, an antibody of the invention is tested for its antigen binding activity, e.g., by known methods such as ELISA, BIACore[®], FACS, or Western blot.

[0254] In another aspect, competition assays may be used to identify an antibody that competes with any of the antibodies described herein for binding to PMEL17. In certain embodiments, such a competing antibody binds to the same epitope (e.g., a linear or a conformational epitope) that is bound by an antibody described herein. Detailed exemplary methods for mapping an epitope to which an antibody binds are provided in Morris (1996) "Epitope Mapping Protocols," in *Methods in Molecular Biology* vol. 66 (Humana Press, Totowa, NJ).

[0255] In an exemplary competition assay, immobilized PMEL17 is incubated in a solution comprising a first labeled antibody that binds to PMEL17 (e.g., any of the antibodies described herein) and a second unlabeled antibody that is being tested for its ability to compete with the first antibody for binding to PMEL17. The second antibody may be present in a hybridoma supernatant. As a control, immobilized PMEL17 is incubated in a solution comprising the first labeled antibody but not the second unlabeled antibody. After incubation under conditions permissive for binding of the first antibody to PMEL17, excess unbound antibody is removed, and the amount of label associated with immobilized PMEL17 is measured. If the amount of label associated with immobilized PMEL17 is substantially reduced in the test sample relative to the control sample, then that indicates that the second antibody is competing with the first antibody for binding to PMEL17. See Harlow and Lane (1988) *Antibodies: A Laboratory Manual* ch.14 (Cold Spring Harbor Laboratory, Cold Spring Harbor, NY).

D. Immunoconjugates

[0256] The invention also provides immunoconjugates comprising an anti-PMEL17 antibody herein conjugated to one or more cytotoxic agents, such as chemotherapeutic agents

or drugs, growth inhibitory agents, toxins (e.g., protein toxins, enzymatically active toxins of bacterial, fungal, plant, or animal origin, or fragments thereof), or radioactive isotopes (i.e., a radioconjugate).

[0257] Immunoconjugates allow for the targeted delivery of a drug moiety to a tumor, and, in some embodiments intracellular accumulation therein, where systemic administration of unconjugated drugs may result in unacceptable levels of toxicity to normal cells (Polakis P. (2005) *Current Opinion in Pharmacology* 5:382-387).

[0258] Antibody-drug conjugates (ADC) are targeted chemotherapeutic molecules which combine properties of both antibodies and cytotoxic drugs by targeting potent cytotoxic drugs to antigen-expressing tumor cells (Teicher, B.A. (2009) *Current Cancer Drug Targets* 9:982-1004), thereby enhancing the therapeutic index by maximizing efficacy and minimizing off-target toxicity (Carter, P.J. and Senter P.D. (2008) *The Cancer Jour.* 14(3):154-169; Chari, R.V. (2008) *Acc. Chem. Res.* 41:98-107 .

[0259] The ADC compounds of the invention include those with anticancer activity. In some embodiments, the ADC compounds include an antibody conjugated, i.e. covalently attached, to the drug moiety. In some embodiments, the antibody is covalently attached to the drug moiety through a linker. The antibody-drug conjugates (ADC) of the invention selectively deliver an effective dose of a drug to tumor tissue whereby greater selectivity, i.e. a lower efficacious dose, may be achieved while increasing the therapeutic index ("therapeutic window").


[0260] The drug moiety (D) of the antibody-drug conjugates (ADC) may include any compound, moiety or group that has a cytotoxic or cytostatic effect. Drug moieties may impart their cytotoxic and cytostatic effects by mechanisms including but not limited to tubulin binding, DNA binding or intercalation, and inhibition of RNA polymerase, protein synthesis, and/or topoisomerase. Exemplary drug moieties include, but are not limited to, a maytansinoid, dolastatin, auristatin, calicheamicin, pyrrolobenzodiazepine (PBD), nemorubicin and its derivatives, PNU-159682, anthracycline, duocarmycin, vinca alkaloid, taxane, trichothecene, CC1065, camptothecin, elinafide, and stereoisomers, isosteres, analogs, and derivatives thereof that have cytotoxic activity. Nonlimiting examples of such immunoconjugates are discussed in further detail below.

1. Exemplary Antibody-drug Conjugates

[0261] An exemplary embodiment of an antibody-drug conjugate (ADC) compound comprises an antibody (Ab) which targets a tumor cell, a drug moiety (D), and a linker moiety

(L) that attaches Ab to D. In some embodiments, the antibody is attached to the linker moiety (L) through one or more amino acid residues, such as lysine and/or cysteine.

[0262] An exemplary ADC has Formula I:



where p is 1 to about 20. In some embodiments, the number of drug moieties that can be conjugated to an antibody is limited by the number of free cysteine residues. In some embodiments, free cysteine residues are introduced into the antibody amino acid sequence by the methods described herein. Exemplary ADC of Formula I include, but are not limited to, antibodies that have 1, 2, 3, or 4 engineered cysteine amino acids (Lyon, R. et al (2012) *Methods in Enzym.* 502:123-138). In some embodiments, one or more free cysteine residues are already present in an antibody, without the use of engineering, in which case the existing free cysteine residues may be used to conjugate the antibody to a drug. In some embodiments, an antibody is exposed to reducing conditions prior to conjugation of the antibody in order to generate one or more free cysteine residues.

a) Exemplary Linkers

[0263] A “Linker” (L) is a bifunctional or multifunctional moiety that can be used to link one or more drug moieties (D) to an antibody (Ab) to form an antibody-drug conjugate (ADC) of Formula I. In some embodiments, antibody-drug conjugates (ADC) can be prepared using a Linker having reactive functionalities for covalently attaching to the drug and to the antibody. For example, in some embodiments, a cysteine thiol of an antibody (Ab) can form a bond with a reactive functional group of a linker or a drug-linker intermediate to make an ADC.

[0264] In one aspect, a linker has a functionality that is capable of reacting with a free cysteine present on an antibody to form a covalent bond. Nonlimiting exemplary such reactive functionalities include maleimide, haloacetamides, α -haloacetyl, activated esters such as succinimide esters, 4-nitrophenyl esters, pentafluorophenyl esters, tetrafluorophenyl esters, anhydrides, acid chlorides, sulfonyl chlorides, isocyanates, and isothiocyanates. *See, e.g.*, the conjugation method at page 766 of Klussman, et al (2004), *Bioconjugate Chemistry* 15(4):765-773, and the Examples herein.


[0265] In some embodiments, a linker has a functionality that is capable of reacting with an electrophilic group present on an antibody. Exemplary such electrophilic groups include, but are not limited to, aldehyde and ketone carbonyl groups. In some embodiments, a heteroatom of the reactive functionality of the linker can react with an electrophilic group on an antibody and form a covalent bond to an antibody unit. Nonlimiting exemplary such

reactive functionalities include, but are not limited to, hydrazide, oxime, amino, hydrazine, thiosemicarbazone, hydrazine carboxylate, and arylhydrazide.

[0266] A linker may comprise one or more linker components. Exemplary linker components include 6-maleimidocaproyl (“MC”), maleimidopropanoyl (“MP”), valine-citrulline (“val-cit” or “vc”), alanine-phenylalanine (“ala-phe”), p-aminobenzyloxycarbonyl (a “PAB”), N-Succinimidyl 4-(2-pyridylthio) pentanoate (“SPP”), and 4-(N-maleimidomethyl) cyclohexane-1 carboxylate (“MCC”). Various linker components are known in the art, some of which are described below.



[0267] A linker may be a “cleavable linker,” facilitating release of a drug. Nonlimiting exemplary cleavable linkers include acid-labile linkers (e.g., comprising hydrazone), protease-sensitive (e.g., peptidase-sensitive) linkers, photolabile linkers, or disulfide-containing linkers (Chari et al., Cancer Research 52:127-131 (1992); US 5208020).


[0268] In certain embodiments, a linker has the following Formula II:



wherein A is a “stretcher unit”, and a is an integer from 0 to 1; W is an “amino acid unit”, and w is an integer from 0 to 12; Y is a “spacer unit”, and y is 0, 1, or 2; and Ab, D, and p are defined as above for Formula I. Exemplary embodiments of such linkers are described in U.S. Patent No. 7,498,298, which is expressly incorporated herein by reference.

[0269] In some embodiments, a linker component comprises a “stretcher unit” that links an antibody to another linker component or to a drug moiety. Nonlimiting exemplary stretcher units are shown below (wherein the wavy line indicates sites of covalent attachment to an antibody, drug, or additional linker components):






[0270] In some embodiments, a linker component comprises an “amino acid unit”. In some such embodiments, the amino acid unit allows for cleavage of the linker by a protease, thereby facilitating release of the drug from the immunoconjugate upon exposure to intracellular proteases, such as lysosomal enzymes (Doronina et al. (2003) *Nat. Biotechnol.* 21:778-784). Exemplary amino acid units include, but are not limited to, dipeptides, tripeptides, tetrapeptides, and pentapeptides. Exemplary dipeptides include, but are not limited to, valine-citrulline (vc or val-cit), alanine-phenylalanine (af or ala-phe); phenylalanine-lysine (fk or phe-lys); phenylalanine-homolysine (phe-homolys); and N-methyl-valine-citrulline (Me-val-cit). Exemplary tripeptides include, but are not limited to, glycine-valine-citrulline (gly-val-cit) and glycine-glycine-glycine (gly-gly-gly). An amino acid unit may comprise amino acid residues that occur naturally and/or minor amino acids and/or non-naturally occurring amino acid analogs, such as citrulline. Amino acid units can be designed and optimized for enzymatic cleavage by a particular enzyme, for example, a tumor-associated protease, cathepsin B, C and D, or a plasmin protease.

[0271] In some embodiments, a linker component comprises a “spacer” unit that links the antibody to a drug moiety, either directly or through a stretcher unit and/or an amino acid unit. A spacer unit may be “self-immolative” or a “non-self-immolative.” A “non-self-immolative” spacer unit is one in which part or all of the spacer unit remains bound to the drug moiety upon cleavage of the ADC. Examples of non-self-immolative spacer units include, but are not limited to, a glycine spacer unit and a glycine-glycine spacer unit. In some embodiments, enzymatic cleavage of an ADC containing a glycine-glycine spacer unit by a tumor-cell associated protease results in release of a glycine-glycine-drug moiety from the remainder of the ADC. In some such embodiments, the glycine-glycine-drug moiety is subjected to a hydrolysis step in the tumor cell, thus cleaving the glycine-glycine spacer unit from the drug moiety.

[0272] A “self-immolative” spacer unit allows for release of the drug moiety. In certain embodiments, a spacer unit of a linker comprises a p-aminobenzyl unit. In some such embodiments, a p-aminobenzyl alcohol is attached to an amino acid unit via an amide bond, and a carbamate, methylcarbamate, or carbonate is made between the benzyl alcohol and the drug (Hamann et al. (2005) *Expert Opin. Ther. Patents* (2005) 15:1087-1103). In some embodiments, the spacer unit is p-aminobenzylloxycarbonyl (PAB). In some embodiments, an ADC comprising a self-immolative linker has the structure:






wherein Q is -C₁-C₈ alkyl, -O-(C₁-C₈ alkyl), -halogen, -nitro, or -cyano; m is an integer ranging from 0 to 4; and p ranges from 1 to about 20. In some embodiments, p ranges from 1 to 10, 1 to 7, 1 to 5, or 1 to 4.


[0273] Other examples of self-immolative spacers include, but are not limited to, aromatic compounds that are electronically similar to the PAB group, such as 2-aminoimidazol-5-methanol derivatives (U.S. Patent No. 7,375,078; Hay et al. (1999) *Bioorg. Med. Chem. Lett.* 9:2237) and ortho- or para-aminobenzylacetals. In some embodiments, spacers can be used that undergo cyclization upon amide bond hydrolysis, such as substituted and unsubstituted 4-aminobutyric acid amides (Rodrigues et al (1995) *Chemistry Biology* 2:223), appropriately substituted bicyclo[2.2.1] and bicyclo[2.2.2] ring systems (Storm et al (1972) *J. Amer. Chem. Soc.* 94:5815) and 2-aminophenylpropionic acid amides (Amsberry, et al (1990) *J. Org. Chem.* 55:5867). Linkage of a drug to the α-carbon of a glycine residue is another example of a self-immolative spacer that may be useful in ADC (Kingsbury et al (1984) *J. Med. Chem.* 27:1447).

[0274] In some embodiments, linker L may be a dendritic type linker for covalent attachment of more than one drug moiety to an antibody through a branching, multifunctional linker moiety (Sun et al (2002) *Bioorganic & Medicinal Chemistry Letters* 12:2213-2215; Sun et al (2003) *Bioorganic & Medicinal Chemistry* 11:1761-1768). Dendritic linkers can increase the molar ratio of drug to antibody, i.e. loading, which is related to the potency of the ADC. Thus, where an antibody bears only one reactive cysteine thiol group, a multitude of drug moieties may be attached through a dendritic linker.


[0275] Nonlimiting exemplary linkers are shown below in the context of an ADC of Formula I:




[0276] Further nonlimiting exemplary ADCs include the structures:



where X is:



Y is:




each R is independently H or C₁–C₆ alkyl; and n is 1 to 12.

[0277] Typically, peptide-type linkers can be prepared by forming a peptide bond between two or more amino acids and/or peptide fragments. Such peptide bonds can be prepared, for example, according to a liquid phase synthesis method (e.g., E. Schröder and K. Lübke (1965) “The Peptides”, volume 1, pp 76-136, Academic Press).

[0278] In some embodiments, a linker is substituted with groups that modulate solubility and/or reactivity. As a nonlimiting example, a charged substituent such as sulfonate (–SO₃[–]) or ammonium may increase water solubility of the linker reagent and facilitate the coupling reaction of the linker reagent with the antibody and/or the drug moiety, or facilitate the coupling reaction of Ab-L (antibody-linker intermediate) with D, or D-L (drug-linker intermediate) with Ab, depending on the synthetic route employed to prepare the ADC. In some embodiments, a portion of the linker is coupled to the antibody and a portion of the linker is coupled to the drug, and then the Ab-(linker portion)^a is coupled to drug-(linker portion)^b to form the ADC of Formula I. In some such embodiments, the antibody comprises more than one (linker portion)^a substituents, such that more than one drug is coupled to the antibody in the ADC of Formula I.

[0279] The compounds of the invention expressly contemplate, but are not limited to, ADC prepared with the following linker reagents: bis-maleimido-trioxyethylene glycol (BMPEO), N-(β-maleimidopropoxy)-N-hydroxy succinimide ester (BMPS), N-(ε-maleimidocaproxy) succinimide ester (EMCS), N-[γ-maleimidobutyryloxy]succinimide ester (GMBS), 1,6-hexane-bis-vinylsulfone (HBVS), succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxy-(6-amidocaproate) (LC-SMCC), m-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS), 4-(4-N-Maleimidophenyl)butyric acid

hydrazide (MPBH), succinimidyl 3-(bromoacetamido)propionate (SBAP), succinimidyl iodoacetate (SIA), succinimidyl (4-iodoacetyl)aminobenzoate (SIAB), N-succinimidyl-3-(2-pyridyldithio) propionate (SPDP), N-succinimidyl-4-(2-pyridylthio)pentanoate (SPP), succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC), succinimidyl 4-(p-maleimidophenyl)butyrate (SMPB), succinimidyl 6-[(beta-maleimidopropionamido)hexanoate] (SMPH), iminothiolane (IT), sulfo-EMCS, sulfo-GMBS, sulfo-KMUS, sulfo-MBS, sulfo-SIAB, sulfo-SMCC, and sulfo-SMPB, and succinimidyl-(4-vinylsulfone)benzoate (SVSB), and including bis-maleimide reagents: dithiobismaleimidoethane (DTME), 1,4-Bismaleimidobutane (BMB), 1,4 Bismaleimidyl-2,3-dihydroxybutane (BMDB), bismaleimidohexane (BMH), bismaleimidoethane (BMOE), BM(PEG)₂ (shown below), and BM(PEG)₃ (shown below); bifunctional derivatives of imidoesters (such as dimethyl adipimidate HCl), active esters (such as disuccinimidyl suberate), aldehydes (such as glutaraldehyde), bis-azido compounds (such as bis (p-azidobenzoyl) hexanediamine), bis-diazonium derivatives (such as bis-(p-diazoniumbenzoyl)-ethylenediamine), diisocyanates (such as toluene 2,6-diisocyanate), and bis-active fluorine compounds (such as 1,5-difluoro-2,4-dinitrobenzene). In some embodiments, bis-maleimide reagents allow the attachment of the thiol group of a cysteine in the antibody to a thiol-containing drug moiety, linker, or linker-drug intermediate. Other functional groups that are reactive with thiol groups include, but are not limited to, iodoacetamide, bromoacetamide, vinyl pyridine, disulfide, pyridyl disulfide, isocyanate, and isothiocyanate.



[0280] Certain useful linker reagents can be obtained from various commercial sources, such as Pierce Biotechnology, Inc. (Rockford, IL), Molecular Biosciences Inc. (Boulder, CO), or synthesized in accordance with procedures described in the art; for example, in Toki et al (2002) *J. Org. Chem.* 67:1866-1872; Dubowchik, et al. (1997) *Tetrahedron Letters*, 38:5257-60; Walker, M.A. (1995) *J. Org. Chem.* 60:5352-5355; Frisch et al (1996) *Bioconjugate Chem.* 7:180-186; US 6214345; WO 02/088172; US 2003130189; US2003096743; WO 03/026577; WO 03/043583; and WO 04/032828.

[0281] Carbon-14-labeled 1-isothiocyanatobenzyl-3-methyldiethylene triaminepentaacetic acid (MX-DTPA) is an exemplary chelating agent for conjugation of radionucleotide to the antibody. See, e.g., WO94/11026.

b) Exemplary Drug Moieties*(1) Maytansine and maytansinoids*

[0282] In some embodiments, an immunoconjugate comprises an antibody conjugated to one or more maytansinoid molecules. Maytansinoids are derivatives of maytansine, and are mitototic inhibitors which act by inhibiting tubulin polymerization. Maytansine was first isolated from the east African shrub *Maytenus serrata* (U.S. Patent No. 3896111).

Subsequently, it was discovered that certain microbes also produce maytansinoids, such as maytansinol and C-3 maytansinol esters (U.S. Patent No. 4,151,042). Synthetic maytansinoids are disclosed, for example, in U.S. Patent Nos. 4,137,230; 4,248,870; 4,256,746; 4,260,608; 4,265,814; 4,294,757; 4,307,016; 4,308,268; 4,308,269; 4,309,428; 4,313,946; 4,315,929; 4,317,821; 4,322,348; 4,331,598; 4,361,650; 4,364,866; 4,424,219; 4,450,254; 4,362,663; and 4,371,533.

[0283] Maytansinoid drug moieties are attractive drug moieties in antibody-drug conjugates because they are: (i) relatively accessible to prepare by fermentation or chemical modification or derivatization of fermentation products, (ii) amenable to derivatization with functional groups suitable for conjugation through non-disulfide linkers to antibodies, (iii) stable in plasma, and (iv) effective against a variety of tumor cell lines.

[0284] Certain maytansinoids suitable for use as maytansinoid drug moieties are known in the art and can be isolated from natural sources according to known methods or produced using genetic engineering techniques (see, e.g., Yu et al (2002) PNAS 99:7968-7973). Maytansinoids may also be prepared synthetically according to known methods.


[0285] Exemplary maytansinoid drug moieties include, but are not limited to, those having a modified aromatic ring, such as: C-19-dechloro (US Pat. No. 4256746) (prepared, for example, by lithium aluminum hydride reduction of ansamycin P2); C-20-hydroxy (or C-20-demethyl) +/-C-19-dechloro (US Pat. Nos. 4361650 and 4307016) (prepared, for example, by demethylation using *Streptomyces* or *Actinomyces* or dechlorination using LAH); and C-20-demethoxy, C-20-acyloxy (-OCOR), +/-dechloro (U.S. Pat. No. 4,294,757) (prepared, for example, by acylation using acyl chlorides), and those having modifications at other positions of the aromatic ring.

[0286] Exemplary maytansinoid drug moieties also include those having modifications such as: C-9-SH (US Pat. No. 4424219) (prepared, for example, by the reaction of maytansinol with H₂S or P₂S₅); C-14-alkoxymethyl(demethoxy/CH₂ OR)(US 4331598); C-14-hydroxymethyl or acyloxymethyl (CH₂OH or CH₂OAc) (US Pat. No. 4450254) (prepared, for example, from *Nocardia*); C-15-hydroxy/acyloxy (US 4364866) (prepared, for example, by the

conversion of maytansinol by *Streptomyces*); C-15-methoxy (US Pat. Nos. 4313946 and 4315929) (for example, isolated from *Trewia nudiflora*); C-18-N-demethyl (US Pat. Nos. 4362663 and 4322348) (prepared, for example, by the demethylation of maytansinol by *Streptomyces*); and 4,5-deoxy (US 4371533) (prepared, for example, by the titanium trichloride/LAH reduction of maytansinol).


[0287] Many positions on maytansinoid compounds are useful as the linkage position. For example, an ester linkage may be formed by reaction with a hydroxyl group using conventional coupling techniques. In some embodiments, the reaction may occur at the C-3 position having a hydroxyl group, the C-14 position modified with hydroxymethyl, the C-15 position modified with a hydroxyl group, and the C-20 position having a hydroxyl group. In some embodiments, the linkage is formed at the C-3 position of maytansinol or a maytansinol analogue.

[0288] Maytansinoid drug moieties include those having the structure:






where the wavy line indicates the covalent attachment of the sulfur atom of the maytansinoid drug moiety to a linker of an ADC. Each R may independently be H or a C₁–C₆ alkyl. The alkylene chain attaching the amide group to the sulfur atom may be methanyl, ethanyl, or propyl, i.e., m is 1, 2, or 3 (US 633410; US 5208020; Chari et al (1992) *Cancer Res.* 52:127-131; Liu et al (1996) *Proc. Natl. Acad. Sci USA* 93:8618-8623).

[0289] All stereoisomers of the maytansinoid drug moiety are contemplated for the ADC of the invention, i.e. any combination of *R* and *S* configurations at the chiral carbons (US 7276497; US 6913748; US 6441163; US 633410 (RE39151); US 5208020; Widdison et al (2006) *J. Med. Chem.* 49:4392-4408, which are incorporated by reference in their entirety). In some embodiments, the maytansinoid drug moiety has the following stereochemistry:





[0290] Exemplary embodiments of maytansinoid drug moieties include, but are not limited to, DM1; DM3; and DM4, having the structures:






wherein the wavy line indicates the covalent attachment of the sulfur atom of the drug to a linker (L) of an antibody-drug conjugate.

[0291] Other exemplary maytansinoid antibody-drug conjugates have the following structures and abbreviations (wherein Ab is antibody and p is 1 to about 20. In some embodiments, p is 1 to 10, p is 1 to 7, p is 1 to 5, or p is 1 to 4):



[0292] Exemplary antibody-drug conjugates where DM1 is linked through a BMPEO linker to a thiol group of the antibody have the structure and abbreviation:



where Ab is antibody; n is 0, 1, or 2; and p is 1 to about 20. In some embodiments, p is 1 to 10, p is 1 to 7, p is 1 to 5, or p is 1 to 4.

[0293] Immunoconjugates containing maytansinoids, methods of making the same, and their therapeutic use are disclosed, for example, in U.S. Patent Nos. 5,208,020 and 5,416,064; US 2005/0276812 A1; and European Patent EP 0 425 235 B1, the disclosures of which are hereby expressly incorporated by reference. *See also* Liu et al. *Proc. Natl. Acad. Sci. USA* 93:8618-8623 (1996); and Chari et al. *Cancer Research* 52:127-131 (1992).


[0294] In some embodiments, antibody-maytansinoid conjugates may be prepared by chemically linking an antibody to a maytansinoid molecule without significantly diminishing the biological activity of either the antibody or the maytansinoid molecule. *See, e.g.*, U.S. Patent No. 5,208,020 (the disclosure of which is hereby expressly incorporated by reference). In some embodiments, ADC with an average of 3-4 maytansinoid molecules conjugated per antibody molecule has shown efficacy in enhancing cytotoxicity of target cells without negatively affecting the function or solubility of the antibody. In some instances, even one molecule of toxin/antibody is expected to enhance cytotoxicity over the use of naked antibody.

[0295] Exemplary linking groups for making antibody-maytansinoid conjugates include, for example, those described herein and those disclosed in U.S. Patent No. 5208020; EP Patent 0 425 235 B1; Chari et al. *Cancer Research* 52:127-131 (1992); US 2005/0276812 A1; and US 2005/016993 A1, the disclosures of which are hereby expressly incorporated by reference.

(2) Auristatins and dolastatins

[0296] Drug moieties include dolastatins, auristatins, and analogs and derivatives thereof (US 5635483; US 5780588; US 5767237; US 6124431). Auristatins are derivatives of the marine mollusk compound dolastatin-10. While not intending to be bound by any particular theory, dolastatins and auristatins have been shown to interfere with microtubule dynamics, GTP hydrolysis, and nuclear and cellular division (Woyke et al (2001) *Antimicrob. Agents and Chemother.* 45(12):3580-3584) and have anticancer (US 5663149) and antifungal activity (Pettit et al (1998) *Antimicrob. Agents Chemother.* 42:2961-2965). The dolastatin/auristatin drug moiety may be attached to the antibody through the N (amino) terminus or the C (carboxyl) terminus of the peptidic drug moiety (WO 02/088172; Doronina et al (2003) *Nature Biotechnology* 21(7):778-784; Francisco et al (2003) *Blood* 102(4):1458-1465).

[0297] Exemplary auristatin embodiments include the N-terminus linked monomethylauristatin drug moieties D_E and D_F, disclosed in US 7498298 and US 7659241, the disclosures of which are expressly incorporated by reference in their entirety:



wherein the wavy line of D_E and D_F indicates the covalent attachment site to an antibody or antibody-linker component, and independently at each location:

R² is selected from H and C₁-C₈ alkyl;

R³ is selected from H, C₁-C₈ alkyl, C₃-C₈ carbocycle, aryl, C₁-C₈ alkyl-aryl, C₁-C₈ alkyl-(C₃-C₈ carbocycle), C₃-C₈ heterocycle and C₁-C₈ alkyl-(C₃-C₈ heterocycle);

R⁴ is selected from H, C₁-C₈ alkyl, C₃-C₈ carbocycle, aryl, C₁-C₈ alkyl-aryl, C₁-C₈ alkyl-(C₃-C₈ carbocycle), C₃-C₈ heterocycle and C₁-C₈ alkyl-(C₃-C₈ heterocycle);

R⁵ is selected from H and methyl;

or R^4 and R^5 jointly form a carbocyclic ring and have the formula $-(CR^aR^b)_n-$ wherein R^a and R^b are independently selected from H, C_1 - C_8 alkyl and C_3 - C_8 carbocycle and n is selected from 2, 3, 4, 5 and 6;

R^6 is selected from H and C_1 - C_8 alkyl;

R^7 is selected from H, C_1 - C_8 alkyl, C_3 - C_8 carbocycle, aryl, C_1 - C_8 alkyl-aryl, C_1 - C_8 alkyl- $(C_3$ - C_8 carbocycle), C_3 - C_8 heterocycle and C_1 - C_8 alkyl- $(C_3$ - C_8 heterocycle);

each R^8 is independently selected from H, OH, C_1 - C_8 alkyl, C_3 - C_8 carbocycle and O- $(C_1$ - C_8 alkyl);

R^9 is selected from H and C_1 - C_8 alkyl;

R^{10} is selected from aryl or C_3 - C_8 heterocycle;

Z is O, S, NH, or NR^{12} , wherein R^{12} is C_1 - C_8 alkyl;

R^{11} is selected from H, C_1 - C_{20} alkyl, aryl, C_3 - C_8 heterocycle, $-(R^{13}O)_m-R^{14}$, or $-(R^{13}O)_m-CH(R^{15})_2$;

m is an integer ranging from 1-1000;

R^{13} is C_2 - C_8 alkyl;

R^{14} is H or C_1 - C_8 alkyl;

each occurrence of R^{15} is independently H, COOH, $-(CH_2)_n-N(R^{16})_2$, $-(CH_2)_n-SO_3H$, or $-(CH_2)_n-SO_3-C_1$ - C_8 alkyl;

each occurrence of R^{16} is independently H, C_1 - C_8 alkyl, or $-(CH_2)_n-COOH$;

R^{18} is selected from $-C(R^8)_2-C(R^8)_2$ -aryl, $-C(R^8)_2-C(R^8)_2$ -(C_3 - C_8 heterocycle), and $-C(R^8)_2-C(R^8)_2$ -(C_3 - C_8 carbocycle); and

n is an integer ranging from 0 to 6.

[0298] In one embodiment, R^3 , R^4 and R^7 are independently isopropyl or sec-butyl and R^5 is -H or methyl. In an exemplary embodiment, R^3 and R^4 are each isopropyl, R^5 is -H, and R^7 is sec-butyl.

[0299] In yet another embodiment, R^2 and R^6 are each methyl, and R^9 is -H.

[0300] In still another embodiment, each occurrence of R^8 is $-OCH_3$.

[0301] In an exemplary embodiment, R^3 and R^4 are each isopropyl, R^2 and R^6 are each methyl, R^5 is -H, R^7 is sec-butyl, each occurrence of R^8 is $-OCH_3$, and R^9 is -H.

[0302] In one embodiment, Z is -O- or -NH-.

[0303] In one embodiment, R^{10} is aryl.


[0304] In an exemplary embodiment, R^{10} is -phenyl.

[0305] In an exemplary embodiment, when Z is -O-, R^{11} is -H, methyl or t-butyl.


[0306] In one embodiment, when Z is -NH, R^{11} is $-\text{CH}(R^{15})_2$, wherein R^{15} is $-(\text{CH}_2)_n-\text{N}(R^{16})_2$, and R^{16} is $-\text{C}_1-\text{C}_8$ alkyl or $-(\text{CH}_2)_n-\text{COOH}$.

[0307] In another embodiment, when Z is -NH, R^{11} is $-\text{CH}(R^{15})_2$, wherein R^{15} is $-(\text{CH}_2)_n-\text{SO}_3\text{H}$.

[0308] An exemplary auristatin embodiment of formula D_E is MMAE, wherein the wavy line indicates the covalent attachment to a linker (L) of an antibody-drug conjugate:




[0309] An exemplary auristatin embodiment of formula D_F is MMAF, wherein the wavy line indicates the covalent attachment to a linker (L) of an antibody-drug conjugate:




[0310] Other exemplary embodiments include monomethylvaline compounds having phenylalanine carboxy modifications at the C-terminus of the pentapeptide auristatin drug moiety (WO 2007/008848) and monomethylvaline compounds having phenylalanine sidechain modifications at the C-terminus of the pentapeptide auristatin drug moiety (WO 2007/008603).


[0311] Nonlimiting exemplary embodiments of ADC of Formula I comprising MMAE or MMAF and various linker components have the following structures and abbreviations (wherein “Ab” is an antibody; p is 1 to about 8, “Val-Cit” is a valine-citrulline dipeptide; and “S” is a sulfur atom:




Ab-MC-vc-PAB-MMAF



Ab-MC-vc-PAB-MMAE



Ab-MC-MMAE



Ab-MC-MMAF

[0312] Nonlimiting exemplary embodiments of ADCs of Formula I comprising MMAF and various linker components further include Ab-MC-PAB-MMAF and Ab-PAB-MMAF. Immunoconjugates comprising MMAF attached to an antibody by a linker that is not proteolytically cleavable have been shown to possess activity comparable to immunoconjugates comprising MMAF attached to an antibody by a proteolytically cleavable linker (Doronina et al. (2006) *Bioconjugate Chem.* 17:114-124). In some such embodiments, drug release is believed to be effected by antibody degradation in the cell.

[0313] Typically, peptide-based drug moieties can be prepared by forming a peptide bond between two or more amino acids and/or peptide fragments. Such peptide bonds can be prepared, for example, according to a liquid phase synthesis method (see, e.g., E. Schröder and K. Lübke, "The Peptides", volume 1, pp 76-136, 1965, Academic Press). Auristatin/dolastatin drug moieties may, in some embodiments, be prepared according to the methods of: US 7498298; US 5635483; US 5780588; Pettit et al (1989) *J. Am. Chem. Soc.* 111:5463-5465; Pettit et al (1998) *Anti-Cancer Drug Design* 13:243-277; Pettit, G.R., et al. *Synthesis*, 1996, 719-725; Pettit et al (1996) *J. Chem. Soc. Perkin Trans. 1* 5:859-863; and Doronina (2003) *Nat. Biotechnol.* 21(7):778-784.

[0314] In some embodiments, auristatin/dolastatin drug moieties of formulas D_E such as MMAE, and D_F, such as MMAF, and drug-linker intermediates and derivatives thereof, such as MC-MMAF, MC-MMAE, MC-vc-PAB-MMAF, and MC-vc-PAB-MMAE, may be prepared using methods described in US 7498298; Doronina et al. (2006) *Bioconjugate Chem.* 17:114-124; and Doronina et al. (2003) *Nat. Biotech.* 21:778-784 and then conjugated to an antibody of interest.

(3) *Calicheamicin*


[0315] In some embodiments, the immunoconjugate comprises an antibody conjugated to one or more calicheamicin molecules. The calicheamicin family of antibiotics, and analogues thereof, are capable of producing double-stranded DNA breaks at sub-picomolar concentrations (Hinman et al., (1993) *Cancer Research* 53:3336-3342; Lode et al., (1998) *Cancer Research* 58:2925-2928). Calicheamicin has intracellular sites of action but, in certain instances, does not readily cross the plasma membrane. Therefore, cellular uptake of these agents through antibody-mediated internalization may, in some embodiments, greatly enhance their cytotoxic effects. Nonlimiting exemplary methods of preparing antibody-drug conjugates with a calicheamicin drug moiety are described, for example, in US 5712374; US 5714586; US 5739116; and US 5767285.

(4) *Pyrrolobenzodiazepines*

[0316] In some embodiments, an ADC comprises a pyrrolobenzodiazepine (PBD). In some embodiments, PBD dimers recognize and bind to specific DNA sequences. The natural product anthramycin, a PBD, was first reported in 1965 (Leimgruber, et al., (1965) *J. Am. Chem. Soc.*, 87:5793-5795; Leimgruber, et al., (1965) *J. Am. Chem. Soc.*, 87:5791-5793). Since then, a number of PBDs, both naturally-occurring and analogues, have been reported (Thurston, et al., (1994) *Chem. Rev.* 1994, 433-465 including dimers of the tricyclic PBD scaffold (US 6884799; US 7049311; US 7067511; US 7265105; US 7511032; US 7528126; US 7557099). Without intending to be bound by any particular theory, it is believed that the dimer structure imparts the appropriate three-dimensional shape for isohelicity with the minor groove of B-form DNA, leading to a snug fit at the binding site (Kohn, In *Antibiotics III*. Springer-Verlag, New York, pp. 3-11 (1975); Hurley and Needham-VanDevanter, (1986) *Acc. Chem. Res.*, 19:230-237). Dimeric PBD compounds bearing C2 aryl substituents have been shown to be useful as cytotoxic agents (Hartley et al (2010) *Cancer Res.* 70(17):6849-6858; Antonow (2010) *J. Med. Chem.* 53(7):2927-2941; Howard et al (2009) *Bioorganic and Med. Chem. Letters* 19(22):6463-6466).

[0317] PBD dimers have been conjugated to antibodies and the resulting ADC shown to have anti-cancer properties. Nonlimiting exemplary linkage sites on the PBD dimer include the five-membered pyrrolo ring, the tether between the PBD units, and the N10-C11 imine group (WO 2009/016516; US 2009/304710; US 2010/047257; US 2009/036431; US 2011/0256157; WO 2011/130598).

[0318] Nonlimiting exemplary PBD dimer components of ADCs are of Formula A:



and salts and solvates thereof, wherein:

the wavy line indicates the covalent attachment site to the linker;

the dotted lines indicate the optional presence of a double bond between C1 and C2 or C2 and C3;

R^2 is independently selected from H, OH, =O, =CH₂, CN, R, OR, =CH-R^D, =C(R^D)₂, O-SO₂-R, CO₂R and COR, and optionally further selected from halo or dihalo, wherein R^D is independently selected from R, CO₂R, COR, CHO, CO₂H, and halo;

R^6 and R^9 are independently selected from H, R, OH, OR, SH, SR, NH₂, NHR, NRR', NO₂, Me₃Sn and halo;

R^7 is independently selected from H, R, OH, OR, SH, SR, NH₂, NHR, NRR', NO₂, Me₃Sn and halo;

Q is independently selected from O, S and NH;

R^{11} is either H, or R or, where Q is O, SO₃M, where M is a metal cation;

R and R' are each independently selected from optionally substituted C₁₋₈ alkyl, C₁₋₁₂ alkyl, C₃₋₈ heterocyclyl, C₃₋₂₀ heterocycle, and C₅₋₂₀ aryl groups, and optionally in relation to the group NRR', R and R' together with the nitrogen atom to which they are attached form an optionally substituted 4-, 5-, 6- or 7-membered heterocyclic ring;

R^{12} , R^{16} , R^{19} and R^{17} are as defined for R^2 , R^6 , R^9 and R^7 respectively;

R'' is a C₃₋₁₂ alkylene group, which chain may be interrupted by one or more heteroatoms, e.g. O, S, N(H), NMe and/or aromatic rings, e.g. benzene or pyridine, which rings are optionally substituted; and

X and X' are independently selected from O, S and N(H).

[0319] In some embodiments, R^9 and R^{19} are H.

[0320] In some embodiments, R^6 and R^{16} are H.

[0321] In some embodiments, R^7 and R^{17} are both OR^{7A}, where R^{7A} is optionally substituted C₁₋₄ alkyl. In some embodiments, R^{7A} is Me. In some embodiments, R^{7A} is is CH₂Ph, where Ph is a phenyl group.


[0322] In some embodiments, X is O.

[0323] In some embodiments, R^{11} is H.


[0324] In some embodiments, there is a double bond between C2 and C3 in each monomer unit.

[0325] In some embodiments, R^2 and R^{12} are independently selected from H and R. In some embodiments, R^2 and R^{12} are independently R. In some embodiments, R^2 and R^{12} are independently optionally substituted C_{5-20} aryl or C_{5-7} aryl or C_{8-10} aryl. In some embodiments, R^2 and R^{12} are independently optionally substituted phenyl, thienyl, naphthyl, pyridyl, quinoliny, or isoquinoliny. In some embodiments, R^2 and R^{12} are independently selected from $=O$, $=CH_2$, $=CH-R^D$, and $=C(R^D)_2$. In some embodiments, R^2 and R^{12} each $=CH_2$. In some embodiments, R^2 and R^{12} are each H. In some embodiments, R^2 and R^{12} are each $=O$. In some embodiments, R^2 and R^{12} are each $=CF_2$. In some embodiments, R^2 and/or R^{12} are independently $=C(R^D)_2$. In some embodiments, R^2 and/or R^{12} are independently $=CH-R^D$.

[0326] In some embodiments, when R^2 and/or R^{12} is $=CH-R^D$, each group may independently have either configuration shown below:



(I)




(II)

In some embodiments, a $=CH-R^D$ is in configuration (I).

[0327] In some embodiments, R'' is a C_3 alkylene group or a C_5 alkylene group.


[0328] In some embodiments, an exemplary PBD dimer component of an ADC has the structure of Formula A(I):



A(I);

wherein n is 0 or 1.


[0329] In some embodiments, an exemplary PBD dimer component of an ADC has the structure of Formula A(II):



A(II);

wherein n is 0 or 1.

[0330] In some embodiments, an exemplary PBD dimer component of an ADC has the structure of Formula A(III):




wherein R^E and $R^{E''}$ are each independently selected from H or R^D , wherein R^D is defined as above; and

wherein n is 0 or 1.

[0331] In some embodiments, n is 0. In some embodiments, n is 1. In some embodiments, R^E and/or $R^{E''}$ is H. In some embodiments, R^E and $R^{E''}$ are H. In some embodiments, R^E and/or $R^{E''}$ is R^D , wherein R^D is optionally substituted C_{1-12} alkyl. In some embodiments, R^E and/or $R^{E''}$ is R^D , wherein R^D is methyl.


[0332] In some embodiments, an exemplary PBD dimer component of an ADC has the structure of Formula A(IV):



wherein Ar^1 and Ar^2 are each independently optionally substituted C_{5-20} aryl; wherein Ar^1 and Ar^2 may be the same or different; and

wherein n is 0 or 1.

[0333] In some embodiments, an exemplary PBD dimer component of an ADC has the structure of Formula A(V):




wherein Ar^1 and Ar^2 are each independently optionally substituted C_{5-20} aryl; wherein Ar^1 and Ar^2 may be the same or different; and

wherein n is 0 or 1.

[0334] In some embodiments, Ar¹ and Ar² are each independently selected from optionally substituted phenyl, furanyl, thiophenyl and pyridyl. In some embodiments, Ar¹ and Ar² are each independently optionally substituted phenyl. In some embodiments, Ar¹ and Ar² are each independently optionally substituted thien-2-yl or thien-3-yl. In some embodiments, Ar¹ and Ar² are each independently optionally substituted quinolinyl or isoquinolinyl. The quinolinyl or isoquinolinyl group may be bound to the PBD core through any available ring position. For example, the quinolinyl may be quinolin-2-yl, quinolin-3-yl, quinolin-4-yl, quinolin-5-yl, quinolin-6-yl, quinolin-7-yl and quinolin-8-yl. In some embodiments, the quinolinyl is selected from quinolin-3-yl and quinolin-6-yl. The isoquinolinyl may be isoquinolin-1-yl, isoquinolin-3-yl, isoquinolin-4-yl, isoquinolin-5-yl, isoquinolin-6-yl, isoquinolin-7-yl and isoquinolin-8-yl. In some embodiments, the isoquinolinyl is selected from isoquinolin-3-yl and isoquinolin-6-yl.

[0335] Further nonlimiting exemplary PBD dimer components of ADCs are of Formula B:



and salts and solvates thereof, wherein:

the wavy line indicates the covalent attachment site to the linker;

the wavy line connected to the OH indicates the S or R configuration;



R^{V1} and R^{V2} are independently selected from H, methyl, ethyl and phenyl (which phenyl may be optionally substituted with fluoro, particularly in the 4 position) and C₅₋₆ heterocyclyl; wherein R^{V1} and R^{V2} may be the same or different; and

n is 0 or 1.

[0336] In some embodiments, R^{V1} and R^{V2} are independently selected from H, phenyl, and 4-fluorophenyl.

[0337] In some embodiments, a linker may be attached at one of various sites of the PBD dimer drug moiety, including the N10 imine of the B ring, the C-2 endo/exo position of the C ring, or the tether unit linking the A rings (see structures C(I) and C(II) below).

[0338] Nonlimiting exemplary PBD dimer components of ADCs include Formulas C(I) and C(II):



[0339] Formulas C(I) and C(II) are shown in their N10-C11 imine form. Exemplary PBD drug moieties also include the carbinolamine and protected carbinolamine forms as well, as shown in the table below:

 Imine	 Carbinolamine	 Protected Carbinolamine
-----------	-------------------	-----------------------------

wherein:

X is CH₂ (n = 1 to 5), N, or O;

Z and Z' are independently selected from OR and NR₂, where R is a primary, secondary or tertiary alkyl chain containing 1 to 5 carbon atoms;

R₁, R'₁, R₂ and R'₂ are each independently selected from H, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, C₅₋₂₀ aryl (including substituted aryls), C₅₋₂₀ heteroaryl groups, -NH₂, -NHMe, -OH, and -SH, where, in some embodiments, alkyl, alkenyl and alkynyl chains comprise up to 5 carbon atoms;

R₃ and R'₃ are independently selected from H, OR, NHR, and NR₂, where R is a primary, secondary or tertiary alkyl chain containing 1 to 5 carbon atoms;

R₄ and R'₄ are independently selected from H, Me, and OMe;


R₅ is selected from C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, C₅₋₂₀ aryl (including aryls substituted by halo, nitro, cyano, alkoxy, alkyl, heterocyclyl) and C₅₋₂₀ heteroaryl groups, where, in some embodiments, alkyl, alkenyl and alkynyl chains comprise up to 5 carbon atoms;

R₁₁ is H, C₁-C₈ alkyl, or a protecting group (such as acetyl, trifluoroacetyl, t-butoxycarbonyl (BOC), benzyloxycarbonyl (CBZ), 9-fluorenylmethylenoxycarbonyl (Fmoc), or a moiety comprising a self-immolating unit such as valine-citrulline-PAB);


R₁₂ is H, C₁-C₈ alkyl, or a protecting group;


wherein a hydrogen of one of R_1 , R'_1 , R_2 , R'_2 , R_5 , or R_{12} or a hydrogen of the $-OCH_2CH_2(X)_nCH_2CH_2O-$ spacer between the A rings is replaced with a bond connected to the linker of the ADC.

[0340] Exemplary PDB dimer portions of ADC include, but are not limited to (the wavy line indicates the site of covalent attachment to the linker):



[0341] Nonlimiting exemplary embodiments of ADCs comprising PBD dimers have the following structures:





PBD dimer-Phe-Lys-PAB-Ab, wherein:

n is 0 to 12. In some embodiments, n is 2 to 10. In some embodiments, n is 4 to 8. In some embodiments, n is selected from 4, 5, 6, 7, and 8.

[0342] The linkers of PBD dimer-val-cit-PAB-Ab and the PBD dimer-Phe-Lys-PAB-Ab are protease cleavable, while the linker of PBD dimer-maleimide-acetal is acid-labile.

[0343] PBD dimers and ADC comprising PBD dimers may be prepared according to methods known in the art. *See, e.g.*, WO 2009/016516; US 2009/304710; US 2010/047257; US 2009/036431; US 2011/0256157; WO 2011/130598.

(5) Anthracyclines


[0344] In some embodiments, an ADC comprising anthracycline. Anthracyclines are antibiotic compounds that exhibit cytotoxic activity. While not intending to be bound by any particular theory, studies have indicated that anthracyclines may operate to kill cells by a number of different mechanisms, including: 1) intercalation of the drug molecules into the DNA of the cell thereby inhibiting DNA-dependent nucleic acid synthesis; 2) production by the drug of free radicals which then react with cellular macromolecules to cause damage to the cells, and/or 3) interactions of the drug molecules with the cell membrane (see, e.g., C. Peterson et al., "Transport And Storage Of Anthracycline In Experimental Systems And Human Leukemia" in Anthracycline Antibiotics In Cancer Therapy; N.R. Bachur, "Free Radical Damage" id. at pp.97-102). Because of their cytotoxic potential anthracyclines have been used in the treatment of numerous cancers such as leukemia, breast carcinoma, lung carcinoma, ovarian adenocarcinoma and sarcomas (see e.g., P.H- Wiernik, in Anthracycline: Current Status And New Developments p 11).

[0345] Nonlimiting exemplary anthracyclines include doxorubicin, epirubicin, idarubicin, daunomycin, nemorubicin, and derivatives thereof. Immunoconjugates and

prodrugs of daunorubicin and doxorubicin have been prepared and studied (Kratz et al (2006) *Current Med. Chem.* 13:477-523; Jeffrey et al (2006) *Bioorganic & Med. Chem. Letters* 16:358-362; Torgov et al (2005) *Bioconj. Chem.* 16:717-721; Nagy et al (2000) *Proc. Natl. Acad. Sci. USA* 97:829-834; Dubowchik et al (2002) *Bioorg. & Med. Chem. Letters* 12:1529-1532; King et al (2002) *J. Med. Chem.* 45:4336-4343; EP 0328147; US 6630579). The antibody-drug conjugate BR96-doxorubicin reacts specifically with the tumor-associated antigen Lewis-Y and has been evaluated in phase I and II studies (Saleh et al (2000) *J. Clin. Oncology* 18:2282-2292; Ajani et al (2000) *Cancer Jour.* 6:78-81; Tolcher et al (1999) *J. Clin. Oncology* 17:478-484).

[0346] PNU-159682 is a potent metabolite (or derivative) of nemorubicin (Quintieri, et al. (2005) *Clinical Cancer Research* 11(4):1608-1617). Nemorubicin is a semisynthetic analog of doxorubicin with a 2-methoxymorpholino group on the glycoside amino of doxorubicin and has been under clinical evaluation (Grandi et al (1990) *Cancer Treat. Rev.* 17:133; Ripamonti et al (1992) *Brit. J. Cancer* 65:703;), including phase II/III trials for hepatocellular carcinoma (Sun et al (2003) *Proceedings of the American Society for Clinical Oncology* 22, Abs1448; Quintieri (2003) *Proceedings of the American Association of Cancer Research*, 44:1st Ed, Abs 4649; Pacciarini et al (2006) *Jour. Clin. Oncology* 24:14116).

[0347] A nonlimiting exemplary ADC comprising nemorubicin or nemorubicin derivatives is shown in Formula Ia:



wherein R_1 is hydrogen atom, hydroxy or methoxy group and R_2 is a C_1 - C_5 alkoxy group, or a pharmaceutically acceptable salt thereof;


L_1 and Z together are a linker (L) as described herein;

T is an antibody (Ab) as described herein; and

m is 1 to about 20. In some embodiments, m is 1 to 10, 1 to 7, 1 to 5, or 1 to 4.

[0348] In some embodiments, R_1 and R_2 are both methoxy (-OMe).

[0349] A further nonlimiting exemplary ADC comprising nemorubicin or nemorubicin derivatives is shown in Formula Ib:



wherein R_1 is hydrogen atom, hydroxy or methoxy group and R_2 is a C_1 - C_5 alkoxy group, or a pharmaceutically acceptable salt thereof;


L_2 and Z together are a linker (L) as described herein;


T is an antibody (Ab) as described herein; and

m is 1 to about 20. In some embodiments, m is 1 to 10, 1 to 7, 1 to 5, or 1 to 4.

[0350] In some embodiments, R_1 and R_2 are both methoxy ($-OMe$).

[0351] In some embodiments, the nemorubicin component of a nemorubicin-containing ADC is PNU-159682. In some such embodiments, the drug portion of the ADC may have one of the following structures:







wherein the wavy line indicates the attachment to the linker (L).

[0352] Anthracyclines, including PNU-159682, may be conjugated to antibodies through several linkage sites and a variety of linkers (US 2011/0076287; WO2009/099741; US 2010/0034837; WO 2010/009124), including the linkers described herein.


[0353] Exemplary ADCs comprising a nemorubicin and linker include, but are not limited to:




PNU-159682 maleimide acetal-Ab;



PNU-159682-val-cit-PAB-Ab;




PNU-159682-val-cit-PAB-spacer-Ab;



PNU-159682-val-cit-PAB-spacer(R¹R²)-Ab, wherein:

R₁ and R₂ are independently selected from H and C₁-C₆ alkyl; and



PNU-159682-maleimide-Ab.

[0354] The linker of PNU-159682 maleimide acetal-Ab is acid-labile, while the linkers of PNU-159682-val-cit-PAB-Ab, PNU-159682-val-cit-PAB-spacer-Ab, and PNU-159682-val-cit-PAB-spacer(R¹R²)-Ab are protease cleavable.

(6) Other Drug Moieties

[0355] Drug moieties also include geldanamycin (Mandler et al (2000) *J. Nat. Cancer Inst.* 92(19):1573-1581; Mandler et al (2000) *Bioorganic & Med. Chem. Letters* 10:1025-1028; Mandler et al (2002) *Bioconjugate Chem.* 13:786-791); and enzymatically active toxins and fragments thereof, including, but not limited to, diphtheria A chain, nonbinding active

fragments of diphtheria toxin, exotoxin A chain (from *Pseudomonas aeruginosa*), ricin A chain, abrin A chain, modeccin A chain, alpha-sarcin, Aleurites fordii proteins, dianthin proteins, Phytolacca americana proteins (PAPI, PAPII, and PAP-S), momordica charantia inhibitor, curcumin, croton, saponaria officinalis inhibitor, gelonin, mitogellin, restrictocin, phenomycin, enomycin and the tricothecenes. See, e.g., WO 93/21232.

[0356] Drug moieties also include compounds with nucleolytic activity (e.g., a ribonuclease or a DNA endonuclease).

[0357] In certain embodiments, an immunoconjugate may comprise a highly radioactive atom. A variety of radioactive isotopes are available for the production of radioconjugated antibodies. Examples include At^{211} , I^{131} , I^{125} , Y^{90} , Re^{186} , Re^{188} , Sm^{153} , Bi^{212} , P^{32} , Pb^{212} and radioactive isotopes of Lu. In some embodiments, when an immunoconjugate is used for detection, it may comprise a radioactive atom for scintigraphic studies, for example Tc^{99} or I^{123} , or a spin label for nuclear magnetic resonance (NMR) imaging (also known as magnetic resonance imaging, MRI), such as zirconium-89, iodine-123, iodine-131, indium-111, fluorine-19, carbon-13, nitrogen-15, oxygen-17, gadolinium, manganese or iron. Zirconium-89 may be complexed to various metal chelating agents and conjugated to antibodies, e.g., for PET imaging (WO 2011/056983).

[0358] The radio- or other labels may be incorporated in the immunoconjugate in known ways. For example, a peptide may be biosynthesized or chemically synthesized using suitable amino acid precursors comprising, for example, one or more fluorine-19 atoms in place of one or more hydrogens. In some embodiments, labels such as Tc^{99} , I^{123} , Re^{186} , Re^{188} and In^{111} can be attached via a cysteine residue in the antibody. In some embodiments, yttrium-90 can be attached via a lysine residue of the antibody. In some embodiments, the IODOGEN method (Fraker et al (1978) *Biochem. Biophys. Res. Commun.* 80: 49-57) can be used to incorporate iodine-123. "Monoclonal Antibodies in Immunoscintigraphy" (Chatal, CRC Press 1989) describes certain other methods.

[0359] In certain embodiments, an immunoconjugate may comprise an antibody conjugated to a prodrug-activating enzyme. In some such embodiments, a prodrug-activating enzyme converts a prodrug (e.g., a peptidyl chemotherapeutic agent, see WO 81/01145) to an active drug, such as an anti-cancer drug. Such immunoconjugates are useful, in some embodiments, in antibody-dependent enzyme-mediated prodrug therapy ("ADEPT"). Enzymes that may be conjugated to an antibody include, but are not limited to, alkaline phosphatases, which are useful for converting phosphate-containing prodrugs into free drugs; arylsulfatases, which are useful for converting sulfate-containing prodrugs into free drugs; cytosine deaminase, which is useful for converting non-toxic 5-fluorocytosine into the anti-

cancer drug, 5-fluorouracil; proteases, such as serratia protease, thermolysin, subtilisin, carboxypeptidases and cathepsins (such as cathepsins B and L), which are useful for converting peptide-containing prodrugs into free drugs; D-alanylcarboxypeptidases, which are useful for converting prodrugs that contain D-amino acid substituents; carbohydrate-cleaving enzymes such as β -galactosidase and neuraminidase, which are useful for converting glycosylated prodrugs into free drugs; β -lactamase, which is useful for converting drugs derivatized with β -lactams into free drugs; and penicillin amidases, such as penicillin V amidase and penicillin G amidase, which are useful for converting drugs derivatized at their amine nitrogens with phenoxyacetyl or phenylacetyl groups, respectively, into free drugs. In some embodiments, enzymes may be covalently bound to antibodies by recombinant DNA techniques well known in the art. See, e.g., Neuberger et al., *Nature* 312:604-608 (1984).

c) Drug Loading

[0360] Drug loading is represented by p , the average number of drug moieties per antibody in a molecule of Formula I. Drug loading may range from 1 to 20 drug moieties (D) per antibody. ADCs of Formula I include collections of antibodies conjugated with a range of drug moieties, from 1 to 20. The average number of drug moieties per antibody in preparations of ADC from conjugation reactions may be characterized by conventional means such as mass spectroscopy, ELISA assay, and HPLC. The quantitative distribution of ADC in terms of p may also be determined. In some instances, separation, purification, and characterization of homogeneous ADC where p is a certain value from ADC with other drug loadings may be achieved by means such as reverse phase HPLC or electrophoresis.

[0361] For some antibody-drug conjugates, p may be limited by the number of attachment sites on the antibody. For example, where the attachment is a cysteine thiol, as in certain exemplary embodiments above, an antibody may have only one or several cysteine thiol groups, or may have only one or several sufficiently reactive thiol groups through which a linker may be attached. In certain embodiments, higher drug loading, e.g. $p > 5$, may cause aggregation, insolubility, toxicity, or loss of cellular permeability of certain antibody-drug conjugates. In certain embodiments, the average drug loading for an ADC ranges from 1 to about 8; from about 2 to about 6; or from about 3 to about 5. Indeed, it has been shown that for certain ADCs, the optimal ratio of drug moieties per antibody may be less than 8, and may be about 2 to about 5 (US 7498298).

[0362] In certain embodiments, fewer than the theoretical maximum of drug moieties are conjugated to an antibody during a conjugation reaction. An antibody may contain, for example, lysine residues that do not react with the drug-linker intermediate or linker reagent, as

discussed below. Generally, antibodies do not contain many free and reactive cysteine thiol groups which may be linked to a drug moiety; indeed most cysteine thiol residues in antibodies exist as disulfide bridges. In certain embodiments, an antibody may be reduced with a reducing agent such as dithiothreitol (DTT) or tricarboylethylphosphine (TCEP), under partial or total reducing conditions, to generate reactive cysteine thiol groups. In certain embodiments, an antibody is subjected to denaturing conditions to reveal reactive nucleophilic groups such as lysine or cysteine.

[0363] The loading (drug/antibody ratio) of an ADC may be controlled in different ways, and for example, by: (i) limiting the molar excess of drug-linker intermediate or linker reagent relative to antibody, (ii) limiting the conjugation reaction time or temperature, and (iii) partial or limiting reductive conditions for cysteine thiol modification.

[0364] It is to be understood that where more than one nucleophilic group reacts with a drug-linker intermediate or linker reagent, then the resulting product is a mixture of ADC compounds with a distribution of one or more drug moieties attached to an antibody. The average number of drugs per antibody may be calculated from the mixture by a dual ELISA antibody assay, which is specific for antibody and specific for the drug. Individual ADC molecules may be identified in the mixture by mass spectroscopy and separated by HPLC, e.g. hydrophobic interaction chromatography (*see, e.g.*, McDonagh et al (2006) Prot. Engr. Design & Selection 19(7):299-307; Hamblett et al (2004) Clin. Cancer Res. 10:7063-7070; Hamblett, K.J., et al. "Effect of drug loading on the pharmacology, pharmacokinetics, and toxicity of an anti-CD30 antibody-drug conjugate," Abstract No. 624, American Association for Cancer Research, 2004 Annual Meeting, March 27-31, 2004, Proceedings of the AACR, Volume 45, March 2004; Alley, S.C., et al. "Controlling the location of drug attachment in antibody-drug conjugates," Abstract No. 627, American Association for Cancer Research, 2004 Annual Meeting, March 27-31, 2004, Proceedings of the AACR, Volume 45, March 2004). In certain embodiments, a homogeneous ADC with a single loading value may be isolated from the conjugation mixture by electrophoresis or chromatography.

d) Certain Methods of Preparing Immunoconjugates

[0365] An ADC of Formula I may be prepared by several routes employing organic chemistry reactions, conditions, and reagents known to those skilled in the art, including: (1) reaction of a nucleophilic group of an antibody with a bivalent linker reagent to form Ab-L via a covalent bond, followed by reaction with a drug moiety D; and (2) reaction of a nucleophilic group of a drug moiety with a bivalent linker reagent, to form D-L, via a covalent bond, followed by reaction with a nucleophilic group of an antibody. Exemplary methods for

preparing an ADC of Formula I via the latter route are described in US 7498298, which is expressly incorporated herein by reference.

[0366] Nucleophilic groups on antibodies include, but are not limited to: (i) N-terminal amine groups, (ii) side chain amine groups, e.g. lysine, (iii) side chain thiol groups, e.g. cysteine, and (iv) sugar hydroxyl or amino groups where the antibody is glycosylated. Amine, thiol, and hydroxyl groups are nucleophilic and capable of reacting to form covalent bonds with electrophilic groups on linker moieties and linker reagents including: (i) active esters such as NHS esters, HOBt esters, haloformates, and acid halides; (ii) alkyl and benzyl halides such as haloacetamides; and (iii) aldehydes, ketones, carboxyl, and maleimide groups. Certain antibodies have reducible interchain disulfides, i.e. cysteine bridges. Antibodies may be made reactive for conjugation with linker reagents by treatment with a reducing agent such as DTT (dithiothreitol) or tricarboylethylphosphine (TCEP), such that the antibody is fully or partially reduced. Each cysteine bridge will thus form, theoretically, two reactive thiol nucleophiles. Additional nucleophilic groups can be introduced into antibodies through modification of lysine residues, e.g., by reacting lysine residues with 2-iminothiolane (Traut's reagent), resulting in conversion of an amine into a thiol. Reactive thiol groups may also be introduced into an antibody by introducing one, two, three, four, or more cysteine residues (e.g., by preparing variant antibodies comprising one or more non-native cysteine amino acid residues).

[0367] Antibody-drug conjugates of the invention may also be produced by reaction between an electrophilic group on an antibody, such as an aldehyde or ketone carbonyl group, with a nucleophilic group on a linker reagent or drug. Useful nucleophilic groups on a linker reagent include, but are not limited to, hydrazide, oxime, amino, hydrazine, thiosemicarbazone, hydrazine carboxylate, and arylhydrazide. In one embodiment, an antibody is modified to introduce electrophilic moieties that are capable of reacting with nucleophilic substituents on the linker reagent or drug. In another embodiment, the sugars of glycosylated antibodies may be oxidized, e.g. with periodate oxidizing reagents, to form aldehyde or ketone groups which may react with the amine group of linker reagents or drug moieties. The resulting imine Schiff base groups may form a stable linkage, or may be reduced, e.g. by borohydride reagents to form stable amine linkages. In one embodiment, reaction of the carbohydrate portion of a glycosylated antibody with either galactose oxidase or sodium meta-periodate may yield carbonyl (aldehyde and ketone) groups in the antibody that can react with appropriate groups on the drug (Hermanson, Bioconjugate Techniques). In another embodiment, antibodies containing N-terminal serine or threonine residues can react with sodium meta-periodate, resulting in production of an aldehyde in place of the first amino acid (Geoghegan & Stroh,

(1992) *Bioconjugate Chem.* 3:138-146; US 5362852). Such an aldehyde can be reacted with a drug moiety or linker nucleophile.

[0368] Exemplary nucleophilic groups on a drug moiety include, but are not limited to: amine, thiol, hydroxyl, hydrazide, oxime, hydrazine, thiosemicarbazone, hydrazine carboxylate, and arylhydrazide groups capable of reacting to form covalent bonds with electrophilic groups on linker moieties and linker reagents including: (i) active esters such as NHS esters, HOBt esters, haloformates, and acid halides; (ii) alkyl and benzyl halides such as haloacetamides; (iii) aldehydes, ketones, carboxyl, and maleimide groups.

[0369] Nonlimiting exemplary cross-linker reagents that may be used to prepare ADC are described herein in the section titled "Exemplary Linkers." Methods of using such cross-linker reagents to link two moieties, including a proteinaceous moiety and a chemical moiety, are known in the art. In some embodiments, a fusion protein comprising an antibody and a cytotoxic agent may be made, e.g., by recombinant techniques or peptide synthesis. A recombinant DNA molecule may comprise regions encoding the antibody and cytotoxic portions of the conjugate either adjacent to one another or separated by a region encoding a linker peptide which does not destroy the desired properties of the conjugate.

[0370] In yet another embodiment, an antibody may be conjugated to a "receptor" (such as streptavidin) for utilization in tumor pre-targeting wherein the antibody-receptor conjugate is administered to the patient, followed by removal of unbound conjugate from the circulation using a clearing agent and then administration of a "ligand" (e.g., avidin) which is conjugated to a cytotoxic agent (e.g., a drug or radionucleotide).

E. Methods and Compositions for Diagnostics and Detection

[0371] In certain embodiments, any of the anti-PMEL17 antibodies provided herein is useful for detecting the presence of PMEL17 in a biological sample. The term "detecting" as used herein encompasses quantitative or qualitative detection. A "biological sample" comprises, e.g., a cell or tissue (e.g., biopsy material, including cancerous or potentially cancerous skin tissue, including possible or confirmed melanoma; biopsy material from lymphoma, such as cutaneous T-cell lymphoma; and biopsy material from kidney tumors).

[0372] In one embodiment, an anti-PMEL17 antibody for use in a method of diagnosis or detection is provided. In a further aspect, a method of detecting the presence of PMEL17 in a biological sample is provided. In certain embodiments, the method comprises contacting the biological sample with an anti-PMEL17 antibody as described herein under conditions permissive for binding of the anti-PMEL17 antibody to PMEL17, and detecting whether a complex is formed between the anti-PMEL17 antibody and PMEL17 in the biological sample.

Such method may be an *in vitro* or *in vivo* method. In one embodiment, an anti-PMEL17 antibody is used to select subjects eligible for therapy with an anti-PMEL17 antibody, e.g. where PMEL17 is a biomarker for selection of patients. In a further embodiment, the biological sample is a cell or tissue (cancerous or potentially cancerous skin tissue, including possible or confirmed melanoma; biopsy material from lymphoma, such as cutaneous T-cell lymphoma; and biopsy material from kidney tumors).

[0373] In a further embodiment, an anti-PMEL17 antibody is used *in vivo* to detect, e.g., by *in vivo* imaging, a PMEL17-positive cancer in a subject, e.g., for the purposes of diagnosing, prognosing, or staging cancer, determining the appropriate course of therapy, or monitoring response of a cancer to therapy. One method known in the art for *in vivo* detection is immuno-positron emission tomography (immuno-PET), as described, e.g., in van Dongen et al., *The Oncologist* 12:1379-1389 (2007) and Verel et al., *J. Nucl. Med.* 44:1271-1281 (2003). In such embodiments, a method is provided for detecting a PMEL17-positive cancer in a subject, the method comprising administering a labeled anti-PMEL17 antibody to a subject having or suspected of having a PMEL17-positive cancer, and detecting the labeled anti-PMEL17 antibody in the subject, wherein detection of the labeled anti-PMEL17 antibody indicates a PMEL17-positive cancer in the subject. In certain of such embodiments, the labeled anti-PMEL17 antibody comprises an anti-PMEL17 antibody conjugated to a positron emitter, such as ^{68}Ga , ^{18}F , ^{64}Cu , ^{86}Y , ^{76}Br , ^{89}Zr , and ^{124}I . In a particular embodiment, the positron emitter is ^{89}Zr .

[0374] In further embodiments, a method of diagnosis or detection comprises contacting a first anti-PMEL17 antibody immobilized to a substrate with a biological sample to be tested for the presence of PMEL17, exposing the substrate to a second anti-PMEL17 antibody, and detecting whether the second anti-PMEL17 is bound to a complex between the first anti-PMEL17 antibody and PMEL17 in the biological sample. A substrate may be any supportive medium, e.g., glass, metal, ceramic, polymeric beads, slides, chips, and other substrates. In certain embodiments, a biological sample comprises a cell or tissue (cancerous or potentially cancerous skin tissue, including possible or confirmed melanoma; biopsy material from a lymphoma, such as cutaneous T-cell lymphoma; and biopsy material from a kidney tumor). In certain embodiments, the first or second anti-PMEL17 antibody is any of the antibodies described herein.

[0375] Exemplary disorders that may be diagnosed or detected according to any of the above embodiments include PMEL17-positive cancers, such as PMEL17-positive skin cancer (such as melanoma); PMEL17-positive lymphomas (such as cutaneous T-cell lymphoma); and PMEL17-positive kidney tumors. In some embodiments, a PMEL17-positive cancer is a

cancer that receives an anti-PMEL17 immunohistochemistry (IHC) score greater than “0,” which corresponds to very weak or no staining in >90% of tumor cells, under the conditions described herein in Example K. In some embodiments, a PMEL17-positive cancer expresses PMEL17 at a 1+, 2+ or 3+ level, as defined under the conditions described herein in Example K, using the 31D1 antibody (the 31D1-expressing hybridoma was deposited at the ATCC as 7509(31D1.6.7) on April 24, 2012). In some embodiments, a PMEL17-positive cancer is a cancer that expresses PMEL17 according to an in situ hybridization (ISH) assay. In some such embodiments, a scoring system similar to that used for IHC is used. In some embodiments, a PMEL17-positive cancer is a cancer that expresses PMEL17 according to a reverse-transcriptase PCR (RT-PCR) assay that detects PMEL17 mRNA. In some embodiments, the RT-PCR is quantitative RT-PCR.

[0376] In certain embodiments, labeled anti-PMEL17 antibodies are provided. Labels include, but are not limited to, labels or moieties that are detected directly (such as fluorescent, chromophoric, electron-dense, chemiluminescent, and radioactive labels), as well as moieties, such as enzymes or ligands, that are detected indirectly, e.g., through an enzymatic reaction or molecular interaction. Exemplary labels include, but are not limited to, the radioisotopes ^{32}P , ^{14}C , ^{125}I , ^3H , and ^{131}I , fluorophores such as rare earth chelates or fluorescein and its derivatives, rhodamine and its derivatives, dansyl, umbelliferone, luciferases, e.g., firefly luciferase and bacterial luciferase (U.S. Patent No. 4,737,456), luciferin, 2,3-dihydrophthalazinediones, horseradish peroxidase (HRP), alkaline phosphatase, β -galactosidase, glucoamylase, lysozyme, saccharide oxidases, e.g., glucose oxidase, galactose oxidase, and glucose-6-phosphate dehydrogenase, heterocyclic oxidases such as uricase and xanthine oxidase, coupled with an enzyme that employs hydrogen peroxide to oxidize a dye precursor such as HRP, lactoperoxidase, or microperoxidase, biotin/avidin, spin labels, bacteriophage labels, stable free radicals, and the like. In another embodiment, a label is a positron emitter. Positron emitters include but are not limited to ^{68}Ga , ^{18}F , ^{64}Cu , ^{86}Y , ^{76}Br , ^{89}Zr , and ^{124}I . In a particular embodiment, a positron emitter is ^{89}Zr .

F. Pharmaceutical Formulations

[0377] Pharmaceutical formulations of an anti-PMEL17 antibody or immunoconjugate as described herein are prepared by mixing such antibody or immunoconjugate having the desired degree of purity with one or more optional pharmaceutically acceptable carriers (*Remington's Pharmaceutical Sciences* 16th edition, Osol, A. Ed. (1980)), in the form of lyophilized formulations or aqueous solutions. Pharmaceutically acceptable carriers are generally nontoxic to recipients at the dosages and concentrations employed, and include, but

are not limited to: buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (such as octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride; benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrans; chelating agents such as EDTA; sugars such as sucrose, mannitol, trehalose or sorbitol; salt-forming counter-ions such as sodium; metal complexes (*e.g.* Zn-protein complexes); and/or non-ionic surfactants such as polyethylene glycol (PEG). Exemplary pharmaceutically acceptable carriers herein further include interstitial drug dispersion agents such as soluble neutral-active hyaluronidase glycoproteins (sHASEGP), for example, human soluble PH-20 hyaluronidase glycoproteins, such as rHuPH20 (HYLENEX[®], Baxter International, Inc.). Certain exemplary sHASEGPs and methods of use, including rHuPH20, are described in US Patent Publication Nos. 2005/0260186 and 2006/0104968. In one aspect, a sHASEGP is combined with one or more additional glycosaminoglycanases such as chondroitinases.

[0378] Exemplary lyophilized antibody or immunoconjugate formulations are described in US Patent No. 6,267,958. Aqueous antibody or immunoconjugate formulations include those described in US Patent No. 6,171,586 and WO2006/044908, the latter formulations including a histidine-acetate buffer.

[0379] The formulation herein may also contain more than one active ingredient as necessary for the particular indication being treated, preferably those with complementary activities that do not adversely affect each other.

[0380] Active ingredients may be entrapped in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, for example, hydroxymethylcellulose or gelatin-microcapsules and poly-(methylmethacrylate) microcapsules, respectively, in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nano-particles and nanocapsules) or in macroemulsions. Such techniques are disclosed in *Remington's Pharmaceutical Sciences* 16th edition, Osol, A. Ed. (1980).

[0381] Sustained-release preparations may be prepared. Suitable examples of sustained-release preparations include semipermeable matrices of solid hydrophobic polymers

containing the antibody or immunoconjugate, which matrices are in the form of shaped articles, *e.g.* films, or microcapsules.

[0382] The formulations to be used for *in vivo* administration are generally sterile. Sterility may be readily accomplished, *e.g.*, by filtration through sterile filtration membranes.

G. Therapeutic Methods and Compositions

[0383] Any of the anti-PMEL17 antibodies or immunoconjugates provided herein may be used in methods, *e.g.*, therapeutic methods.

[0384] In one aspect, an anti-PMEL17 antibody or immunoconjugate provided herein is used in a method of inhibiting proliferation of a PMEL17-positive cell, the method comprising exposing the cell to the anti-PMEL17 antibody or immunoconjugate under conditions permissive for binding of the anti-PMEL17 antibody or immunoconjugate to PMEL17 on the surface of the cell, thereby inhibiting the proliferation of the cell. In certain embodiments, the method is an *in vitro* or an *in vivo* method. In some embodiments, the cell is a melanoma cell. In some embodiments, the cell is a lymphoma cell, such as a cutaneous T cell lymphoma cell. In some embodiments, the cell is a kidney tumor cell.

[0385] Inhibition of cell proliferation *in vitro* may be assayed using the CellTiter-Glo™ Luminescent Cell Viability Assay, which is commercially available from Promega (Madison, WI). That assay determines the number of viable cells in culture based on quantitation of ATP present, which is an indication of metabolically active cells. *See* Crouch et al. (1993) *J. Immunol. Meth.* 160:81-88, US Pat. No. 6602677. The assay may be conducted in 96- or 384-well format, making it amenable to automated high-throughput screening (HTS). *See* Cree et al. (1995) *AntiCancer Drugs* 6:398-404. The assay procedure involves adding a single reagent (CellTiter-Glo® Reagent) directly to cultured cells. This results in cell lysis and generation of a luminescent signal produced by a luciferase reaction. The luminescent signal is proportional to the amount of ATP present, which is directly proportional to the number of viable cells present in culture. Data can be recorded by luminometer or CCD camera imaging device. The luminescence output is expressed as relative light units (RLU).

[0386] In another aspect, an anti-PMEL17 antibody or immunoconjugate for use as a medicament is provided. In further aspects, an anti-PMEL17 antibody or immunoconjugate for use in a method of treatment is provided. In certain embodiments, an anti-PMEL17 antibody or immunoconjugate for use in treating PMEL17-positive cancer is provided. In certain embodiments, the invention provides an anti-PMEL17 antibody or immunoconjugate for use in a method of treating an individual having a PMEL17-positive cancer, the method comprising administering to the individual an effective amount of the anti-PMEL17 antibody or

immunoconjugate. In one such embodiment, the method further comprises administering to the individual an effective amount of at least one additional therapeutic agent, e.g., as described below.

[0387] In a further aspect, the invention provides for the use of an anti-PMEL17 antibody or immunoconjugate in the manufacture or preparation of a medicament. In one embodiment, the medicament is for treatment of PMEL17-positive cancer. In a further embodiment, the medicament is for use in a method of treating PMEL17-positive cancer, the method comprising administering to an individual having PMEL17-positive cancer an effective amount of the medicament. In one such embodiment, the method further comprises administering to the individual an effective amount of at least one additional therapeutic agent, e.g., as described below.

[0388] In a further aspect, the invention provides a method for treating PMEL17-positive cancer. In one embodiment, the method comprises administering to an individual having such PMEL17-positive cancer an effective amount of an anti-PMEL17 antibody or immunoconjugate. In one such embodiment, the method further comprises administering to the individual an effective amount of at least one additional therapeutic agent, as described below.

[0389] A PMEL17 -positive cancer according to any of the above embodiments may be, e.g., PMEL17-positive skin cancer (including melanoma); PMEL17-positive lymphoms (such as cutaneous T-cell lymphoma); and PMEL17-positive kidney tumors. In some embodiments, a PMEL17-positive cancer is a cancer that receives an anti-PMEL17 immunohistochemistry (IHC) or in situ hybridization (ISH) score greater than "0," which corresponds to very weak or no staining in >90% of tumor cells, under the conditions described herein in Example K. In another embodiment, a PMEL17-positive cancer expresses PMEL17 at a 1+, 2+ or 3+ level, as defined under the conditions described herein in Example K, using the 31D1 antibody (the 31D1-expressing hybridoma was deposited at the ATCC as 7509(31D1.6.7) on April 24, 2012). In some embodiments, a PMEL17-positive cancer is a cancer that expresses PMEL17 according to a reverse-transcriptase PCR (RT-PCR) assay that detects PMEL17 mRNA. In some embodiments, the RT-PCR is quantitative RT-PCR.

[0390] In some embodiments, methods of treating an individual having a PMEL17-positive cancer are provided, wherein the PMEL17-positive cancer is resistant to a first therapeutic. In some embodiments, the method comprises administering to the individual an effective amount of an immunoconjugate comprising an antibody that binds to PMEL17. In some embodiments, the PMEL17-positive cancer is melanoma. In some embodiments, the first therapeutic comprises a first antibody that binds an antigen other than PMEL17. In some

embodiments, the first therapeutic is a first immunoconjugate comprising a first antibody that binds an antigen other than PMEL17 and a first cytotoxic agent. In some embodiments, the first antibody binds an antigen selected from endothelin B receptor (ETBR), tyrosinase-related protein 1 (TYRP1), cytotoxic T lymphocyte antigen 4 (CTLA-4), and glycoprotein NMB (GPNMB). In some embodiments, the first antibody binds ETBR. In some such embodiments, the first immunoconjugate comprises anti-ETBR antibody hu5E9.v1, such as the immunoconjugate hu5E9.v1-MC-val-cit-PAB-MMAE. *See* U.S. Publication No. US 2011/0206702. The hypervariable regions (HVRs) of hu5E9.v1 are shown herein, e.g., in SEQ ID NOs: 33 to 38. The heavy and light chain variable regions of hu5E9.v1 are shown herein, e.g., in SEQ ID NOs: 40 and 39, respectively. In some embodiments, the first cytotoxic agent and the cytotoxic agent of the immunoconjugate comprising an antibody that binds to PMEL17 are different. In some such embodiments, the first cytotoxic agent is MMAE (such as, for example, when the first immunoconjugate is hu5E9.v1-MC-val-cit-PAB-MMAE) and the cytotoxic agent of the immunoconjugate comprising an antibody that binds to PMEL17 is selected from a calicheamicin, a pyrrolobenzodiazepine, and a nemorubicin derivative. In some embodiments, the cytotoxic agent of the immunoconjugate comprising an antibody that binds to PMEL17 is selected from a pyrrolobenzodiazepine and a nemorubicin derivative.

[0391] In some embodiments, methods of treating an individual with cancer are provided, wherein the cancer is resistant to a first therapeutic. In some embodiments, the first therapeutic is a first immunoconjugate comprising a first antibody linked to a first cytotoxic agent through a first linker. In some embodiments, a method of treating an individual with a cancer that is resistant to a first therapeutic (such as a first immunoconjugate) comprises administering a second immunoconjugate comprising a second antibody linked to a second cytotoxic agent through a second linker. In some embodiments, the first antibody and the second antibody bind to different antigens and the first cytotoxic agent and the second cytotoxic agents are the same or different. In some embodiments, the first antibody and the second antibody bind to different antigens that are present on at least some of the same cells. In some embodiments, the first antibody and the second antibody bind to different antigens and the first cytotoxic agent and the second cytotoxic agents are different. In some embodiments, the first antibody and the second antibody bind to the same antigens, and the first cytotoxic agent and the second cytotoxic agent are different. In any of the foregoing embodiments, the first linker and the second linker may be the same or different. In some embodiments, the first antibody and the second antibody bind to different antigens, the first and second linkers are different, and the first and second cytotoxic agents are different.

[0392] An “individual” according to any of the above embodiments may be a human.

[0393] In a further aspect, the invention provides pharmaceutical formulations comprising any of the anti-PMEL17 antibodies or immunoconjugate provided herein, e.g., for use in any of the above therapeutic methods. In one embodiment, a pharmaceutical formulation comprises any of the anti-PMEL17 antibodies or immunoconjugates provided herein and a pharmaceutically acceptable carrier. In another embodiment, a pharmaceutical formulation comprises any of the anti-PMEL17 antibodies or immunoconjugates provided herein and at least one additional therapeutic agent, e.g., as described below.

[0394] Antibodies or immunoconjugates of the invention can be used either alone or in combination with other agents in a therapy. For instance, an antibody or immunoconjugate of the invention may be co-administered with at least one additional therapeutic agent.

[0395] In some embodiments, methods of treating cancer comprise administering an immunoconjugate described herein in combination with a second immunoconjugate comprising an antibody that binds an antigen selected from endothelin B receptor (ETBR), tyrosinase-related protein 1 (TYRP1), cytotoxic T lymphocyte antigen 4 (CTLA-4), and glycoprotein NMB (GPNMB). In some such embodiments, the cytotoxic agent of the second immunoconjugate is selected from MMAE, a calicheamicin, a nemorubicin derivative, and a pyrrolobenzodiazepine. The cytotoxic agent of the immunoconjugate described herein and the cytotoxic agent of the second immunoconjugate may be the same or different. In some embodiments, the cytotoxic agents are different. In some embodiments, each cytotoxic agent is selected from MMAE, a nemorubicin derivative, and a pyrrolobenzodiazepine.

[0396] In some embodiments, methods of treating cancer comprise administering an immunoconjugate described herein in combination with a second immunoconjugate comprising an antibody that binds ETBR. In some such embodiments, the cancer is a PMEL17-positive cancer and also an ETBR-positive cancer. Determination of whether a cancer is also ETBR-positive may be carried out by any method, including, but not limited to, the methods described herein for determining whether a cancer is PMEL17-positive, and methods described in U.S. Publication No. US 2011/0206702. In some embodiments, the antibody that binds ETBR is hu5E9.v1, which is described, e.g., in U.S. Publication No. US 2011/0206702. In some embodiments, the antibody that binds ETBR comprises an HVR H1 comprising a sequence of SEQ ID NO: 33, an HVR H2 comprising a sequence of SEQ ID NO: 34, an HVR H3 comprising a sequence of SEQ ID NO: 35, an HVR L1 comprising a sequence of SEQ ID NO: 36, an HVR L2 comprising a sequence of SEQ ID NO: 37, and an HVR L3 comprising a sequence of SEQ ID NO: 38. In some embodiments, the antibody that binds ETBR comprises a heavy chain variable region that comprises the sequence of SEQ ID NO: 40 and a light chain variable region that comprises the sequence of SEQ ID NO: 39.

[0397] In some embodiments, methods of treating cancer comprise administering an anti-ETBR-MC-val-cit-PAB-MMAE immunoconjugate, such as hu5E9.v1-MC-val-cit-PAB-MMAE (see, e.g., U.S. Publication No. US 2011/0206702), in combination with an immunoconjugate comprising an anti-PMEL17 antibody, such as those described herein. The immunoconjugate comprising an anti-PMEL17 antibody may comprise the same or different cytotoxic agent as the immunoconjugate comprising an anti-ETBR antibody. In some embodiments, the immunoconjugate comprising an anti-PMEL17 antibody comprises a different cytotoxic agent, such as a nemorubicin derivative or a pyrrolobenzodiazepine, e.g., when the anti-ETBR immunoconjugate comprises MMAE.

[0398] Administration “in combination” encompasses combined administration (where two or more therapeutic agents are included in the same or separate formulations), and separate administration, in which case, administration of the antibody or immunoconjugate of the invention can occur prior to, simultaneously, and/or following, administration of the additional therapeutic agent (such as the anti-ETBR immunoconjugate) and/or adjuvant. In some embodiments, administration of the anti-PMEL17 immunoconjugate and administration of an anti-ETBR immunoconjugate occur within about one month, or within about one, two, or three weeks, or within about one, two, three, four, five, or six days of one another. Antibodies or immunoconjugates of the invention can also be used in combination with radiation therapy.

[0399] An antibody or immunoconjugate of the invention (and any additional therapeutic agent) can be administered by any suitable means, including parenteral, intrapulmonary, and intranasal, and, if desired for local treatment, intralesional administration. Parenteral infusions include intramuscular, intravenous, intraarterial, intraperitoneal, or subcutaneous administration. Dosing can be by any suitable route, e.g. by injections, such as intravenous or subcutaneous injections, depending in part on whether the administration is brief or chronic. Various dosing schedules including but not limited to single or multiple administrations over various time-points, bolus administration, and pulse infusion are contemplated herein.

[0400] Antibodies or immunoconjugates of the invention would be formulated, dosed, and administered in a fashion consistent with good medical practice. Factors for consideration in this context include the particular disorder being treated, the particular mammal being treated, the clinical condition of the individual patient, the cause of the disorder, the site of delivery of the agent, the method of administration, the scheduling of administration, and other factors known to medical practitioners. The antibody or immunoconjugate need not be, but is optionally formulated with one or more agents currently used to prevent or treat the disorder in question. The effective amount of such other agents depends on the amount of antibody or

immunoconjugate present in the formulation, the type of disorder or treatment, and other factors discussed above. These are generally used in the same dosages and with administration routes as described herein, or about from 1 to 99% of the dosages described herein, or in any dosage and by any route that is empirically/clinically determined to be appropriate.

[0401] For the prevention or treatment of disease, the appropriate dosage of an antibody or immunoconjugate of the invention (when used alone or in combination with one or more other additional therapeutic agents) will depend on the type of disease to be treated, the type of antibody or immunoconjugate, the severity and course of the disease, whether the antibody or immunoconjugate is administered for preventive or therapeutic purposes, previous therapy, the patient's clinical history and response to the antibody or immunoconjugate, and the discretion of the attending physician. The antibody or immunoconjugate is suitably administered to the patient at one time or over a series of treatments. Depending on the type and severity of the disease, about 1 $\mu\text{g/kg}$ to 15 mg/kg (e.g. 0.1 mg/kg -10 mg/kg) of antibody or immunoconjugate can be an initial candidate dosage for administration to the patient, whether, for example, by one or more separate administrations, or by continuous infusion. One typical daily dosage might range from about 1 $\mu\text{g/kg}$ to 100 mg/kg or more, depending on the factors mentioned above. For repeated administrations over several days or longer, depending on the condition, the treatment would generally be sustained until a desired suppression of disease symptoms occurs. One exemplary dosage of the antibody or immunoconjugate would be in the range from about 0.05 mg/kg to about 10 mg/kg . Thus, one or more doses of about 0.5 mg/kg , 2.0 mg/kg , 4.0 mg/kg or 10 mg/kg (or any combination thereof) may be administered to the patient. Such doses may be administered intermittently, e.g. every week or every three weeks (e.g. such that the patient receives from about two to about twenty, or e.g. about six doses of the antibody). An initial higher loading dose, followed by one or more lower doses may be administered. However, other dosage regimens may be useful. The progress of this therapy is easily monitored by conventional techniques and assays.

[0402] It is understood that any of the above formulations or therapeutic methods may be carried out using both an immunoconjugate of the invention and an anti-PMEL17 antibody.

H. Articles of Manufacture

[0403] In another aspect of the invention, an article of manufacture containing materials useful for the treatment, prevention and/or diagnosis of the disorders described above is provided. The article of manufacture comprises a container and a label or package insert on or associated with the container. Suitable containers include, for example, bottles, vials, syringes, IV solution bags, etc. The containers may be formed from a variety of materials such

as glass or plastic. The container holds a composition which is by itself or combined with another composition effective for treating, preventing and/or diagnosing the disorder and may have a sterile access port (for example the container may be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle). At least one active agent in the composition is an antibody or immunoconjugate of the invention. The label or package insert indicates that the composition is used for treating the condition of choice. Moreover, the article of manufacture may comprise (a) a first container with a composition contained therein, wherein the composition comprises an antibody or immunoconjugate of the invention; and (b) a second container with a composition contained therein, wherein the composition comprises a further cytotoxic or otherwise therapeutic agent. The article of manufacture in this embodiment of the invention may further comprise a package insert indicating that the compositions can be used to treat a particular condition. Alternatively, or additionally, the article of manufacture may further comprise a second (or third) container comprising a pharmaceutically-acceptable buffer, such as bacteriostatic water for injection (BWFI), phosphate-buffered saline, Ringer's solution or dextrose solution. It may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, and syringes.

I. Deposit of Biological Material

[0404] The following biological material has been deposited with the American Type Culture Collection, 10801 University Boulevard, Manassas, VA 20110-2209, USA (ATCC):

Hybridoma Designation	ATCC No.	Deposit Date
7509(31D1.6.7)	PTA-12862	April 24, 2012

The above-referenced deposited hybridoma produces the 31D1 antibody referred to herein.

[0405] This deposit was made under the provisions of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purpose of Patent Procedure and the Regulations thereunder (Budapest Treaty). This assures the maintenance of a viable culture of the deposit for 30 years from the date of deposit and for at least five (5) years after the most recent request for furnishing of a sample of the deposit. The deposit will be made available by the ATCC under the terms of the Budapest Treaty, and subject to an agreement between Genentech, Inc., and the ATCC, which assures that all restrictions imposed by the depositor on the availability to the public of the deposited material will be irrevocably removed upon the granting of the pertinent U.S. patent, assures permanent and unrestricted availability of the progeny of the culture of the deposit to the public upon issuance of the pertinent U.S. patent or upon laying open to the public of any U.S. or foreign patent

application, whichever comes first, and assures availability of the progeny to one determined by the U.S. Commissioner of Patents and Trademarks to be entitled thereto according to 35 U.S.C. § 122 and the Commissioner's rules pursuant thereto (including 37 C.F.R. § 1.14 with particular reference to 886 OG 638).

III. EXAMPLES

[0406] The following are examples of methods and compositions of the invention. It is understood that various other embodiments may be practiced, given the general description provided above.

A. Human PMEL17 Gene Expression

[0407] For the analysis of PMEL17 mRNA expression in multiple human tumor and normal biopsy samples was analyzed using Affymetrix data obtained from Gene Logic, Inc. (Gaithersburg, MD). The analysis shown is for probe set ID 209848_s_at, performed using the HGU133 Plus v2 GeneChip on 3879 normal human tissue samples, 1605 human cancer tissue samples (1291 primary and 314 metastatic), and 3872 human non-cancer disease tissue samples. Microarray data were normalized using the Affymetrix MAS (Microarray Analysis Suite) version 5.0 software, with sample expression values scaled to a trimmed mean of 500. Analysis of cultured cell lines was performed in similar fashion.

[0408] The results are shown in Figure 1A and B. The scale on the y-axis indicates gene expression levels based on hybridization signal intensity. In Figure 1A, dots appear both above and below the line extending from the name of each listed tissue. The dots appearing above the line represent gene expression in normal tissue, and the dots appearing below the line represent gene expression in tumor and diseased tissue. As shown in Figure 1A, high-level expression of PMEL17 mRNA was largely restricted to neoplasms derived from skin, and all of these were classified as melanoma. A small number of benign kidney tumors that were also positive were classified as epitheloid angiomyolipomas, and a handful of positive lymphomas were identified as cutaneous T-cell lymphomas. Figure 1B shows that PMEL17 is overexpressed in many melanoma cell lines, whereas there was little or no expression in cell lines derived from other human cancers. BC, breast cancer; CRC, colorectal cancer; GB, glioblastoma; NSCLC, non-small cell lung cancer; SC, small cell lung cancer; NHL, Non-Hodgkin's lymphoma; MEL, melanoma; MM, multiple myeloma; OVCA, ovarian cancer; PANC, pancreatic cancer; PROS, prostate cancer. Only 5% of the 487 different cell lines analyzed are identified on the figure.

B. Mouse Monoclonal Antibody Generation

[0409] Monoclonal antibodies against human PMEL17 were generated using the following procedures. Two separate groups of Balb/C mice (Charles River Laboratories, Hollister, CA) were hyperimmunized with either purified human PMEL17 ECD (amino acids 25 to 591 with a C-terminal Fc expressed in CHO cells) in Ribi adjuvant (Group 1) or with plasmid DNA encoding full length PMEL17 (Group 2) via hydrodynamic tail vein (HTV) injection using a modified version of a previously described protocol (see, e.g., Herweijer, H., and Wolff, J. A. (2003) *Gene Ther* 10(6), 453-458; Liu, F., Song, Y., and Liu, D. (1999) *Gene Ther* 6(7), 1258-1266; and Zhang, et al. (1999) *Hum Gene Ther* 10(10), 1735-1737). Following a final boost with protein (Group1) or PC3 cells over-expressing PMEL17 (Group 2) 3 days prior to fusion, B cells from mice demonstrating strong specific binding to PC3 cells by FACS from both groups were electro-fused (BTX ECM 2001, Harvard Apparatus) at a 1:1 ratio with X63-Ag8.653 mouse myeloma cells (American Type Culture Collection, Rockville, MD), plated at 100,000 cells/well in culture media containing 1x azaserine and hypoxanthine (HA, Sigma-Aldrich, St. Louis, MO) and incubated at 37°C, 7% CO₂.

[0410] After 10-14 days, the supernatants were harvested and screened by ELISA and FACS. For FACS analysis, melanoma cell lines SK-MEL-23 (provided by Paul Robbins, Center for Cancer Research, Tumor Immunology Section), 1300mel (provided by Paul Robbins, Center for Cancer Research, Tumor Immunology Section), SKMEL5 (ATCC HTB-70), and UACC257 (National Cancer Institute), normal melanocytes (Invitrogen, Carlsbad, CA), and the prostate cancer cell line PC3 stably expressing human PMEL17 were contacted with antibody. One antibody from the PMEL17-immunized mice, designated 17A9, reacted strongly by fluorescent activated cell sorting (FACS) with live melanoma cells, normal human melanocytes and a PC3 cell line stably expressing PMEL17 cDNA, but not the parental PC3 cell line. Another antibody, 77E6, obtained from the DNA-immunized mice, was also positive by FACS, although 77E6 reacted with live cell lines expressing PMEL17 somewhat inconsistently and more weakly than 17A9.

[0411] Positive clones demonstrating strong PMEL17 specific binding by FACS were then expanded and subcloned by limiting dilution. Following two rounds of subcloning and screening, the final clones were cultured in bioreactors (Integra Biosciences, Chur, Switzerland) and supernatants purified by Protein A affinity chromatography as described previously (Hongo, et al. (2000) *Hybridoma* 19(4), 303-315). Three antibody clones, 8G3, 15F2, 17A9, and 31D1 from the PMEL17 ECD-immunized mice, and one antibody clone, 77E6, from the DNA-immunized mice, were selected for further analysis.

C. Mouse Monoclonal Antibody Cloning

[0412] Total RNA was extracted from hybridoma cells producing murine 8G3, 15F2, and 17A9 using standard methods. The variable light (VL) and variable heavy (VH) domains were amplified using RT-PCR with degenerate primers to the heavy and light chains. The forward primers were specific for the N-terminal amino acid sequence of the VL and VH regions. Respectively, the LC and HC reverse primers were designed to anneal to a region in the constant light (CL) and constant heavy domain 1 (CH1), which are highly conserved across species. The polynucleotide sequence of the inserts was determined using routine sequencing methods. The 17A9 VH and VL amino acid sequences are shown in SEQ ID NOs: 50 and 2, respectively. The heavy chain hypervariable regions (HVRs) H1, H2, and H3 are shown in SEQ ID NOs: 3, 4, and 5, respectively. The light chain hypervariable regions (HVRs) L1, L2, and L3 are shown in SEQ ID NOs: 6, 7, and 8, respectively. The 8G3 VH and VL amino acid sequences are shown in SEQ ID NOs: 49 and 10, respectively. The heavy chain hypervariable regions (HVRs) H1, H2, and H3 are shown in SEQ ID NOs: 13, 14, and 15, respectively. The light chain hypervariable regions (HVRs) L1, L2, and L3 are shown in SEQ ID NOs: 16, 7, and 8, respectively. The 15F2 VH and VL amino acid sequences are shown in SEQ ID NOs: 51 and 12, respectively. The heavy chain hypervariable regions (HVRs) H1, H2, and H3 are shown in SEQ ID NOs: 20, 21, and 22, respectively. The light chain hypervariable regions (HVRs) L1, L2, and L3 are shown in SEQ ID NOs: 23, 24, and 25, respectively.

[0413] An alignment of the light chain and heavy chain variable regions of antibodies 8G3, 17A9, and 15F2 are shown in Figures 2A and 2B, respectively.

D. Monoclonal Antibody Epitope Mapping

[0414] All the constructs for epitope mapping were made by PCR amplification of each fragment and subcloning into either pRKtkneo vector with an N-terminal gD tag, or pRKtkneo vector with an N-terminal gD tag and a C-terminal GPI anchor. Transfections were performed using FuGene 6 (Roche Applied Science), and empty vector was used as control. Full-length human PMEL17 was subcloned into pRKtkneo vector with an N-terminal gD tag.

[0415] A signal sequence and a gD epitope tag were fused to the N-terminal sequence of a series of deletion mutants, which were then expressed in mammalian cells and the lysates analyzed by immunoblotting for reactivity with 17A9 or 77E6. The N-terminal deletions tested included $\Delta 100$, $\Delta 255$, $\Delta 292$, $\Delta 315$, $\Delta 444$, $\Delta 515$, and $\Delta 567$.

[0416] In addition, C-terminal deletions with an N-terminal gD tag and a C-terminal GPI anchor were transiently transfected into 293 cells and analyzed for antibody binding by

FACS. The C-terminal deletions tested included PMEL17₂₅₋₁₂₅, PMEL17₂₅₋₁₀₅, PMEL17₂₅₋₈₅, PMEL17₂₅₋₆₅, and PMEL17₂₅₋₄₅. Finally, a PMEL17 fragment comprising the region from amino acid 515 through the transmembrane domain, but lacking the cytoplasmic region (“Δ515-C”) and a PMEL17 fragment comprising just the cytoplasmic domain with an N-terminal gD tag and a C-terminal GPI anchor were analyzed by immunoblotting for reactivity with 77E6.

[0417] The results of that experiment are shown in Figures 3. Figure 3A shows a diagram of the N-terminal PMEL17 deletion mutants, and immunoblots showing reactivity with an anti-gD antibody and 77E6. 77E6 reacted with all of the N-terminal deletions tested. Figure 3B shows a diagram of the Δ515-C fragment and the cytoplasmic domain fragment, and immunoblots showing reactivity with an anti-gD antibody and 77E6. 77E6 bound to all deletion mutants that contained the cytoplasmic domain, but not to the Δ515-C mutant, which lacks the cytoplasmic domain. These results confirm that 77E6 binds to an epitope within the cytoplasmic domain of PMEL17.

[0418] Figure 3C shows immunoblots showing reactivity with an anti-gD antibody and 17A6. 17A6 bound only to full-length PMEL17 and not to the Δ225 or Δ100 mutants. Figure 3D shows a diagram of the C-terminal PMEL17 deletion mutants, and FACS analysis of anti-gD, 17A9, and 31D1 antibody binding to those mutants. 17A9 bound only to PMEL17₂₅₋₁₂₅, and not to any of the other mutants, including PMEL17₂₅₋₁₀₅, suggesting that 17A9 binds to an epitope within the region of amino acids 105 to 125 of PMEL17. 31D1 bound to all of the fragments tested, including PMEL17₂₅₋₄₅, suggesting that 31D1 binds to an epitope within the region of amino acids 25 to 45 of PMEL17.

E. Subcellular Localization of PMEL17 Epitopes

[0419] PMEL17 is known to undergo rather complex processing during its routing to the melanosome, some of which involves proteolytic cleavages ultimately resulting in deposition of limited RPT domain-containing fragments into fibrillar structures within the mature organelle. This processing involves cleavage at Arg-469 by a proprotein convertase, resulting in an N-terminal Mα and a C-terminal Mβ fragment that remain tethered by a disulfide bond. The Mβ fragment is cleaved further by a metalloproteinase at Gln-583 and by γ-secretase in the transmembrane region. Thus, regions of PMEL17 containing the cytoplasmic and N-terminal epitopes are dissociated during this processing.

[0420] Because PMEL17 undergoes this complex processing, the subcellular distribution of PMEL17 antibody epitopes in fixed permeabilized 928mel cells (provided by Paul Robbins, Center for Cancer Research, Tumor Immunology Section) cells was determined

using 77E6 labeled with Cy3 Fluorophor and 14C10 labeled with Alexa 488. Antibody 14C10 binds to the same deletion fragments as 17A9. A large pool of PMEL17 containing both cytoplasmic (detected by 77E6) and N-terminal epitopes (detected by 14C10) was present in the perinuclear structure, likely the endoplasmic reticulum. However, in extending toward the cell periphery, a downward gradient of staining intensity by 77E6 is evident, followed by an upward gradient of 14C10 staining, which includes reactivity at the cell membrane. These results suggest that the cytoplasmic epitope recognized by 77E6 is removed during trafficking of PMEL17 to the plasma membrane whereas that the N-terminal epitope progresses to the cell surface.

[0421] Consistent with the release of cytoplasmic structure during secretory processing, PMEL17 recovered from conditioned media also failed to react with 77E6. When excised from non-reducing SDS-gels, this secreted PMEL17 generated peptide sequences derived from both M α and M β , but not from the cytoplasmic region, as determined by mass spectrometry. Upon reduction with 2-mercaptoethanol, the secreted PMEL17 exhibited enhanced mobility on SDS-gels and M α , but not M β , sequences were generated from this excised band. These results suggest that the secreted PMEL17 contains M α and M β regions tethered by a disulfide, but lacks cytoplasmic sequence.

[0422] The predominance of the N-terminal epitope at the cell surface relative to the cytoplasmic epitope is consistent with stronger FACS signals observed with 17A9 over 77E6. Nevertheless, it appears that some portion of the cytoplasmic region is present at the cell surface to account for the FACS signals observed with 77E6. To address this, live cells were reacted with the 77E6 and 17A9 antibodies that were directly labeled with Alexa Fluors 555 and 488, respectively. To demonstrate that the antibodies did not compete with each other for binding to live cells, 928mel cells were incubated with either of the labeled antibodies alone or both together and FACS analysis was performed, gated for the individual fluorophors. The binding of the individual antibodies was unaffected by the presence of the other antibody. Visualization of live-labeled cells revealed uniform cell surface staining with 17A9, consistent with ample N-terminal epitopes accessible at the plasma membrane. By contrast, 77E6 staining was more isolated and patchy and largely non-overlapping with 17A9 reactivity. Further, although 17A9 stained all cells uniformly and consistently, 77E6 staining was variable from cell to cell and the overall degree of staining varied across preparations. Subsequent experiments demonstrated that suspension of cells greatly enhanced the presence of 77E6 staining at the cell surface, suggesting that culture conditions may account for this variability. Overall, the uniform and intense reactivity of 17A9 on melanoma cells makes this antibody a good candidate for drug conjugation.

F. Species Cross-Reactivity

[0423] Antibody 17A9 was tested to determine if it cross-reacts with PMEL17 from species other than human. Figure 9 shows an alignment between human (SEQ ID NO: 26), cynomolgus monkey (SEQ ID NO: 28), rat (SEQ ID NO: 29) and mouse (SEQ ID NO: 31) PMEL17. All of the sequences include the signal sequence except for the cynomolgus monkey PMEL17. Residues that are identical among all four species are indicated by asterisks (*). In the region where the rat sequence has a deletion, residues that are identical among the remaining three species are indicated by a plus (+). Binding to each species of PMEL17 was determined by FACS analysis using 293S cells stably transfected with an N-terminal gD tagged PMEL17 (human, cynomolgus monkey, rat, or mouse PMEL17); stained with 10 µg/ml 17A9 antibody; and detected with R-Phycoerythrin conjugated goat anti-mouse antibody. Untransfected 293 cells do not normally express PMEL17. 17A9 was found to bind to all four species of PMEL17 tested: human, cynomolgus monkey, rat, and mouse.

G. Internalization of anti-PMEL17 Antibody

[0424] One desirable attribute of an ADC target is the ability to internalize the antibody into a degradative compartment in the cell. 1300mel melanoma cells were seeded in Lab-Tek II cell culture treated 4-well chamber slides (Nalge Nunc International), and incubated with PMEL17 mAb, in the presence of lysosomal protease inhibitors leupeptin and pepstatin A (Sigma-Aldrich) at 50 nM and 5 nM respectively, at 2 µg/ml for either 2 hours or 20 hours in a 37°C incubator with 5% CO₂. Cells were then washed with PBS, and fixed in 4% Para formaldehyde (Polysciences, Inc.) for 5 min. at room temperature and permeabilized with 0.05% saponin (Sigma-Aldrich) in PBS with 0.5% BSA for 5 minutes at 37°C; cells were then incubated for one hour with 2 µg/ml rabbit polyclonal anti-LAMP1 (Sigma-Aldrich), an antibody to a lysosomal marker, followed by one hour incubation of Cy3 labeled anti-mouse IgG (Jackson Immuno Research Laboratories, Inc.) and Alexa-488 labeled anti-rabbit IgG (Invitrogen Life Technology). PMEL17 antibodies were also directly labeled with either Alexa Fluor 555 or Alexa Fluor 488 (Invitrogen Life Technology), and stained cells after they were fixed and permeabilized as above. Leica SP5 confocal microscope (Leica Microsystems) was used for imaging.

[0425] As shown in Figure 4, considerable overlap of 17A9 and LAMP1 staining was apparent within the cells. Rapid uptake of 17A9 into additional PMEL17+ melanoma cell lines, including 526mel, SK-MEL-5, and UACC257, was consistently observed. These results

predict that a 17A9 ADC should effectively internalize, undergo degradation and release drug to kill melanoma cells.

H. Production of Anti-PMEL17 Antibody Drug Conjugates

[0426] For larger scale antibody production, antibodies were produced in CHO cells. Vectors coding for VL and VH were transfected into CHO cells and IgG was purified from cell culture media by protein A affinity chromatography.

[0427] Anti-PMEL17 antibody-drug conjugate (ADC) comprising a protease-cleavable val-cit linker and the drug MMAE was produced by conjugating 17A9 or ch17A9 (see, e.g., SEQ ID NOs: 47 and 48) to the drug-linker moiety MC-vc-PAB-MMAE, which is depicted herein. Anti-ETBR ADCs comprising a protease-cleavable val-cit linker and the drug MMAE were produced by conjugating ch5E9 (*see, e.g.*, SEQ ID NOs: 43 and 44) or hu5E9.v1 (*see, e.g.*, SEQ ID NOs: 45 and 46) to the drug-linker moiety MC-vc-PAB-MMAE. For convenience, the drug-linker moiety MC-vc-PAB-MMAE is sometimes referred to in these Examples and in the Figures as “vcMMAE” or “VCE.”

[0428] Prior to conjugation, the antibody was partially reduced with TCEP using standard methods in accordance with the methodology described in WO 2004/010957 A2. The partially reduced antibody was conjugated to the drug-linker moiety using standard methods in accordance with the methodology described, e.g., in Doronina et al. (2003) *Nat. Biotechnol.* 21:778-784 and US 2005/0238649 A1. Briefly, the partially reduced antibody was combined with the drug-linker moiety to allow conjugation of the drug-linker moiety to reduced cysteine residues of the antibody. The conjugation reaction was quenched by adding excess N-acetyl-cysteine to react with any free linker-drug moiety, and the ADC was purified. The drug load (average number of drug moieties per antibody) for the ADC was determined to be 2.78. The structure of the ADCs comprising val-cit-MMAE linker-drug (also referred to as MC-val-cit-PAB-MMAE) is shown in Figure 15A.

[0429] Anti-PMEL17 antibody-drug conjugate (ADC) comprising a protease-cleavable val-cit linker and the drug PNU-159682 was produced by conjugating ch17A9 to the drug-linker moiety MC-vc-PAB-PNU-159682, substantially as described above. Anti-ETBR ADC comprising a protease-cleavable val-cit linker and the drug PNU-159682 was produced by conjugating ch5E9 to the drug-linker moiety MC-vc-PAB-PNU-159682, substantially as described above. The structure of the ADCs comprising MC-val-cit-PAB-PNU-159682 is shown in Figure 15C.

[0430] Anti-PMEL17 antibody-drug conjugate (ADC) comprising an acid-labile acetal linker and the drug PNU-159682 was produced by conjugating ch17A9 to the drug-linker

moiety MC-acetal-PNU-159682, substantially as described above. Anti-ETBR ADC comprising an acid-labile acetal linker and the drug PNU-159682 was produced by conjugating ch5E9 to the drug-linker moiety MC-acetal-PNU-159682, substantially as described above. The structure of the ADCs comprising MC-acetal-PNU-159682 is shown in Figure 15B.

[0431] Anti-PMEL17 antibody-drug conjugate (ADC) comprising non-cleavable linker and the drug PNU-159682 was produced by conjugating ch17A9 to the drug-linker moiety MC-PNU-159682, substantially as described above. Anti-ETBR ADC comprising non-cleavable linker and the drug PNU-159682 was produced by conjugating ch5E9 to the drug-linker moiety MC-PNU-159682, substantially as described above. The structure of the ADCs comprising PNU-159682 is shown in Figure 15E.

[0432] Antibody drug conjugates (ADCs) comprising a protease-cleavable val-cit linker and a PBD dimer drug are produced by conjugating an antibody to the drug-linker moiety MC-val-cit-PAB-PBD, substantially as described above. The structure of an antibody-MC-val-cit-PAB-PBD is shown in Figure 15D.

I. Inhibition of In Vitro Cell Proliferation by an Anti-PMEL17 Antibody Drug Conjugate

[0433] Proliferation in the presence of 17A9 ADC was assessed using PMEL17+ melanoma cells and PC3 cells stably expressing PMEL17 plated at 2,000 per well in 50 μ L of normal growth medium in 96-well clear-bottom plates (PerkinElmer). Twenty-four hours later, an additional 50 μ L of culture medium with serial dilutions of 17A9 ADC were added to triplicate wells. Three or five days later, cell numbers were determined using CellTiter-GloII (Promega Corp.) and with an EnVision 2101 Multilabel Reader (PerkinElmer).

[0434] As shown in Figure 5, titration of a panel of PMEL17+ melanoma cells with the 17A9 ADC resulted in effective cell killing with IC₅₀'s ranging from 10 to 100 ng/ml of ADC. The prostate cancer cell line, PC3, stably expressing PMEL17 was effectively killed, but no killing of the vector control PC3 parental cell line was noted out to 10 μ g/ml of ADC.

[0435] While not intending to be bound by any particular theory, the variation in ADC IC₅₀ values for the melanoma cell lines could reflect the variation in the levels of PMEL17 accessible to the ADC, although additional factors likely contribute. For example, the 1300mel cell line expresses significantly more cell surface PMEL17 than the SK-MEL-5 cell line, yet the ADC IC₅₀ is slightly higher for 1300mel. In addition, variation in response of the cell lines to the released MMAE drug product could be another contributing factor. The IC₅₀ values for free MMAE across eight melanoma cell lines ranged from approximately 0.1 to 0.5 nM. While there was not a strict correlation between the response to free drug and 17A9 ADC,

a several-fold difference in free drug sensitivity could, in some instances, account for variation in sensitivity to ADC. Indeed, the SK-MEL-5 was more sensitive to free MMAE than 1300mel, which may compensate for having lower levels of cell surface PMEL17 than 1300mel. Other factors, including the relative rate of antibody internalization might also affect the response to the ADC. Accordingly, the ability of four different melanoma cell lines to accumulate and internalize antibody over time was compared. As expected, cells with higher levels of cell surface PMEL17 accumulated more antibody, but the percentage of that amount internalized appeared comparable, indicating little difference in the relative efficiency of uptake.

J. Toxicity of Anti-PMEL17 ADC in Normal Melanocytes

[0436] To assess the potential liability of targeting PMEL17 on normal melanocytes, the level of expression of this target in normal human skin was evaluated by immunohistochemistry. Immunohistochemistry (IHC) was performed on 4 µm thick formalin-fixed paraffin embedded tissue sections mounted on glass slides. All IHC steps were carried out on the Ventana Discovery XT (Ventana Medical Systems; Tucson, AZ) autostainer. Pretreatment was done with Cell Conditioner 1, standard time. Primary antibody, PMEL17 clone 31D1 was used at a concentration of 10 µg/ml and was incubated on slides for 1 hour at 37°C. Ventana Mouse OmniMap (Ventana Medical Systems; AZ) was used as the detection system. Ventana DAB and Hematoxylin II were used for chromogenic detection and counterstain.

[0437] The results of that experiment are shown in Figure 6A. Staining with PMEL17 antibody 31D1 revealed intermittent reactivity along the basal layer of the dermis, consistent with the distribution of melanocytes in skin.

[0438] Normal human melanocytes and SK-MEL-5 melanoma cells were reacted with chimeric 17A9, or no primary antibody, followed by Alexa 488-labeled anti-human IgG and analyzed by flow cytometry. As shown in Figure 6B, cultured normal human melanocytes were also FACS+ with antibody 17A9 and the intensity was comparable to that observed with melanoma cell line SK-MEL-5.

[0439] Finally, SK-MEL-5 and SK-MEL-23 melanoma cells, or normal human melanocytes, were incubated with serial dilutions of the 17A9 ADC and five days later cell numbers were determined using CellTiter-GloII. As shown in Figure 6C, titration of the normal melanocytes with the 17A9 ADC resulted in cell killing with an IC50 nearly 100-fold higher than that observed with melanoma cell lines. These results are consistent with the

mechanism of action of the antimitotic drug MMAE and the reduced proliferative capacity of normal melanocytes relative to melanoma cells.

K. Expression of PMEL17 on Human Melanoma Tissue Specimens

[0440] The expression of PMEL17 was evaluated across a panel of human melanoma tissue specimens by immunohistochemistry substantially as described above, using both 17A9 and 31D1. Staining was scored on an arbitrary scale ranging from zero, for absent, to 3+ for most intense:

0 (negative): very weak or no staining in >90% of melanoma cells

1+ (mild): predominant staining pattern is weak

2+ (moderate): predominant staining pattern is moderately strong in the majority (> 50%) of melanoma cells

3+ (strong): predominant staining pattern is strong in the majority (>50%) of melanoma cells

Exemplary staining for each of the levels of the scale is shown in Figure 7A, left panels.

[0441] Fifty-eight specimens were obtained from 30 primary and 28 metastatic melanomas. As shown in the table at Figure 7B, the full spectrum of staining was observed across the 58 human melanoma specimens with the majority scoring positive with either antibody. 83% (48/58) of the human melanoma specimens were PMEL17+ when detected with 31D1, and 64% (37/58) were PMEL17+ when detected with 17A9. Relative to 17A9, the staining with 31D1 was more highly skewed toward the upper end of the scale. Fixed paraffin-embedded pellets of melanoma cell lines were also sectioned and stained them alongside the tissue specimens to gauge their staining intensity relative to actual melanoma. *See* Figure 7A, right panels.

L. Efficacy of Anti-PMEL17 Antibody Drug Conjugates in SK-MEL-23 Melanoma Cell Line Xenograft

[0442] All studies were conducted in accordance with the Guide for the Care and Use of Laboratory Animals (Ref- Institute of Laboratory Animal Resources, "Guide for the Care and Use of Laboratory Animals", (NIH Publication #85-23). Washington (DC): National Academy Press; 1996.

[0443] The efficacy of the anti-PMEL17 ADCs was investigated using an SK-MEL-23 melanoma cell line xenograft model. Female CRL Nu/Nu mice from Charles River Laboratories were inoculated subcutaneously in the dorsal right flank with five million SK-MEL-23 cells in HBSS with Matrigel. SK-MEL-23 cells exhibit a staining intensity of 2+ to

3+. When tumor volumes reached $\sim 200 \text{ mm}^3$ (day 0), animals were randomized into groups of 10 each and administered a single IV injection of 2 or 6 mg/kg 17A9 ADC. MMAE conjugated to anti-GP120 antibody was used as a control. Tumor volumes were measured twice per week until study end. Tumor volumes were determined using digital calipers (Fred V. Fowler Company, Inc.) using the formula $(L \times W \times W)/2$. Tumor growth inhibition (%TGI) was calculated as the percentage of the area under the fitted curve (AUC) for the respective dose group per day in relation to the vehicle, such that $\%TGI = 100 \times [1 - (AUC_{\text{treatment/day}})/(AUC_{\text{vehicle/day}})]$. Curve fitting was applied to Log_2 transformed individual tumor volume data using a linear mixed-effects model using the R package nlme, version 3.1–96 in R v2.10.1.

[0444] As shown in Figure 8, the 6 mg/kg dose of 17A9 ADC was found to retard tumor growth for several weeks, while neither dose of the control ADC had an appreciable effect on tumor growth. These results demonstrate robust and specific efficacy with an ADC targeting PMEL17 on a human melanoma tumor xenograft.

M. Efficacy of Anti-PMEL17 Antibody Drug Conjugates in UACC-257X2.2 Melanoma Cells Resistant to anti-ETBR-vc-MMAE

[0445] To determine the efficacy of an anti-PMEL17 ADC in melanoma that had developed resistance to another therapeutic, UACC-257X2.2 melanoma cells that are resistant to an anti-endothelin B receptor (ETBR) immunoconjugate comprising a val-cit linker and MMAE drug (anti-ETBR-vc-MMAE, also referred to as anti-EDNRB-vc-MMAE, anti-ETBR-MC-val-cit-PAB-MMAE, etc.; *see, e.g.*, U.S. Publication No. US 2011/0206702) were developed *in vivo* and *in vitro*.

[0446] For resistance developed *in vivo*, NCr nude mice (Taconic, Hudson, NY) were inoculated subcutaneously in the dorsal right flank with 5 million UACC-257X2.2 cells in HBSS with Matrigel. UACC-257X2.2 cells are derived from UACC-257 cells (National Cancer Institute) and optimized for growth *in vivo* as follows. UACC-257 cells were injected subcutaneously in the right flank of female NCr nude mice to induce tumor growth. One tumor was harvested and grown *in vitro* (referred to as UACC-257X1.2 cell line). The UACC-257X1.2 line was injected again subcutaneously in the right flank of female NCr nude mice to improve the growth of the cell line *in vivo*. A tumor from the second injection round was collected and again adapted for *in vitro* growth to generate UACC-257X2.2. The UACC-257X2.2 cell line and tumors derived from this line express ETBR at levels comparable to the parental cell line UACC-257.

[0447] Ten mice inoculated with UACC-257X2.2 cells were dosed with 3 mg/kg hu5E9.v1-MC-vc-PAB-MMAE intravenously on day 0 (the heavy chain and light chain sequences for hu5E9.v1 are shown in SEQ ID NOs: 46 and 45, respectively). To determine when the mice would be dosed again, and at what doses, the following was taken into consideration: whether or not tumors re-grew after the initial treatment (i.e., tumors that grew back to initial tumor volume size at day 0), and the rate of re-growth. Frequency of doses administered varied over time but did not exceed 2 doses/week. Intravenous doses did not exceed 300 μ L. The range of doses administered were 3 mg/kg, 6 mg/kg, 8 mg/kg, and 10 mg/kg. Dosing was discontinued once a tumor no longer responded (i.e., it showed resistance to) a series of increasing doses.

[0448] As shown in Figure 10A, the UACC-257X2.2 tumor #359 developed resistance to anti-ETBR-vc-MMAE after about 120 days, whereas tumor #368 developed resistance more slowly. Tumor # 359 was harvested and the cells were dissociated for growth *in vitro* (referred to herein as *in vivo*-derived resistant UACC-257X2.2 cells).

[0449] For resistance developed *in vitro*, UACC-257X2.2 cells were adapted to increasing concentrations of anti-ETBR-vc-MMAE in culture dishes over the course of two months. Figure 10B shows the resistant UACC-257X2.2 cell line derived *in vitro* (referred to herein as *in vitro*-derived resistant UACC-257X2.2 cells), which was relatively unaffected by concentrations of anti-ETBR-vc-MMAE up to at least 10 μ g/ml. Figure 10B also shows the *in vitro*-derived resistant UACC-257X2.2 cells incubated with a control ADC, α -gD-vc-MMAE, and the parental UACC-257X2.2 cells incubated with α -ETBR-vc-MMAE.

[0450] Expression of ETBR and PMEL17 on the surface of the *in vivo*- and *in vitro*-derived resistant UACC-257X2.2 cells and the parental UACC-257X2.2 cells was then determined by FACS. Cells were stained with anti-ETBR antibody (hu5E9.v1 or ch5E9) or with anti-PMEL17 antibody (ch17A9), followed by an anti-human Alexa 488 antibody conjugate. As shown in Figures 11A and B, both the *in vivo*-derived and *in vitro*-derived resistant UACC-257X2.2 cells had decreased expression of ETBR on the surface of the cells relative to the parental cell line. Surface expression of PMEL17 was unchanged in the resistant cells as compared to the parental cells. See Figures 11C and D. The control peak in each figure shows staining with secondary antibody only.

[0451] *In vivo*- and *in vitro*-derived resistant UACC-257X2.2 cells were then assayed for sensitivity to increasing concentrations of anti-ETBR-vc-MMAE, anti-PMEL17-vc-MMAE, and a control ADC, anti-gD-vc-MMAE. See Example H and Figure 15A.

[0452] *In vitro* cell proliferation of the cell lines in the presence of the immunoconjugates was assessed. Cells were plated at 1,500 cells per well in 50 μ L of normal

growth medium in 96-well clear-bottom plates. Twenty-four hours later, an additional 50 μ L of culture medium with serial dilutions of immunoconjugates were added to triplicate wells. Five days later, cell survival was determined using CellTiter-Glo Luminescent Cell Viability Reagent (G7572, Promega Corporation, Madison, WI) using an EnVision 2101 Multilabel Reader (Perkin-Elmer, Waltham, MA).

[0453] The results of that experiment are shown in Figure 12. The parental UACC-257X2.2 cell line was sensitive to both anti-ETBR-vc-MMAE and anti-PMEL17-vc-MMAE, with EC50s of 45 ng/mL and 33 ng/mL, respectively. *See* Figure 12A. The parental line was also sensitive to linker-drug (without antibody; MC-vc-PAB-MMAE; referred to as “free drug” in Figure 12), with an EC50 of 0.28 nM. The *in vivo* derived resistant UACC-257X2.2 cells were somewhat less sensitive to anti-PMEL17-vc-MMAE and significantly less sensitive to anti-ETBR-vc-MMAE, with EC50s of 119 ng/mL and 235 ng/mL, respectively. *See* Figure 12B. The *in vivo* derived resistant UACC-257X2.2 cells were also less sensitive to linker-drug (without antibody), with an EC50 of 0.77 nM. The *in vitro* derived resistant UACC-257X2.2 cells were significantly less sensitive to anti-PMEL17-vc-MMAE, with an EC50 of 764 ng/mL, and insensitive to anti-ETBR-vc-MMAE. *See* Figure 12C. The *in vitro* derived resistant UACC-257X2.2 cells were also less sensitive to linker-drug (without antibody), with an EC50 of 3.5 nM. These results suggest that resistance may be developed to both the antibody and drug portions of the ADC.

[0454] To determine the effect of the antibody portion of the ADC on resistance in UACC-257X2.2 cells, the *in vivo*- and *in vitro*-derived resistant UACC-257X2.2 cells were assayed for sensitivity to ADCs with different linkers and different drugs than were used to develop the resistant cells. The ADCs tested in this experiment were anti-ETBR linked to PNU-159682 through a non-cleavable linker (anti-ETBR-PNU) and anti-PMEL17 linked to PNU-159682 through a non-cleavable linker (anti-PMEL17-PNU). *See* Example H and Figure 15E. An unrelated antibody, anti-gD, linked to PNU-159682 through a non-cleavable linker (anti-gD-PNU) was used as a control.

[0455] The results of that experiment are shown in Figure 13. The parental UACC-257X2.2 cell line was sensitive to both anti-ETBR-PNU and anti-PMEL17-PNU, with EC50s of 4.2 ng/mL and 5.5 ng/mL, respectively. *See* Figure 13A. The parental line was also sensitive to linker-drug (without antibody; MC-PNU-159682; referred to as “free drug” in Figure 13), with an EC50 of 0.18 nM in this experiment. The *in vivo* derived resistant UACC-257X2.2 cells were as sensitive as the parental line to anti-PMEL17-PNU, but somewhat less sensitive to anti-ETBR-PNU, with EC50s of 4.7 ng/mL and 14.3 ng/mL, respectively. *See* Figure 13B. The *in vivo* derived resistant UACC-257X2.2 cells were also as sensitive to

linker-drug (without antibody) as the parental line, with an EC₅₀ of 0.133 nM. Similar to the *in vivo* derived resistant UACC-257X2.2 cells, the *in vitro* derived resistant UACC-257X2.2 cells were as sensitive to anti-PMEL17-PNU, but somewhat less sensitive to anti-ETBR-PNU, with EC₅₀s of 4.8 ng/mL and 14.6 ng/mL, respectively. See Figure 13C. The *in vitro* derived resistant UACC-257X2.2 cells were also as sensitive to linker-drug (without antibody) as the parental line, with an EC₅₀ of 0.15 nM. These results demonstrate the extent of resistance in the *in vivo*- and *in vitro*-derived resistant UACC-257X2.2 cells that is attributable to the antibody portion of the ADC (for example, because of a decrease in expression of ETBR), as opposed to resistance to the MMAE drug portion of the ADC. Similar results were obtained with anti-ETBR and anti-PMEL17 linked to PNU-159682 through an acid labile linker.

[0456] The *in vivo*- and *in vitro*-derived resistant UACC-257X2.2 cells were assayed for sensitivity to anti-ETBR linked to PNU-159682 through the vc linker used in the MMAE immunoconjugate (anti-ETBR-vc-PNU) and anti-PMEL17 linked to PNU-159682 through the vc linker (anti-PMEL17-vc-PNU). See Example H and Figure 15C. An unrelated antibody, anti-gD, linked to PNU-159682 through the vc linker (anti-gD-vc-PNU) was used as a control.

[0457] The results of that experiment are shown in Figure 14. The parental UACC-257X2.2 cell line was sensitive to both anti-ETBR-vc-PNU and anti-PMEL17-vc-PNU, with EC₅₀s of 3 ng/mL and 2.5 ng/mL, respectively. See Figure 14A. The parental line was also sensitive to linker-drug (without antibody; MC-vc-PAB-PNU-159682), with an EC₅₀ of 2 nM in this experiment. The *in vivo* derived resistant UACC-257X2.2 cells were slightly less sensitive than the parental line to anti-PMEL17-vc-PNU, and less sensitive to anti-ETBR-vc-PNU, with EC₅₀s of 6.4 ng/mL and 23 ng/mL, respectively. See Figure 14B. The *in vivo* derived resistant UACC-257X2.2 cells were also slightly less sensitive to linker-drug (without antibody) than the parental line, with an EC₅₀ of 4.2 nM. Similarly, the *in vitro* derived resistant UACC-257X2.2 cells were less sensitive to anti-PMEL17-PNU and anti-ETBR-PNU, with EC₅₀s of 11.6 ng/mL and 41 ng/mL, respectively. See Figure 14C. The *in vitro* derived resistant UACC-257X2.2 cells were also slightly less sensitive to linker-drug (without antibody) than the parental line, with an EC₅₀ of 6.6 nM. These results suggest that the linker component of the ADC may contribute to the resistance in the *in vivo*- and *in vitro*-derived resistant UACC-257X2.2 cells. Compare, e.g., the sensitivity of the parental line and *in vitro*-derived resistant line to anti-PMEL17-vc-PNU (EC₅₀s 2.5 ng/ml and 11.6 ng/ml, respectively), which has a different antibody and drug but the same linker as the ADC used to develop the resistant lines, versus the sensitivity of the parental line and *in vitro*-derived resistant line to anti-PMEL17-PNU (EC₅₀s 5.5 ng/ml and 4.8 ng/ml, respectively), which has a different antibody, drug, and linker.

[0458] The *in vivo*- and *in vitro*-derived resistant UACC-257X2.2 cells were assayed for sensitivity to anti-ETBR linked to a PBD dimer through the vc linker used in the MMAE immunoconjugate (anti-ETBR-vc-PBD). The vc-PBD had the structure shown as “PBD dimer-val-cit-PAB-Ab” herein. *See also* Example H and Figure 15D. In that experiment, similar to the results with anti-ETBR-vc-PNU, the resistant cell lines were less sensitive to anti-ETBR-vc-PBD than the parental line, although they were not completely resistant, suggesting that some of the resistance is due to the antibody and linker portions, but some sensitivity can be restored by changing the drug portion of the immunoconjugate.

[0459] Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, the descriptions and examples should not be construed as limiting the scope of the invention. The disclosures of all patent and scientific literature cited herein are expressly incorporated in their entirety by reference.

Table of Sequences

SEQ ID NO	Description	Sequence
1	17A9 heavy chain variable region	EVQLQQSGPE LVKPGASMKI SCKSSGYSFT RYTMNWVKQS HGKNLEWIGV INPYNGGTVY NQKFKGKATL TVDKSSSTAY MELLSLTSED SAVYYCARTD YDGYAMDYWG QGTSVTVSSA KT
2	17A9 light chain variable region	DVQITQSPSY LAASPGETIT INCRATKSIS KYLAWYQEQP GKTNNLLIYS GSTLQSGIPS RFSGSGSGTD FTLTISSELP EDFAMYQCQ HNEYPTFGS GTKLEIK
3	17A9 HVR H1	GYSFTRYTMN
4	17A9 HVR H2	VINPYNGGTVYNQKFKG
5	17A9 HVR H3	TDYDGYAMDY
6	17A9 HVR L1	RATKISKYLA
7	17A9 HVR L2; 8G3 HVR L2	SGSTLQS
8	17A9 HVR L3; 8G3 HVR L3	QQHNEYPYT
9	8G3 heavy chain variable region	EVQLQQSGPE LVKPGASMRI SCKASGYSFT GYTMNWVKQS HGKNLEWIGV YNPYNGGTVY NQKFKGKATL TVDKSSSTTY MELLSLTSED SAVYYCARTD SGGYAMDCWG QGTSVTVSSA KT
10	8G3 light chain variable region	DVQITQSPSY LDASPGETIT INCRASKTIS KYLAWYQEQP GKTNNLLIYS GSTLQSGIPS RFSGSGSGTD FTLTISSELP EDFAMYQCQ HNEYPTFGS GTKLEIK
11	15F2 heavy chain variable region	QVQLKESGPG LVAPSQSLSI TCTVSGFSLT KYGVHWVRQP PGKGLEWLGV IWAGGNTNYN SALMSRLSIN KDNSKSQVFL KMNSLQTDDET AMYYCATFDV WGAGTTVTVS SAKT
12	15F2 light chain variable region	DIVMTQAAPS VPVTPGESVS ISCRSSKSLI HSNNGNTFLYW FLQRPQGSPQ LLIYRMSNLV SGVPDRFSGS GSGTAFTLRI SRVEAEDVGF YYCMQHLEYF YTFGGGTKLE LK
13	8G3 HVR H1	GYSFTGYTMN
14	8G3 HVR H2	VYNPYNGGTVYNQKFKG
15	8G3 HVR H3	TDSGGYAMDC
16	8G3 HVR L1	RASKTISKYLA
17	8G3 / 17A9 HVR H1 consensus	GYSFTX ₁ YTMN
18	8G3 / 17A9 HVR H2 consensus	VX ₂ NPYNGGTVYNQKFKG
19	8G3 / 17A9 HVR L1 consensus	RAX ₃ KX ₄ ISKYLA
20	15F2 HVR H1	GFSLTKYGVH
21	15F2 HVR H2	VIWAGGNTNYNSALMS
22	15F2 HVR H3	TFDV
23	15F2 HVR L1	RSSKSLHNSNGNTFLY
24	15F2 HVR L2	RMSNLVS
25	15F2 HVR L3	MQHLEYPYT
26	Human PMEL17 preproprotein; NP_008859; signal sequence = amino acids 1 to 24	MDLVLRCLL HLAIVIGALLA VGATKVPNRQ DWLGVSRQLR TKAWNROLYP EWTEAQRLLD WRGGQVSLKV SNDGPTLIGA NASFSIALNF PGSQKVLDPG QVIWVNNTII NGSQVWGGQP VYPQETDDAC IFPDGGGPCPS GWSQKRSFV YVKTWQYQW QVLGGPVSGI SIGTGRAMLG THTMVETVYH RGRSRSYVPL AHSSSAFTIT DQVPFVSVS QLRALDGGNK HFLRNQPLTF ALQLHDPSPGY LAEADLSYTW DFGDSSGTLI SRALVVTHTY LEPGPVTAQV VLQAAIPLTS CGSSPVPGTT DGHRTAEAP NNTAGQVPTT EVVGTPGQA PTAEPSTGTS VQVPTTEVIS TAPVQMPTAE STGMTPEKVP VSEVMGTTLA EMSTPEATGM TPAEVSIVVL SGTAAQVTT TEWVETTARE LPIPEPEGPD ASSIMSTESI TGSGLPPLDG TATLRLVKRQ VPLDCVLYRY GSFSVTLDIV QGIESAEILQ AVPSGEGDAF ELTVSCQGL PKEACMEISS PGCQPPAQL CQFVLPSPAC QLVLHQILKG GSGTYCLNVS LADTNSLAVV STQLIMPGQE AGLGQVPLIV GILLVLMNAV LASLIYRRRL MKQDFSVPL PHSSSHWLRL PRIFCSCPIG ENSPLLSGQQ V

27	Human PMEL17 proprotein, without signal sequence; amino acids 25 to 661	KVPRNQ DWLGVSRQLR TKAWNRLQYP EWTEAQRLLDC WRGGQVSLKV SNDGPTLIGA NASFSIALNF PGSQKVLDPG QVIWVNNTII NGSQVWGGQP VYPQETDDAC IFPDGGPCPS GWSQKRSFV YVWKTWGQYW QVLGGPVSGL SIGTGRAMLG THTMEVTYH RRGSRSYVPL AHSSSAFTIT DQVPFVSVS QLRALDGGNK HFLRNQPLTF ALQLHDPSGY LAEADLSYTW DFGDSSGTLI SRALVVTHTY LEPGPVTAQV VLQAAIPLTS CGSSPVP GTT DGHRTAEAP NTTAGQVPTT EVVGTTPGQA PTAEPSTGTS VQVPTTEVIS TAPVQMPTAE STGMTPEKVP VSEVMGTTLA EMSTPEATGM TPAEVSIVVL SGTAAQVTT TEWVETTARE LPIPEPEGPD ASSIMSTESI TGSGLPLLDG TATLRLVKRQ VPLDCVLYRY GSFSVTLDIV QGIESAEILQ AVPSGEGDAF ELTVSCQGGL PKEACMEISS PGCQPPAQR L CQPVLPSPAC QLVLHQILKG GSGTYCLNVS LADTNSLAVV STQLIMPGQE AGLGQVPLIV GILLVLMVAV LASLIYRRRL MKQDFSVPL PHSSSHWLRL PRIFCSCPIG ENSPLLSGQQ V
28	Cynomolgus monkey PMEL17, without signal sequence	KGPRNQDWLG VSRQLRTKAW NRQLYPEWTE AQRLLDCWRGG QVSLKVSNDG PTLIGANASF SIALNFPQS QVLPDQGVW VNNNTIINGSQ VWGGQVPVYPQ ETDDACIFPD GGPCSPGWS QKRSFVYVWK TWGQYWQVLG GPFVSGLSIGT GRAMLGTHM EVTVYHRRGS RSYVPLAHSS SAFTITDQVP FSVSVSQLRA LDGGNKHFLR NQPLTFALQL HDPSGYLAEA DLSYTWDFGD SSGTLISRAL VVTHTYLEPG PVTAQVVLQA AIPLTSCGSS PVP GTT DGHRTAEAPDTTA GRGPTTEVVG TTPGQVPTTQ PSGTTSVQVP TTEVISTTPV QMPTAESTGT TPEKVPVSEV MGTTLAEMST PEAIGMTPAE VSIVVPSGTT AAQVTTTEWV ETTAGELPTP EPEGPDTSI MSTESITGSL GPLLDGTATL RLEKRVPLD CVLYRYGSFS VTLDIVQGIE SAEILQVVP S SEGDAFELTV SCQGGLPTEA CMEISSPGCQ PPAQQLCQPV PPSPACQLVL YQILKGGGLT YCLNVSLADA NSLAVVSTQL IVPQGEAGL QAPLFGVILL VLMVAVLASL IYRRRLMKQA FSIPQLPHGS SHWLRLPRIF RSCPIGENSP LLSGQEV
29	Rat PMEL17 precursor; NP_068682; signal sequence = amino acids 1 to 25	MGVQRRCLF VLVLGALLAL GSI EGSRNQN WHGVSRLVLT KVWNKQLYPE WTEVQGSNCW RGGQVSLKVR NDGPTLVGAN TSFSIALHFP GSQKVLDPGQ VIWVNNTIIN GSQVWGGQPV YPREDDACI FPDGGPCPSG PKPPRRSFVY VWKTWGQYWQ VLGGPESKLS IPTGHARLGT HTMEVTYH RGSQSYVPLA HSSSTFTITG SVSRLDDTD TIMLVKRQVP LDCVLYRYGS FSLTLDIVQG IESAEILQAV PSSEGDAFEL TVSCRGGLPK EACMDISSPG CQPPAQR L CQ PVPPSPDCQL VLHQILKGGGL GTYCLNVSLA DANSLAVAST QLVVPGQEGS LGQAPLLVGV LLVLVAVVLA SLIYRHLRKK QDSVSQTPHG STHWLRLPPV FCARRLGESS PLLSGQQV
30	Rat PMEL17, without signal sequence, amino acids 26 to 418	SRNQ WHGVSRLVLT KVWNKQLYPE WTEVQGSNCW RGGQVSLKVR NDGPTLVGAN TSFSIALHFP GSQKVLDPGQ VIWVNNTIIN GSQVWGGQPV YPREDDACI FPDGGPCPSG PKPPRRSFVY VWKTWGQYWQ VLGGPESKLS IPTGHARLGT HTMEVTYH RGSQSYVPLA HSSSTFTITG SVSRLDDTD TIMLVKRQVP LDCVLYRYGS FSLTLDIVQG IESAEILQAV PSSEGDAFEL TVSCRGGLPK EACMDISSPG CQPPAQR L CQ PVPPSPDCQL VLHQILKGGGL GTYCLNVSLA DANSLAVAST QLVVPGQEGS LGQAPLLVGV LLVLVAVVLA SLIYRHLRKK QDSVSQTPHG STHWLRLPPV FCARRLGESS PLLSGQQV
31	Mouse PMEL17 precursor; NP_068682; signal sequence = amino acids 1 to 25	MGVQRRCLF VLVLSALLAV GALEGSRNQD WLGVPRLVLT KTWNRQLYPE WTEVQGSNCW RGGQVSLRVI NDGPTLVGAN ASFSIALHFP GSQKVLDPGQ VIWANNTIIN GSQVWGGQPV YQEPDDACV FPDGGPCPSG PKPPKRSFVY VWKTWGKYWQ VLGGPVSRLS IATGHAKLGT HTMEVTYH RGSQSYVPLA HASSTFTITD QVPFVSVSQ LQALDGETKH FLRNHPLIFA LQLHDPSGYL AEADLSYTD FGDGTGTLIS RALDVTHTYL ESGSVTAQVV LQAAIPLVSC GSSPVP GTT GYMPTAEAPG TTSRQGT TTK VVGTT PGMP TTQPSGTTVV QMPTEVTAT TSEQMLTSAV IDTTAEVST TEGTGTTPTR PSGTVAQAT TTEGPDASPL LPTQSSTGSI SPLDDTD TI MLVKRQVPLD CVLYRYGSFS LALDIVQGIE SAEILQAVPF SEGDAFELTV SCQGGLPKEA CMDISSPGCQ PPAQR L CQSV PPSPDCQLVL HQVLKGGSGT YCLNVSLADA NSLAVASTQL VVPQDGGGLG QAPLLVGILL VLVAVVLA SL IHRHLRKKQ SVSQMPHGST HWLRLPPVFR ARGLGENSPL LSGQQV
32	Mouse PMEL17, without signal sequence, amino acids 26 to 626	SRNQD WLGVPRLVLT KTWNRQLYPE WTEVQGSNCW RGGQVSLRVI NDGPTLVGAN ASFSIALHFP GSQKVLDPGQ VIWANNTIIN GSQVWGGQPV YQEPDDACV FPDGGPCPSG PKPPKRSFVY VWKTWGKYWQ VLGGPVSRLS IATGHAKLGT HTMEVTYH RGSQSYVPLA HASSTFTITD QVPFVSVSQ LQALDGETKH FLRNHPLIFA LQLHDPSGYL AEADLSYTD FGDGTGTLIS RALDVTHTYL ESGSVTAQVV LQAAIPLVSC GSSPVP GTT GYMPTAEAPG TTSRQGT TTK VVGTT PGMP TTQPSGTTVV QMPTEVTAT TSEQMLTSAV

		IDTTLAEVST TEGTGTTPTR PSGTTVAQAT TTEGPDASPL LPTQSSTGSI SPLDDDTDI MLVKRQVPLD CVLYRYGSFS LALDIVQGIE SAEILQAVPF SEGDAFELTV SCQGGLPKEA CMDISSPGCQ PPAQRQCQSV PPSPPDCQLVL HQVLKGGSGT YCLNVSLADA NSLAVASTQL VVPGQDGLG QAPLLVGILL VLVAVVLASL IHRHRLKKQG SVSQMPHGST HWLRLPPVFR ARGGLGENSPL LSGQQV
33	5E9 HVR H1	GYTFTSYWMQ
34	5E9 HVR H2	TIYPGDGDTSYAQKFKG
35	5E9 HVR H3	WGYAYDIDN
36	5E9 HVR L1	KSSQSLLDSDGKTYLN
37	5E9 HVR L2	LVSKLDS
38	5E9 HVR L3	WQGTTHFPYT
39	hu5E9.v1 light chain variable region	DIQMTQSPSS LSASVGDRVT ITCKSSQSLD DSDGKTYLNL LQKPGKAPK RLIYLVSKLD SGVPSRFSGS GSGTDFTLTI SSLQPEDFAT YYCWQGTTHFP YTFGGGTKVE IK
40	hu5E9.v1 heavy chain variable region	EVQLVESGGG LVQPGGSLRL SCAASGYTFT SYWMQWVRQA PGKLEWIGT IYPGDGDTSY AQKFKGRATL STDKSKNTAY LQMNSLRAED TAVYYCARWG YAYDIDNWG
41	mu5E9 light chain variable region	DVVMQTPLT LSVTIGQPAS ISCKSSQSLD DSDGKTYLNL LLQRPQGSPK RLIYLVSKLD SGVPDRFTGS GSGTDFTLKI TRVEAEDLGV YYCWQGTTHFP YTFGGGTKLE IK
42	mu5E9 heavy chain variable region	QVQLQSGAE LARPGASVKL SCKASGYTFT SYWMQWVKQR PGKLEWIGT IYPGDGDTSY AQKFKGKATL TTDKYSSTAY MQLSSLASED SAVYYCARWG YAYDIDNWG
43	ch5E9 ligh chain	DVVMQTPLT LSVTIGQPAS ISCKSSQSLD DSDGKTYLNL LLQRPQGSPK RLIYLVSKLD SGVPDRFTGS GSGTDFTLKI TRVEAEDLGV YYCWQGTTHFP YTFGGGTKLE IKRTVAAPSV FIFPPSDEQL KSGTASVCL LNNFYPREAK VQWKVDNALQ SGNSQESVTE QDSKDYSTSL SSTLTLSKAD YEKHKVYACE VTHQGLSSPV TKSFNREGC
44	ch5E9 heavy chain	QVQLQSGAE LARPGASVKL SCKASGYTFT SYWMQWVKQR PGKLEWIGT IYPGDGDTSY AQKFKGKATL TTDKYSSTAY MQLSSLASED SAVYYCARWG YAYDIDNWG GTLVTVSSAS TKGPSVFPLA PSSKSTSGGT AALGCLVKDY FPEPVTVSWN SGALTSGVHT FPAVLQSSGL YSLSSVTVTP SSSLGTQTYI CNVNHKPSNT KVDKKVEPKS CDKTHTCPPC PAPELLGGPS VFLFPPKPKD TLMISRTPEV TCVVVDVSHE DPEVKFNWYV DGVEVHNAKT KPREEQYNST YRVVSVLTVL HQDWLNGKEY KCKVSNKALP APIEKTISKA KGQPREPQVY TLPPSREEMT KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTTPVLD SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH EALHNHYTQK SLSLSPGK
45	hu5E9.v1 light chain	DIQMTQSPSS LSASVGDRVT ITCKSSQSLD DSDGKTYLNL LQKPGKAPK RLIYLVSKLD SGVPSRFSGS GSGTDFTLTI SSLQPEDFAT YYCWQGTTHFP YTFGGGTKVE IKRTVAAPSV FIFPPSDEQL KSGTASVCL LNNFYPREAK VQWKVDNALQ SGNSQESVTE QDSKDYSTSL SSTLTLSKAD YEKHKVYACE VTHQGLSSPV TKSFNREGC
46	hu5E9.v1 heavy chain	EVQLVESGGG LVQPGGSLRL SCAASGYTFT SYWMQWVRQA PGKLEWIGT IYPGDGDTSY AQKFKGRATL STDKSKNTAY LQMNSLRAED TAVYYCARWG YAYDIDNWG GTLVTVSSAS TKGPSVFPLA PSSKSTSGGT AALGCLVKDY FPEPVTVSWN SGALTSGVHT FPAVLQSSGL YSLSSVTVTP SSSLGTQTYI CNVNHKPSNT KVDKKVEPKS CDKTHTCPPC PAPELLGGPS VFLFPPKPKD TLMISRTPEV TCVVVDVSHE DPEVKFNWYV DGVEVHNAKT KPREEQYNST YRVVSVLTVL HQDWLNGKEY KCKVSNKALP APIEKTISKA KGQPREPQVY TLPPSREEMT KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTTPVLD SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH EALHNHYTQK SLSLSPGK
47	ch17A9 light chain	DVQITQSPSY LAASPGETIT INCRATKIS KYLAWEQEQP GKTNNLLIYS GSTLQSGIPS RFGSGSGTD FTLTISSELE EDFAMYYCQQ HNEYPYTFGS GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSTLT LSKADYEKHK VYACEVTHQG LSSPVTKSFN REGC
48	ch17A9 heavy chain	EVQLQSGGPE LVKPGASMKI SCKSSGYSFT RYTMNWVKQS HGKNLEWIGV INPYNNGTVY NQKFKGKATL TVDKSSSTAY MELLSTLSED SAVYYCARTD YDGYAMDYWG QGTSVTVSSA KTKGPSVFPL APSSKSTSGG TAALGCLVKD YFPEPVTVSW NSGALTSGVH TFPVAVLQSSG LYSLSVTVTP PSSSLGTQTY ICNVNHKPSN TKVDKKVEPK SCDKTHTCPP CPAPELLGGP SVFLFPPKPK

		DTLMISRTPE VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV YTLPPSREEM TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTPPVV DSDGSFFFLYS KLTVDKSRWQ QGNVFSCSVM HEALHNHYTQ KSLSLSPGK
49	8G3 heavy chain variable region	EVQLQQSGPE LVKPGASMRI SCKASGYSFT GYTMNWWVKQS HGKNLEWIGV YNPYNGGTVY NQKFKGKATL TVDKSSSTTY MELLSTLSED SAVYYCARTD SGGYAMDCWG QGTSVTVSS
50	17A9 heavy chain variable region	EVQLQQSGPE LVKPGASMRI SCKSSGYSFT RYTMNWWVKQS HGKNLEWIGV INPYNGGTVY NQKFKGKATL TVDKSSSTAY MELLSTLSED SAVYYCARTD YDGYAMDYWG QGTSVTVSS
51	15F2 heavy chain variable region	QVQLKESGPG LVAPSQSLSI TCTVSGFSLT KYGVHWVRQP PGKGLEWLG IWAGGNTNIN SALMSRLSIN KDNSKSKQVFL KMNSLQTDIT AMYYCATFDV WGAGTTVTVS S

WHAT IS CLAIMED IS:

1. An isolated antibody that binds to PMEL17, wherein the antibody binds an epitope within amino acids 105 to 125 of SEQ ID NO: 26, or binds to an epitope within amino acids 25 to 45 of SEQ ID NO: 26.
2. The antibody of claim 1, which is a monoclonal antibody.
3. The antibody of claim 1, which is a human, humanized, or chimeric antibody.
4. The antibody of claim 1, which is an antibody fragment that binds PMEL17.
5. The antibody of claim 1, wherein PMEL17 is human PMEL17.
6. The antibody of claim 5, wherein human PMEL17 has the sequence of SEQ ID NO: 26 or SEQ ID NO: 27.
7. The antibody of claim 1, wherein the antibody comprises:
 - a) (i) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 5, (ii) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 8, and (iii) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 4; or
 - b) (i) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 15, (ii) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 8, and (iii) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 14; or
 - c) HVR-H3, HVR-L3, and HVR-H2 of the antibody produced by hybridoma 7509(31D1.6.7) having ATCC Accession No. PTA-12862.
8. The antibody of claim 1, wherein the antibody comprises:
 - a) (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 3, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 4, and (iii) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 5; or
 - b) (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 13, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 14, and (iii) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 15; or
 - c) HVR-H1, HVR-H2, and HVR-H3 of the antibody produced by hybridoma 7509(31D1.6.7) having ATCC Accession No. PTA-12862.
9. The antibody of claim 8, wherein the antibody comprises:
 - a) (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 3, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 4, (iii) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 5, (iv) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 6, (v) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 7, (vi) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 8; or

b) (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 13, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 14, and (iii) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 15, (iv) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 16, (v) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 7, (vi) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 8; or

c) HVR-H1, HVR-H2, HVR-H3, HVR-L1, HVR-L2, and HVR-L3 of the antibody produced by hybridoma 7509(31D1.6.7) having ATCC Accession No. PTA-12862.

10. The antibody of claim 1, wherein the antibody comprises:

a) (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 6, (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 7, (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 8; or

b) (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 16, (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 7, (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 8; or

c) HVR-L1, HVR-L2, and HVR-L3 of the antibody produced by hybridoma 7509(31D1.6.7) having ATCC Accession No. PTA-12862.

11. The antibody of claim 1, wherein the antibody comprises:

a) a VH sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1; or

b) a VL sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 2; or

c) a VH sequence as in (a) and a VL sequence as in (b); or

d) a VH sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 9; or

e) a VL sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 10; or

f) a VH sequence as in (d) and a VL sequence as in (e); or

g) a VH sequence having at least 95% sequence identity to the VH sequence of the antibody produced by hybridoma 7509(31D1.6.7) having ATCC Accession No. PTA-12862; or

h) a VL sequence having at least 95% sequence identity to the VL sequence of the antibody produced by hybridoma 7509(31D1.6.7) having ATCC Accession No. PTA-12862; or

i) a VH sequence as in (g) and a VL sequence as in (h).

12. The antibody of claim 11, comprising a VH sequence having the amino acid sequence of SEQ ID NO: 1, a VH sequence having the amino acid sequence of SEQ ID NO: 9, or a VH sequence of the antibody produced by hybridoma 7509(31D1.6.7) having ATCC Accession No. PTA-12862.

13. The antibody of claim 11, comprising a VL sequence having the amino acid sequence of SEQ ID NO: 2, a VL sequence having the amino acid sequence of SEQ ID NO: 10, or a VL sequence of the antibody produced by hybridoma 7509(31D1.6.7) having ATCC Accession No. PTA-12862.

14. An isolated antibody comprising (a) a VH sequence having the amino acid sequence of SEQ ID NO: 1 and a VL sequence having the amino acid sequence of SEQ ID NO: 2; or (b) a VH sequence having the amino acid sequence of SEQ ID NO: 9 and a VL sequence having the amino acid sequence of SEQ ID NO: 10; or (c) a VH sequence of the antibody produced by hybridoma 7509(31D1.6.7) having ATCC Accession No. PTA-12862 and a VL sequence of the antibody produced by hybridoma 7509(31D1.6.7) having ATCC Accession No. PTA-12862.

15. An isolated antibody that binds to PMEL17, wherein the antibody comprises:

a) (i) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 22, (ii) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 25, and (iii) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 21; or

b) (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 20, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 21, and (iii) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 22; or

c) (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 23, (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 24, (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 25; or


d) (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 20, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 21, and (iii) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 22, (iv) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 23, (v) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 24, (vi) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 25; or

e) a VH sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 11; or

f) a VL sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 12; or


g) a VH sequence as in (e) and a VL sequence as in (f); or

- h) a VH sequence having the amino acid sequence of SEQ ID NO: 11; or
 i) a VL sequence having the amino acid sequence of SEQ ID NO: 12; or
 j) a VH sequence as in (h) and a VL sequence as in (i).
16. The antibody of any one of claims 1 to 15, which is an IgG1, IgG2a or IgG2b antibody.
17. Isolated nucleic acid encoding the antibody of any one of claims 1 to 16.
18. A host cell comprising the nucleic acid of claim 17.
19. A method of producing an antibody comprising culturing the host cell of claim 18 so that the antibody is produced.
20. An immunoconjugate comprising the antibody of any one of claims 1 to 16 and a cytotoxic agent.
21. The immunoconjugate of claim 20 having the formula Ab-(L-D)p, wherein:
 (a) Ab is the antibody of any one of claim 1 to 16;
 (b) L is a linker;
 (c) D is a drug selected from a maytansinoid, an auristatin, a calicheamicin, a pyrrolobenzodiazepine, and a nemorubicin derivative; and
 (d) p ranges from 1-8.
22. The immunoconjugate of claim 21, wherein D is an auristatin.
23. The immunoconjugate of claim 22, wherein D has formula D_E



and wherein R² and R⁶ are each methyl, R³ and R⁴ are each isopropyl, R⁵ is H, R⁷ is sec-butyl, each R⁸ is independently selected from CH₃, O-CH₃, OH, and H; R⁹ is H; and R¹⁸ is -C(R⁸)₂-C(R⁸)₂-aryl.

24. The immunoconjugate of claim 21, wherein the drug is MMAE.
25. The immunoconjugate of claim 22, wherein D is a pyrrolobenzodiazepine of Formula A:



wherein the dotted lines indicate the optional presence of a double bond between C1 and C2 or C2 and C3;

R^2 is independently selected from H, OH, =O, =CH₂, CN, R, OR, =CH-R^D, =C(R^D)₂, O-SO₂-R, CO₂R and COR, and optionally further selected from halo or dihalo, wherein R^D is independently selected from R, CO₂R, COR, CHO, CO₂H, and halo;

R^6 and R^9 are independently selected from H, R, OH, OR, SH, SR, NH₂, NHR, NRR', NO₂, Me₃Sn and halo;

R^7 is independently selected from H, R, OH, OR, SH, SR, NH₂, NHR, NRR', NO₂, Me₃Sn and halo;

Q is independently selected from O, S and NH;

R^{11} is either H, or R or, where Q is O, SO₃M, where M is a metal cation;


R and R' are each independently selected from optionally substituted C₁₋₈ alkyl, C₃₋₈ heterocyclyl and C₅₋₂₀ aryl groups, and optionally in relation to the group NRR', R and R' together with the nitrogen atom to which they are attached form an optionally substituted 4-, 5-, 6- or 7-membered heterocyclic ring;

R^{12} , R^{16} , R^{19} and R^{17} are as defined for R^2 , R^6 , R^9 and R^7 respectively;

R'' is a C₃₋₁₂ alkylene group, which chain may be interrupted by one or more heteroatoms and/or aromatic rings that are optionally substituted; and

X and X' are independently selected from O, S and N(H).


26. The immunoconjugate of claim 25, wherein D has the structure:






A(II);

wherein n is 0 or 1.

27. The immunoconjugate of claim 25, wherein D has a structure selected from:




A(I);



wherein R^E and $R^{E''}$ are each independently selected from H or R^D , wherein R^D is independently selected from R, CO_2R , COR, CHO, CO_2H , and halo;
 wherein Ar^1 and Ar^2 are each independently optionally substituted C_{5-20} aryl; and
 wherein n is 0 or 1.


28. The immunoconjugate of claim 21, wherein D is a pyrrolobenzodiazepine of Formula B:




wherein the horizontal wavy line indicates the covalent attachment site to the linker;
 R^{V1} and R^{V2} are independently selected from H, methyl, ethyl, phenyl, fluoro-substituted phenyl, and C_{5-6} heterocyclyl; and
 n is 0 or 1.

29. The immunoconjugate of claim 21, wherein D is a nemorubicin derivative.

30. The immunoconjugate of claim 29, wherein D has a structure selected from:




31. The immunoconjugate of any one of claims 21 to 30, wherein the linker is cleavable by a protease.
32. The immunoconjugate of claim 31, wherein the linker comprises a val-cit dipeptide or a Phe-Lys dipeptide.
33. The immunoconjugate of any one of claims 21 to 30, wherein the linker is acid-labile.
34. The immunoconjugate of claim 33, wherein the linker comprises hydrazone.
35. The immunoconjugate of claim 23 having the formula:




wherein S is a sulfur atom.


36. The immunoconjugate of claim 26 having the formula:




37. The immunoconjugate of claim 30 having a formula selected from:




;






;



; and



38. The immunoconjugate of any one of claims 21 to 37, wherein p ranges from 2-5.
39. The immunoconjugate of any one of claims 21 to 38, comprising the antibody of claim 9.
40. The immunoconjugate of any one of claims 21 to 38, comprising the antibody of claim 14.
41. A pharmaceutical formulation comprising the immunoconjugate of any one of claims 21 to 40 and a pharmaceutically acceptable carrier.
42. The pharmaceutical formulation of claim 41, further comprising an additional therapeutic agent.
43. A method of treating an individual having a PMEL17-positive cancer, the method comprising administering to the individual an effective amount of the immunoconjugate of any one of claims 20 to 40.
44. The method of claim 43, wherein the PMEL17-positive cancer is melanoma.
45. The method of claim 44, further comprising administering an additional therapeutic agent to the individual.
46. A method of inhibiting proliferation of a PMEL17-positive cell, the method comprising exposing the cell to the immunoconjugate of any one of claims 20 to 40 under conditions permissive for binding of the immunoconjugate to PMEL17 on the surface of the cell, thereby inhibiting proliferation of the cell.
47. The method of claim 46, wherein the cell is a melanoma cell.
48. The antibody of any one of claims 1 to 16 conjugated to a label.
49. The antibody of claim 48, wherein the label is a positron emitter.
50. The antibody of claim 49, wherein the positron emitter is ⁸⁹Zr.
51. A method of detecting human PMEL17 in a biological sample comprising contacting the biological sample with the anti-PMEL17 antibody of any one of claims 1 to 16 under conditions permissive for binding of the anti-PMEL17 antibody to a naturally occurring human PMEL17, and detecting whether a complex is formed between the anti-PMEL17 antibody and a naturally occurring human PMEL17 in the biological sample.
52. The method of claim 51, wherein the anti-PMEL17 antibody is an antibody as in claim 9 or claim 15.
53. The method of claim 51, wherein the biological sample is a melanoma sample.
54. A method for detecting a PMEL17-positive cancer comprising (i) administering a labeled anti-PMEL17 antibody to a subject having or suspected of having a PMEL17-positive cancer, wherein the labeled anti-PMEL17 antibody comprises the anti-PMEL17

antibody of any one of claims 1 to 16, and (ii) detecting the labeled anti-PMEL17 antibody in the subject, wherein detection of the labeled anti-PMEL17 antibody indicates a PMEL17-positive cancer in the subject.

55. The method of claim 54, wherein the labeled anti-PMEL17 antibody is an antibody as in claim 9 or claim 15 that is labeled.

56. The method of claim 54 or claim 55, wherein the labeled anti-PMEL17 antibody comprises an anti-PMEL17 antibody conjugated to a positron emitter.

57. The method of claim 56, wherein the positron emitter is ⁸⁹Zr.

58. A method of treating an individual having a PMEL17-positive cancer, wherein the PMEL17-positive cancer is resistant to a first therapeutic, the method comprising administering to the individual an effective amount of the immunoconjugate of any one of claims 20 to 40.

59. The method of claim 58, wherein the PMEL17-positive cancer is melanoma.

60. The method of claim 58 or claim 59, wherein the first therapeutic comprises a first antibody that binds an antigen other than PMEL17.

61. The method of claim 60, wherein the first therapeutic is a first immunoconjugate comprising a first antibody that binds an antigen other than PMEL17 and a first cytotoxic agent.

62. The method of claim 60 or claim 61, wherein the first antibody binds an antigen selected from endothelin B receptor (ETBR), tyrosinase-related protein 1 (TYRP1), cytotoxic T lymphocyte antigen 4 (CTLA-4), and glycoprotein NMB (GPNMB).

63. The method of claim 62, wherein the first antibody binds ETBR.

64. The method of claim 63, wherein the first antibody is hu5E9.v1.

65. The method of claim 64, wherein the first immunoconjugate is hu5E9.v1-MC-val-cit-PAB-MMAE.

66. The method of any one of claims 61 to 65, wherein the first cytotoxic agent and the cytotoxic agent of the immunoconjugate of any one of claims 20 to 40 are different.

67. The method of claim 66, wherein the first cytotoxic agent is MMAE and the cytotoxic agent of the immunoconjugate of any one of claims 20 to 40 is selected from a calicheamicin, a pyrrolobenzodiazepine, and a nemorubicin derivative.

68. The method of claim 67, wherein the cytotoxic agent of the immunoconjugate of any one of claims 20 to 40 is selected from a pyrrolobenzodiazepine and a nemorubicin derivative.

69. A method of treating an individual with PMEL17-positive cancer, comprising administering to the individual an effective amount of a first immunoconjugate of any one of

claims 20 to 40 in combination with a second immunoconjugate comprising an antibody that binds ETBR.

70. The method of claim 69, wherein the antibody that binds ETBR comprises an HVR H1 comprising a sequence of SEQ ID NO: 33, an HVR H2 comprising a sequence of SEQ ID NO: 34, an HVR H3 comprising a sequence of SEQ ID NO: 35, an HVR L1 comprising a sequence of SEQ ID NO: 36, an HVR L2 comprising a sequence of SEQ ID NO: 37, and an HVR L3 comprising a sequence of SEQ ID NO: 38.

71. The method of claim 69, wherein the antibody that binds ETBR comprises a heavy chain variable region comprising the sequence of SEQ ID NO: 40 and a light chain variable region comprising the sequence of SEQ ID NO: 39.

72. The method of any one of claims 69 to 71, wherein the first immunoconjugate comprises a cytotoxic agent selected from an auristatin, a pyrrolobenzodiazepine, and a nemorubicin derivative, and the second immunoconjugate comprises a cytotoxic agent selected from an auristatin, a pyrrolobenzodiazepine, and a nemorubicin derivative.

73. The method of any one of claims 69 to 72, wherein the first immunoconjugate comprises a cytotoxic agent selected from a pyrrolobenzodiazepine and a nemorubicin derivative, and the second immunoconjugate comprises an auristatin.

74. The method of claim 73, wherein the second immunoconjugate comprises MMAE.

75. The method of any one of claims 69 to 74, wherein the second immunoconjugate comprises a linker-drug portion comprising MC-val-cit-PAB-MMAE.

76. The method of any one of claims 69 to 75, wherein the second immunoconjugate is hu5E9.v1-MC-val-cit-PAB-MMAE.

77. The method of any one of claims 69 to 76, wherein the PMEL17-positive cancer is melanoma.

78. The method of any one of claims 69 to 77, wherein the PMEL17-positive cancer is also ETBR-positive.




FIG. 1

[illegible]

FIG. 2A

Clone	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																												
PPMEL178G3.11.5	E	V	Q	L	Q	Q	S	G	P	E	L	V	K	P	G	A	S	M	R	I	S	C	K	A	S	G	Y	S	F	T	G	V	T	M	N	.	.	W	V	K	Q	S	H	G	K	N	L																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																
PPMEL1717A9.11.6	E	V	Q	L	Q	Q	S	G	P	E	L	V	K	P	G	A	S	M	K	I	S	C	K	A	S	G	Y	S	F	T	R	Y	T	M	N	.	.	W	V	K	Q	S	H	G	K	N	L																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																
PPMEL1715F2.11.8	Q	V	Q	L	K	E	S	G	P	G	L	V	A	P	S	Q	S	L	S	I	T	C	T	V	S	G	F	S	L	T	K	V	G	V	H	.	.	W	V	R	Q	P	P	G	K	G	L																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																
Kabat - CDR H1																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																															</

FIG. 2B








FIG. 3

**FIG. 4****FIG. 5**

**FIG. 6**

A**B**

IHC scores for human melanoma (n=58)

Score	0	1	2	3
31D1	10	15	20	13
17A9	21	17	13	7

FIG. 7




FIG. 8

FIG. 9A

FIG. 9B





FIG. 10




FIG. 11




FIG. 12




FIG. 13









FIG. 14

A Ab-MC-val-cit-PAB-MMAE**B** Ab-MC-acetal-PNU-159682**C** Ab-MC-val-cit-PAB-PNU-159682**FIG. 15**

D Ab-MC-val-cit-PAB-PBD**E** Ab-PNU-159682**FIG. 15**

INTERNATIONAL SEARCH REPORT

International application No

PCT/US2013/038742

A. CLASSIFICATION OF SUBJECT MATTER
 INV. A61K47/48 C07K16/28 C07K16/30
 ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-Internal, BIOSIS, EMBASE, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>K.-I. YASUMOTO: "Epitope Mapping of the Melanosomal Matrix Protein gp100 (PMEL17): RAPID PROCESSING IN THE ENDOPLASMIC RETICULUM AND GLYCOSYLATION IN THE EARLY GOLGI COMPARTMENT", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 279, no. 27, 27 April 2004 (2004-04-27), pages 28330-28338, XP055068483, ISSN: 0021-9258, DOI: 10.1074/jbc.M401269200 page 28331, left-hand column, paragraph 3; figure 7</p> <p>----- -/--</p>	1-78



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

11 September 2013

Date of mailing of the international search report

23/09/2013

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040,
 Fax: (+31-70) 340-3016

Authorized officer

Cilensek, Zoran

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US2013/038742

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☒ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fees, this Authority did not invite payment of additional fees.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- ☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- ☒ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2013/038742

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	SARAH E. NICHOLS ET AL: "A Novel Splice Variant of Pmel17 Expressed by Human Melanocytes and Melanoma Cells Lacking Some of the Internal Repeats", JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol. 121, no. 4, 1 October 2003 (2003-10-01), pages 821-830, XP055068530, ISSN: 0022-202X, DOI: 10.1046/j.1523-1747.2003.12474.x page 822, left-hand column, paragraph 3; figures 2,6	1-78
Y	----- VALENCIA J C ET AL: "Sorting of Pmel17 to melanosomes through the plasma membrane by AP1 and AP2: evidence for the polarized nature of melanocytes", JOURNAL OF CELL SCIENCE, CAMBRIDGE UNIVERSITY PRESS, LONDON, GB, vol. 119, 1 March 2006 (2006-03-01), pages 1080-1091, XP002480326, ISSN: 0021-9533, DOI: 10.1242/JCS.02804 page 1083, right-hand column - page 1084, left-hand column	1-78
Y	----- WO 2010/135547 A1 (CELLEX THERAPEUTICS INC [US]; JEFERS MICHAEL E [US]; SIMANTOV RONIT []) 25 November 2010 (2010-11-25) paragraphs [0003], [0228] - [0258]	1-78
X,P	----- Y. CHEN ET AL: "The Melanosomal Protein PMEL17 as a Target for Antibody Drug Conjugate Therapy in Melanoma", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 287, no. 29, 13 July 2012 (2012-07-13), pages 24082-24091, XP055068112, ISSN: 0021-9258, DOI: 10.1074/jbc.M112.361485 the whole document	1-78

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/US2013/038742

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2010135547 A1	25-11-2010	EP 2453919 A1	23-05-2012
		US 2013058948 A1	07-03-2013
		WO 2010135547 A1	25-11-2010

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-78(partially)

An isolated antibody that binds to PMEL17, wherein the antibody binds an epitope within amino acids 105 to 125 of SEQ ID NO: 26.

2. claims: 1-78(partially)

An isolated antibody that binds to PMEL17, wherein the antibody binds an epitope within amino acids 25 to 45 of SEQ ID NO: 26.
